 
+  
 
CLINICAL PROTOCOL  
PROTOCOL NUMBER:  LUM001 -[ADDRESS_1147481] OF LU M001, AN API[INVESTIGATOR_827137] -
DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT OF 
CHOLESTATIC LIVER DISEASE IN PEDIATRIC SUBJECTS WITH ALA GILLE 
SYNDROM E 
Protocol Amendment 6.2: 13 May  2019  
 
Protocol History  
Original Protocol:  14 Apr 2014  
Protocol Amendment 1:  29 Jan 2015  
Protocol Amendment 2:  12 Feb 2015  
Protocol Amendment 3:  27 Apr 2016 (not published)  
Protocol Amendment 4:  27 Apr 2016*  
Protocol Amendment 5:  13 Nov 2017*  
Protocol Amendment 6:  25 Jun 2018  
Protocol Amenment 6.1  08 Feb 2019  
Developed in Collaboration with ChiLDReN  
*NIDDK DSMB Approval Date: [ADDRESS_1147482]  
Menlo Park, [LOCATION_004] [ZIP_CODE]  
[LOCATION_003]  
CONFIDENTIAL  
This document is a confidential communication of Mirum Pharmaceuticals, Inc . It is agreed that no 
unpublished information contained herein will be published or disclosed without prior approval from the 
Sponsor. However, this document can be disclosed to an  appropriate Independent Ethics 
Committee/Institutional Review Board (IEC/IRB) or authorized representatives of national regulatory 
authorities under the condition that they respect its confidential information.  
Mirum Pharmauticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147483] OF LU M001, AN API[INVESTIGATOR_827138] -DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN THE 
TREATMENT OF CHOLESTATIC LIVER DISEASE IN PEDIATRIC S UBJECTS WITH 
ALA GILLE SY NDROM E 
 
Protocol Amendment 6.2: 13 May  2019  
Protocol History  
Original Protocol:  14 Apr  2014  
Protocol Amendment 1:  29 Jan 2015  
Protocol Amendment 2:  12 Feb 2015  
Protocol Amendment 3:  27 Apr 2016  
Protocol Amendment 4:  27 Apr 2016*  
Protocol Amendment 5:  13 Nov 2017*  
Protocol Amendment 6:  25 Jun 2018  
Protocol Amendment 6 .1: 08 Feb 2019  
 
 
*NIDDK DSMB Approval Date:  13 May 2019 
 
 
 
 
 
 
 
Sponsor:  
Mirum Pharmaceuticals, Inc.  
[ADDRESS_1147484]  
Menlo Park, [LOCATION_004] [ZIP_CODE]  
[LOCATION_003]  
 
 
Mirum Pharmauticals, Inc.  CONFIDENTIAL  Page 3 
LUM001 -305 Protocol Amendment 6.2  
SHP625  13 May 2019  
 
 TITLE PAGE  
Study Drug:  LUM001  
 
Protocol Number:  LUM001 -305 
 
Amendment Number:  6.2 
 
Date:     13 May 2019  
       
IND No:  119917  
 
Study Phase:  Phase 2  
 
Protocol Title:  A Multicenter Extension Study to Evaluate the Long -Term Safety and 
Durability of the Therapeutic Effect of LUM001, an  Api[INVESTIGATOR_373693] -
Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment 
of Cholestatic Liver Disease in Pediatric Subjects with Alagille 
Syndrome  
 
Sponsor:  Mirum Pharmaceuticals, Inc.  
[ADDRESS_1147485]  
Menlo Park, [LOCATION_004] [ZIP_CODE]  
[LOCATION_003]  
 
Medical  Monitor:  Cagil Ozen, MD  
 Premier Research  
 Office: +[PHONE_17253]  
 Cell: +[PHONE_17254]  
 Email: medmonitorLUM501@premier -research.com  
 
Medical Lead:  Thomas Jaecklin, MD  
Mirum Pharmaceuticals AG  
Innere Margarethenstrasse 5  
4051 Basel  
Switzerland  
 Phone:  +41(0) 79 850 77 18    
 Email:  [EMAIL_15739]  
 
Compliance Statement:  This study will be conducted in accordance with all applicable 
clinical research guidelines including the International Conference on 
Harmonization (ICH) Guidelines for current Good  Clinical Practice 
(GCP). Study documents will be maintained in accordance with 
applic able regulations.  
 
Mirum Pharmauticals, Inc. 
LUMOOl-305 Protocol Amendment 6.2 
SHP625 CONFIDENTIAL 
PROTOCOL SIGNATURE [CONTACT_827239]~nsor's (Mirum) App·[>·ro rovv~al~ . . . . ... 
Signature: / ' /. ,/~ 
Thomas Jaecklin, MD Date: 
SVP Clinical Development Page4 
[ADDRESS_1147486] this study in accordance with the requirements of this clinical study protocol 
and also in accordance with the following: 
• Declaration of Helsinki (Oct 2008) 
• Established principles of Good Clinical Practice (ICH E6; GCP) (Harmonized) 
• US Code of Federal Regulations (CFR); Food and Drug Administration (FDA) 
(where applicable) 
Clinical Study Title: 
A MULTI CENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY 
AND DURABILITY OF THE THERAPEUTIC EFFECT OF LUMOOl , AN API[INVESTIGATOR_827138]-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN THE 
TREATMENT OF CHO LEST A TIC LIVER DISEASE IN PEDIATRIC SUBJECTS WITH 
ALAGILLE SYNDROME 
Protocol Number: 
Amendment Number: 
Date: 
IND No: 
Sponsor: 
As Agreed: 
Investigator's Signature [CONTACT_827240]-[ADDRESS_1147487] 
Menlo Park, [LOCATION_004] [ZIP_CODE] 
[LOCATION_003] 
Date 
Investigator's Name (Please print) 
Mirum Pharmauticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147488] IN FORMATION  
In the event of a serious adverse event (SAE), the investigator must fax or email the Premier 
Research Serious Adverse Event Form within 24 hours to the Premier Research 
Pharmacovigilance Department. Applicable fax numbers and email address can be found on the 
form (sent under separate cover) and below.  
Premier Research SAE Reporting:  
US sites:  
Fax: 215 -972-8765, or  
Email: GlobalPV -US@premier -research.com  
For all urgent protocol - or safety -related issues during and outside of business hours, the 
investigator must contact  [CONTACT_827166]:  
Cagil Ozen, MD, Medical Director  
North America sites:  
Central phone number: +1 -[PHONE_4294] (US)  
For non -emergencies, the Premier Research Medical Monitor may be contact[CONTACT_426] e -mail: 
medmonitorLUM305@premier -research. com  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147489](s) will be returned to the 
sponsor for inspection and analysis according to procedures.  
This includes any instances wherein the quality or performance of a Mirum  product (marketed or 
investigational) does not meet expectations (eg, inadequate or faulty closure, product 
contamination); or that the product did not meet the specifications defined in  the application for 
the product (eg, wrong product such that the label and contents are different products); or a 
product deficiency that relates to identity, quality, durability, reliability, safety and performance 
of the product but did not result in an  AE, which include but are not limited to the following:  
• A failure of a product to exhibit its expected pharmacological activity and/or design function 
(eg, reconstitution difficulty)  
• Missing components  
• Damage to the product or unit carton  
• A mislabeled pro duct (eg, potential counterfeiting/tampering)  
• A bacteriological, chemical or physical change or deterioration of the product causing it to 
malfunction or to present a hazard or fail to meet label claims  
For instructions on reporting AEs related to product complaints, see Section 11. 
Please use the information below as applicable to report the Product Quality Complaint or Non -
Medical Complaint:  
 
Origin of Product Quality Complaint  Email Address  
North and South America  [EMAIL_15740]  
European Union and Rest of World  [EMAIL_15740]  
 
Telephone numbers (provided for reference if needed):  
Mirum, Menlo Park, CA  ([LOCATION_003])  
[PHONE_17255]  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147490] OF ABBREVIATION S AND TERMS ................................ ................................ ......... 33 
3. STUDY OBJECTIVES  ................................ ................................ ................................ .......... 36 
4. BACKGROUND AND RATIONALE  ................................ ................................ ................... 37 
4.1 Therapeutic Rationale  ................................ ................................ .............................. 37 
4.2 Alagille Syndrome  ................................ ................................ ................................ ....38 
4.3 Pruritus  ................................ ................................ ................................ ..................... 38 
4.4 LUM001  ................................ ................................ ................................ ................... 40 
4.4.1  Nonclinical Studies  ................................ ................................ ...................... 40 
[IP_ADDRESS]  Pharmacology  ................................ ................................ .......................... 40 
[IP_ADDRESS]  Pharmacokinetics  ................................ ................................ ..................... 40 
[IP_ADDRESS]  Toxicology  ................................ ................................ ............................... [ADDRESS_1147491]  ................................ ................................ ............................ 47 
5.3 Number o f Study Centers  ................................ ................................ ......................... 48 
5.4 Number of Subjects  ................................ ................................ ................................ ..48 
5.5 Overall Study Duration and Follow -up ................................ ................................ ....48 
5.5.1  Treatment  ................................ ................................ ................................ .....53 
[IP_ADDRESS]  Dose Escalation Period  ................................ ................................ ............ 54 
[IP_ADDRESS]  Dose Optimization Period  ................................ ................................ .......55 
[IP_ADDRESS]  Stable Dosing and Safety Monitoring Periods  ................................ ........ 55 
[IP_ADDRESS]  Long -term, Optional Follow -up Treatment Period  ................................ .55 
[IP_ADDRESS]  Long -term, Optional Follow -up Treatment Period -2 .............................. 56 
5.5.2  Dosing Interruptions  ................................ ................................ ..................... 56 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 8 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 [IP_ADDRESS]  Dose Escalation Following Dose Interruption  ................................ ........ 56 
[IP_ADDRESS]  Visit Schedule Following Dose Interruption for Stable Dosing and 
Safety Monitoring Periods  ................................ ................................ .......57 
[IP_ADDRESS]  Visit Schedule Following Dose Interruption for Long -term, Optional 
Follow -up Treatment Period  ................................ ................................ ....[ADDRESS_1147492] ELIGIBILITY  ................................ ................................ ................................ .......62 
7.1 Inclusion Cr iteria  ................................ ................................ ................................ ......62 
7.2 Exclusion Criteria  ................................ ................................ ................................ .....63 
8. STUDY PROCEDURES  ................................ ................................ ................................ ........ 65 
8.1 Study Schedule  ................................ ................................ ................................ ......... 65 
8.1.1  Baseline (Day 0)  ................................ ................................ ........................... 65 
8.1.2  Dose Escalation Treatment Period (Week 0 to Week 4)  .............................. 65 
8.1.3  Dose Optimization Period (Week 5 to Week 12)  ................................ ......... 66 
8.1.4  Stable Dosing Period (Week 13 to Week 48)  ................................ .............. 66 
8.1.5  Safety Monitoring Period (Week 49 to Week 96)  ................................ ........ 67 
8.1.6  Week 96  ................................ ................................ ................................ ........ 67 
8.1.7  Follow -up Phone Ca ll ([ADDRESS_1147493] Dose)  ................................ ......... 68 
8.1.8  Long -term, Optional Follow -up Treatment Period (Week 96 -148) ............. 68 
8.1.9  Week 144  ................................ ................................ ................................ ......70 
8.1.10  Week 148  ................................ ................................ ................................ ......71 
8.1.11  Long -term, Optional Follow -up Treatment Period -2 (Week 144 -220) ........ 71 
8.1.12  Week 216 (EOT or ET)  ................................ ................................ ................ 72 
8.1.13  Week 220 (EOS)  ................................ ................................ .......................... 72 
8.2 Physical Examination, Weight and Height, Vital Signs  ................................ ........... 72 
8.3 Laboratory Assessments  ................................ ................................ ........................... 73 
8.4 Pruritus and Quality of Life Assessments  ................................ ................................ 73 
8.4.1  Itch Reported Outcome (ItchRO™)  ................................ ............................. 73 
8.4.2  Clinician Scratch Scale  ................................ ................................ ................. 74 
8.4.3  Clinician Xanthoma Scale  ................................ ................................ ............ 75 
8.4.4  Pediatric Quality of Life Inventory (PedsQL)  ................................ .............. 75 
8.4.5  Caregiver Impression of Change  ................................ ................................ ..76 
8.5 Restriction on the Lifestyle of Subjects  ................................ ................................ ...76 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 9 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 8.5.1  Contraception Requirements  ................................ ................................ ........ 76 
8.5.2  Fasting Requirements  ................................ ................................ ................... 76 
9. STUDY DRUG  ................................ ................................ ................................ ....................... 77 
9.1 Study Drug Description  ................................ ................................ ............................ 77 
9.1.1  LUM001  ................................ ................................ ................................ .......77 
9.2 Packaging and Labeling  ................................ ................................ ........................... 77 
9.3 Drug Accountability  ................................ ................................ ................................ .77 
10. TREATMENT OF SUBJECTS  ................................ ................................ .............................. 78 
10.1  Study Drug Administration  ................................ ................................ ...................... 78 
10.2  Treatment Compliance  ................................ ................................ ............................. 78 
10.3  Concomi tant Medications  ................................ ................................ ........................ 78 
10.4  Other Protocol -required Drugs  ................................ ................................ ................. 79 
10.5  Safety Monitoring Rules  ................................ ................................ .......................... 79 
10.5.1  General Monitoring Rules  ................................ ................................ ............ 79 
10.5.2  Safety Monitoring Rules  ................................ ................................ .............. 79 
[IP_ADDRESS]  Safety Monitoring for Liver Chemistry Tests  ................................ ......... 80 
[IP_ADDRESS]  Stoppi[INVESTIGATOR_827139]  ................................ ......81 
[IP_ADDRESS]  Safety Monitoring for Triglycerides  ................................ ........................ 81 
[IP_ADDRESS]  Safety Monitoring for Fat Soluble Vitamins  ................................ ........... 82 
[IP_ADDRESS]  Monitoring/Stoppi[INVESTIGATOR_827140]  .................... 82 
10.6  Adjustment of Dose  ................................ ................................ ................................ ..82 
10.7  Withdrawal of Subjects from the Study  ................................ ................................ ...82 
11. SERIOUS AND NON -SERI OUS ADVERSE EVENT RE PORTING  ................................ .84 
11.1  Regulatory Requirements  ................................ ................................ ......................... 84 
11.2  Definitions  ................................ ................................ ................................ ................ 84 
11.2.1  Adverse Event  ................................ ................................ .............................. 84 
11.2.2  Adverse Reaction and Suspected Adverse Reaction  ................................ ....85 
11.2.3  Serious Adverse Event (SAE)  ................................ ................................ ......85 
11.3  Monitoring and Recording Adverse Events  ................................ ............................. 86 
11.3.1  Serious Adverse Events  ................................ ................................ ................ 86 
11.3.2  Non-Serious Adverse Events  ................................ ................................ .......87 
11.3.3  Evaluation of Adverse Events (Serious and Non -Serious)  .......................... 87 
[IP_ADDRESS]  Relationship to the Study Drug  ................................ ............................... 87 
[IP_ADDRESS]  Severity  ................................ ................................ ................................ ....87 
[IP_ADDRESS]  Action Taken with Study Drug  ................................ ................................ 88 
[IP_ADDRESS]  Treatment Given for Adverse Event  ................................ ........................ 88 
[IP_ADDRESS]  Outcome of the Adverse Event  ................................ ................................ 88 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 10 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 11.4  Procedures for Handling Special Situations  ................................ ............................. 89 
11.4.1  Pregnancy Reporting  ................................ ................................ .................... 89 
11.4.2  Dosing Errors  ................................ ................................ ............................... 89 
11.4.3  Abnormalities of Laboratory Tests ................................ ............................... 90 
12. STATISTICAL CONSIDER ATIONS  ................................ ................................ ................... 91 
12.1  Sample Size Considerations  ................................ ................................ ..................... 92 
12.2  Population  ................................ ................................ ................................ ................. 92 
12.2.1  Safety Populati on ................................ ................................ ......................... 92 
12.2.2  Siblings  ................................ ................................ ................................ ......... 92 
12.2.3  Demographic and Baseline Characteristics  ................................ .................. 92 
[IP_ADDRESS]  Subject Disposition  ................................ ................................ .................. 92 
[IP_ADDRESS]  Baseline Data  ................................ ................................ ........................... 93 
12.2.4  Efficac y Analyses  ................................ ................................ ......................... 93 
[IP_ADDRESS]  Efficacy Variables  ................................ ................................ ................... 93 
[IP_ADDRESS]  Primary Efficacy Analysis  ................................ ................................ .......94 
[IP_ADDRESS] Secondary, Exploratory and Other Efficacy Analyses  ............................ 94 
12.2.5  Safety Analyses  ................................ ................................ ............................ 95 
[IP_ADDRESS]  Safety Assessments  ................................ ................................ ................. 95 
12.2.6  Safety Analysis  ................................ ................................ ............................. 95 
[IP_ADDRESS]  Adverse  Events  ................................ ................................ ........................ 95 
[IP_ADDRESS]  Laboratory Tests  ................................ ................................ ...................... 96 
[IP_ADDRESS]  Physical Exams, Vital Signs and Weight/Height Measurements  ............ 96 
[IP_ADDRESS]  Concomitant Medications  ................................ ................................ ........ 96 
[IP_ADDRESS]  Study Drug Exposure  ................................ ................................ .............. 96 
12.2.7  Additional Analyses  ................................ ................................ ..................... 97 
13. INVESTIGATOR’S REGUL ATORY OBLIGATIONS  ................................ ....................... [ADDRESS_1147494] of the Study  ................................ ................................ ................... 98 
13.3  Independent Ethics Committee/Institutional Review Board  ................................ ....99 
13.4  Confidentiality  ................................ ................................ ................................ .......... 99 
14. ADMINISTRATIVE  AND LEGAL OBLIGATIO NS ................................ ........................ 101 
14.1  Study Personnel  ................................ ................................ ................................ ......101 
14.2  Pre-study Documentation Required  ................................ ................................ .......101 
14.3  Protocol Amendments  ................................ ................................ ............................ 101 
14.4  Study T ermination  ................................ ................................ ................................ ..102 
14.5  Study Documentation and Storage  ................................ ................................ ......... 102 
14.5.1  Parent Report for Teenagers (ages 13 -18 years)  ................................ ........ [ADDRESS_1147495] of Laboratory Analytes  ................................ ................................ ................... 121 
16.3  Itch Reported Outcome Instrument (ItchRO™)  ................................ ..................... 122 
16.3.1  Patient Itch Reported Outcome Instrument, ItchRO(Pt)™  ........................ 123 
16.3.2  Observer Itch Reported Outcome Instrument, ItchRO(Obs)™  .................. 126 
16.4  Clinician Scratch Scale  ................................ ................................ ........................... 129 
16.5  Clinician Xanthoma Scale  ................................ ................................ ...................... 130 
16.6  Pediatric Quality of Life Inventory (PedsQL™)  ................................ .................... 131 
16.6.1  Parent Report for Infants (ages 1 -12 months)  ................................ ............ 132 
16.6.2  Parent Report for Infants (ages 13 to 24 months)  ................................ ......135 
16.6.3  Parent Report for Toddlers (ages 2 -4 years)  ................................ .............. 138 
16.6.4  Parent Report for Young Children (ages 5 -7 years)  ................................ ...140 
16.6.5  Parent Report for Children (ages 8 -12 years)  ................................ ............. 142 
16.6.6  Pediatric Quality of Life Inventory v 4.0 for Young Children (ages 5 -
7 years)  ................................ ................................ ................................ .......144 
16.6.7  Pediatric Quality of Life Inventory for Children (ages 8 -12 years)  ........... 147 
16.6.8  Pediatric Quality of Life Inventory for Teenagers (ages 13 -18 years) .......149 
16.6.9  Multidimensional Fatigue Scale Parent Report for Toddlers (ages 2 -4 
years)  ................................ ................................ ................................ .......... 151 
16.6.10  Multidimensional Fatigue Scale Parent Report for Young Children 
(ages  5-7 years)  ................................ ................................ .......................... 153 
16.6.11  Multidimensional Fatigue Scale Parent Report for Children (ages 8 -12 
years)  ................................ ................................ ................................ .......... 155 
16.6.12  Multidimensional Fatigue Scale Parent Report for Teenagers (ages 
13-18 years)  ................................ ................................ ................................ 157 
16.6.13  Multidimensional Fatigue Scale Young Child Report (ages 5 -7 years)  .....159 
16.6.14  Multidimensional Fatigue Scale Child Report (ages 8 -12 years)  .............. 162 
16.6.15  Multidimensional Fatigue Scale Teen Report (ages 13 -18 years)  ............. [ADDRESS_1147496] Module v  2.0 ................................ ................................ ......166 
16.7  Caregiver Impression of Change (CIC)  ................................ ................................ .169 
16.8  Common Terminology Criteria for Adverse Events (CTCAE) Version 4.[ADDRESS_1147497] OF TABLES  
 
Table  1: Improvement in Biochemical Markers and Pruritus After Partial 
External Biliary Diversion in PFIC Disease and Ala gille Syndrome 
Subjects  ................................ ................................ ................................ .......... 39 
Table  2: Sample Daily Exposure (mg/day) in Pediatric Subjects  ................................ 43 
Table  3: GI-associated Adverse Events in Study 003  ................................ ................. 44 
Table  4: Dose Escalation Regimens  ................................ ................................ ............ 54 
Table  5: Dose Escalation Regimen for Re -initiation of LU M001 Dosing When 
Dosing Interruption is Greater than 7 Consecutive Days  .............................. 57 
Table  6: Dosing Interruptions: Reintegration to Study Visit Schedule  ....................... 58 
Table  7: Composition of LUM001 1.0 mL Oral Solution  ................................ ........... 77 
Table  8: Composition of LUM001 0.[ADDRESS_1147498] OF FIGURES  
 
Figure 1:  Interruption of Enterohepatic Circulation with an ASBT/IBAT 
Inhibitor  ................................ ................................ ................................ ......... 37 
Figure 2:  Serum Bile Salt Concentration and Degree of Itch  ................................ .......39 
Figure 3:  Study Design for LUM001 -305 (Day 0 -Week 48)  ................................ ........ 49 
Figure 4:  Safety Monitoring Period (Week  49-Week  96) ................................ ............. 50 
Figure 5:  Long -term Optional Follow -up Treatment Period (Week 96 -
Week  148) ................................ ................................ ................................ .....51 
Figure 6:  Long -term Optional  Follow -up Treatment Period (Week 96 -
Week  148) ................................ ................................ ................................ .....52 
Figure 7:  Long -term Optional Follow -up Treatment Period -2 (Week 144 -
Week  220) ................................ ................................ ................................ .....53 
Figure 8:  Visit Schedule for Re -initiation of LUM001 when Dosing Interruption 
is Greater than 7 Consecutive Days  ................................ ............................... 57 
 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 14 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 PROTOCOL AMENDMENT 6.2 SUMMARY OF CHANGES  
 
Protocol Number:  LUM001 -305 
Protocol Title:  A MULTICENTER EXTENSION STUDY TO EVALUATE THE 
LONG -TERM SAFETY AND DURABILITY OF THE THERAPEUTIC 
EFFECT OF LUM001, AN API[INVESTIGATOR_827137] -DEPENDENT BILE 
ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT 
OF CHOLESTATIC LIVER DISEASE IN PEDIATRIC SUBJECTS 
WITH ALAGILLE SYNDROME  
Amendment:  6.2 
Date:  [ADDRESS_1147499] the date of the DSMB approval 
(13May2019)   of changes made per Amendment 6.[ADDRESS_1147500] of LUM001, an Api[INVESTIGATOR_373693] -Dependent Bile Acid Transporter Inhibitor 
(ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects with Alagille 
Syndrome   
Study Phase  2 
Indication  Treatment of cholestatic liver disease in Alagille syndrome (ALGS)  
Objectives  The primary objective of the study is to:  
• Evaluate the long -term safety and tolerability of LUM001 in pediatric subjects with ALGS.  
Secondary objectives of the study are to:  
• Evaluate the long -term effect of LUM001 on serum bile acid levels associated with ALGS.  
• Evaluate the long -term effect of LUM001 on pruritus associated with ALGS.  
• Explore the long -term effect of LUM001 on other biochemical markers of cholestasis and 
liver disease.  
• Evaluate the long -term effect of LUM001 on xanthomas associated with ALGS.  
• Explore an expanded dosing range to identify the doses necessary to achieve the optimal 
benefit -to-risk ratio for this patient population.  
Exploratory objective of the study is to:  
• Evaluate the long term effect of LUM001 on weight in pediatric subjects with ALGS.  
Study Design  This is a multicenter, double -blind study of LUM001 in children >[ADDRESS_1147501] completed participation in the LUM001 -301 protocol. All subjects will 
receive active drug (LUM001) in the study . The  study is divided into 6  parts: a dose escalation 
period, a dose optimization period, a stable dosing period, a safety monitoring period, and 2 
long-term optional follow -up treatment periods.  
Dose Escalation Period  
All subjects entering the extension study will participate in a 4 -week double -blind dose 
escalation period during which:  
• Subjects randomized to receive placebo during the LUM001 -301 protocol will receive 
weekly dose increases of LUM001 up to a target dose of 140  μg/kg/day.  
• Subjects randomized to active drug during the LUM00 1-[ADDRESS_1147502] and up to a maximum daily dose of 280 μg/kg LUM001 or [ADDRESS_1147503] on pruritus. Reductions in dose will be based on tolerability. At the 
investigator’s discretion, the doses for subjects who were previously down -titrated may be 
re-challenged during the dose optimization per iod. Each subject will receive one of the 
following dose levels:  
• LUM001 35 μg/kg/day.  
• LUM001 70 μg/kg/day.  
• LUM001 140 μg/kg/day.  
• LUM001 280 μg/kg/day.  
A minimum period of [ADDRESS_1147504] of the study.  
 
Long -term Optional Follow -up Treatment Period:  
The long -term optional follow -up treatment period is for eligible subjects who choose to remain 
on treatment with LUM001 following the initial 96 weeks of treatment. During this long -term 
optional follow -up treatment period, subjects with LUM001 dosing interruptions ≤7 days will 
remain on the same dose they were taking  at Week 96 . Subjects with LUM001 dosing 
interrupt ions >[ADDRESS_1147505]’s previously 
achieved highest tolerated dose. Study drug for each subject will remain blinded an d will be 
prepared by [CONTACT_827167]’s specified dose -
escalation regimen. Subjects’ participation in the long -term optional follow -up treatment period 
will continue until the first of the following occur: (i) sub jects complete 48  weeks of additional 
treatment (after Week 96 [safety monitoring period]), or (ii) the subjects are eligible to enter 
another LUM001 study.  
 
Long -term Optional Follow -up Treatment Period -2: 
The long -term optional follow -up treatment period -[ADDRESS_1147506] according to the protocol’s specified dose -escalation regimen. 
Subjects’ participation in the long -term optional follow -up treatment period will continue until 
the first of the  following occur: (i) subjects complete 72 weeks of additional treatment (after 
Week 144 [Long -term Optional Follow -up Treatment Period]), or (ii) the subjects are eligible 
to enter another LUM001 (SHP625) study.  
Number of 
Subjects  Approximately 36 subjec ts meeting the study’s inclusion and exclusion criteria will be enrolled 
in the study.  
Study 
Population  Original Inclusion and Exclusion Criteria (through Protocol Amendment 4)  
Inclusion Criteria  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147507] meet all of the following criteria:  
1. Male or female, 12 months to 18 years of age.  
2. Competent to provide informed consent and assent (per IRB/EC), as appropriate.  
3. Completed participation in the LUM001 -[ADDRESS_1147508] [ β human 
chorionic gonadotropin (β -hCG)] at the Baseline Visit.  
5. Sexually active females must  be prepared to use an effective method (≤  1% failure rate) of 
contraception during the trial. Effective methods of contraception are considered to be:  
a. Hormonal (eg, contraceptive pi[INVESTIGATOR_4382], patch, intramuscular implant or injection); or  
b. Barrier method, eg, (a) condom with spermicide, or (b) diaphragm, with 
spermicide; or  
c. Intrauterine device (IUD).  
6. Subjects above the age of assent and caregiv ers and children must be able to read and 
understand English or Spanish.  
7. Caregivers (and age appropriate subjects) must have access to phone for scheduled calls 
from study site.  
8. Caregivers (and age appropriate subjects) must be willing and able to complete  a daily 
electronic diary (ItchRO) during the first consecutive 12 weeks of the study and then for 4 
consecutive weeks following the Week 24 and Week 44 visits.  
9. Caregivers (and age appropriate subjects) must digitally accept the licensing agreement in 
the ItchRO electronic diary software at the outset of the study.  
10. Eligible subjects must be able to adhere to local Ethics Committee (EC)or Institutional 
Review Board (IRB) blood volume limits for laboratory testing.  
Exclusion Criteria  
Subjects will be excluded  from the study if they meet any of the following criteria:  
1. Experienced an adverse event (AE) or serious adverse event (SAE) related to the study 
drug during the LUM001 -[ADDRESS_1147509] from 
the LUM001 -301 treatment study.  
2. Any conditions or abnormalities (including laboratory abnormalities ) which, in  the opi[INVESTIGATOR_827141], may compromise the 
safety of the subject, or interfere with the subjec t participating in or completing the study.  
3. History or known presence of gallstones or kidney stones.  
4. History of non -adherence during the subject’s participation in the LUM001 -301 protocol. 
Non-adherence is defined by [CONTACT_827168] 80% in the LUM001 -301 
protocol.  
5. Unlikely to comply with the study protocol, or unsuitable for any other reaso n, as judged 
by [CONTACT_093].  
Protocol Amendment 5 Inclusion and Exclusion Criteria: Eligible subjects for the long -term 
optional follow -up treatment period  
Inclusion Criteria:  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147510] (β -human chorionic gonadotropin [β -HCG]) at the time of entry into the long -term 
optional, follow -up treatment period.  
3. Male and female subjects of child -bearing potential who are sexually active, or are not 
currently sexually active, but become sexually activ e during the study or for [ADDRESS_1147511] agree to use acceptable contraception during the 
study.  
4. Informed consent and assent (per IRB/EC) as appropriate.  
5. Caregivers (and age appropriate subjects) must have access to phone for scheduled calls 
from study site.  
6. Caregivers (and age appropriate subjects) must be willing and able to use an eDiary device 
during the study.  
Exclusion Criteria:  
All exclusion criteria for the original LUM001 -305 study apply upon re -entry into th e long -
term, optional follow -up treatment period.  
Protocol Amendment 6 Inclusion and Exclusion Criteria: Eligible subjects for the long -term 
optional follow -up treatment period -2 
Inclusion Criteria:  
1. The subject has completed the protocol through either Wee k 144, or the ET visit, or has 
received permission from the sponsor and the ChiLDReN protocol chair to re -enter the 
study in the long -term optional follow -up period -2.  
2. Females of child -bearing potential must have a negative urine or serum pregnancy test ( β-
human chorionic gonadotropin [β -HCG]) at the time of entry into the long -term optional 
follow -up treatment period -2. 
3. Males and females of child -bearing potential who are sexually active, or are not currently 
sexually active, but become sexually active du ring the study or for [ADDRESS_1147512] agree to use acceptable contraception during the study.  
4. Informed consent and assent (per IRB/EC) as appropriate.  
5. Caregivers (and age appropriate subjects) must have access to phone f or scheduled calls 
from study site.  
6. Caregivers (and age appropriate subjects) must be willing to follow the rules of eDiary 
completion.  
Exclusion Criteria:  
All exclusion criteria for the original LUM001 -[ADDRESS_1147513] will receive one of the following dose 
levels during the stable dosing, safety monitoring, and long -term, optional, follow -up treatment 
periods:  
• LUM001 35 μg/kg/day (up to a maximum daily dose of 2 .5 mg).  
• LUM001 70 μg/kg/day (up to a maximum daily dose of 5 mg).  
• LUM001 140 μg/kg/day (up to a maximum daily dose of 10 mg).  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 19 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 • LUM001 280 μg/kg/day (up to a maximum daily dose of 20 mg).  
Study Drug 
Dosage and 
Administration  Study drug will be prepared by a central pharmacy based on the subject’s weight. During the 
study, weight will be monitored at each visit. A change from baseline in a subject’s weight that 
is greater than 10% will require a dose adjustment. Each subsequent 10% increase in weight 
will be  considered the new baseline for determination of future dose adjustments. Weight -based 
dose adjustments will be made by [CONTACT_827169]’s next 
LUM001 preparation.  
Study drug will be dispensed to subjects/caregivers at the study site. The appropriate amount of 
study drug will be dispensed at the Study Day [ADDRESS_1147514] (qAM, ac). 
Study drug should be administered approximately at the same time every day.  
Dose Escalation Period  
For subjects randomized to placebo in the LUM001 -[ADDRESS_1147515] 
4 weeks of the study will be increased at weekly intervals to 140 μg/kg/day, or to a maximum 
tolerated dose below 140  μg/kg/day (10 mg maximum total dose) . For sub jects who were 
randomized to receive active drug in the LUM001 -[ADDRESS_1147516] according to a 
specified dose -escalation regimen. This regimen will represent a real dose escalation for 
subjects previously randomized to placebo and a mock  dose escalation for subjects previously 
randomized to active study treatment.  
The dosing regimen for each treatment group during the dose escalation period is summarized 
in the following table.  
 
 
LUM001 -301 
Protocol  Extension Study Protocol LUM001 -305 
Dose Escalation Period  
Week 13  
(μg/kg/day)  Week 1  
Days 1 - 7 
(μg/kg/day)  Week 2  
Days 8 - 14 
(μg/kg/day)  Week 3  
Days 15 - 21 
(μg/kg/day)  Week 4  
Days 22 - 28 
(μg/kg/day)  
Placebo [ADDRESS_1147517] 4 weeks 
of the study will be increased at weekly intervals to 140  μg/kg/day, or to a maximum tolera ted 
dose below 140 μg/kg/day (10 mg maximum total dose) . 
2 LUM001 doses for subjects whose stable dose upon completion of the LUM001 -301 protocol was 
35 μg/kg/day will remain stable at  35 μg/kg/day, or to a maximum daily dose of 2.5 mg/day.  
3 LUM001 doses  for subjects whose stable dose upon completion of the LUM001 -301 protocol was 
70 μg/kg/day will remain stable at  70 μg/kg/day, or to a maximum daily dose of 5 mg/day.  
4 LUM001 doses for subjects whose stable dose upon completion of the LUM001 -301 protocol was 
140 μg/kg/day will remain stable at  140 μg/kg/day, or to a maximum daily dose of 10 mg/day.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 20 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 5 LUM001 doses for subjects whose stable dose upon completion of the LUM001 -301 protocol was 
280 μg/kg/day will remain stable at  280 μg/kg/day, or to a maximum daily dose of 20 mg/day.  
 
The primary anticipated adverse reaction or intolerance is gastrointestinal in nature (eg, 
diarrhea, abdominal pain, crampi[INVESTIGATOR_007], etc.). In the absence of GI intolerance, escalation to the 
next dose level for an individua l patient may occur at the investigator’s discretion, following a 
scheduled phone call or visit (see Schedule of Procedures, Section  16.1). 
If a subject experiences intolerance due to gastrointestinal symptoms,  the investigator, in 
consultation with the ChiLDReN protocol chair and Medical Monitor , may lower the dose to a 
previously tolerated dose for the remainder of the study.  
Dose Optimization Period  
Following the dose escalation peri od, the LUM001 dose for each subject may be increased and 
decreased by [CONTACT_827170] a dose level 
that is tolerated by [CONTACT_423]. Dose optimization will occur in a blinded, titrated manner with 
four dose levels available as treatment options: 35, 70, 140 or 280 μg/kg/day. Adjustments may 
occur at weekly intervals. Once an optimal LUM001 dose is achieved, the dose will be fixed for 
the duration of the study.  
 
The maximum daily dose of LUM001 in this study is 280 μg/kg/day, up to a maximum daily 
dose of [ADDRESS_1147518] further escalation if there are safety or tolerability concerns. Doses of 
LUM001 will not be increased above 280 μg/kg/day or 20 mg per day at any time.  
Stable Dosing and Safety Monitoring Periods  
At the e nd of the dose optimization period, subjects will continue dosing to complete the stable 
dosing and safety monitoring periods for up to 96  weeks of cumulative LUM001 exposure in 
this study.  
 
Subjects  who completed the 48 -week study prior to the implementa tion of Protocol Amendment 
#[ADDRESS_1147519] experiences intolerance due to gastrointestinal 
symptoms, the physician investig ator may lower the dose to a previously tolerated dose.  
Long -term Optional Follow -up Treatment Period:  
At Week 96, all subjects will be assessed by [CONTACT_827171] -term optional fo llow-up treatment period. Following the 
completion of the Week 96 study visit, subjects who choose to participate in the long -term 
optional follow -up treatment period will be maintained at the same Week 96 dose level. 
Subjects with dose interruptions >[ADDRESS_1147520]’s previously 
tolerated dose under Protoc ol Amendment 4. Subjects who do not wish to enter the long -term, 
optional follow -up treatment period will be contact[CONTACT_827172] [ADDRESS_1147521] received permission from the ChiLDReN protocol chair and the 
Medical Monitor , may be recontact[CONTACT_827173] -term, 
optional follow -up treatment period of the  study.  
Study drug administration under Protocol Amendment 5 will not change from Protocol 
Amendment 4.  
Long -term Optional Follow -up Treatment Period -2: 
At Week 144, all subjects will be assessed by [CONTACT_827174] -term optional follow -up treatment period -2. Following 
the completion of the Week [ADDRESS_1147522]’s previously achieved highest tolerated dose.  
Study drug for each subject will remain blinded and will be prepared by [CONTACT_827175]’s specified dose -escalation regimen.  
 
Dose Escalation Regimen for Resumption of LUM001 Dosing When Dosing Interruption 
is Greater Than 7 Consecutive Days  
Week 1  
 (μg/kg/day)  Week 2  
 (μg/kg/day)  Week 3  
 (μg/kg/day)  Week 4  
 (μg/kg/day)  
[ADDRESS_1147523]’s LUM001 dosing interruption is reached.  
 
 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147524] in healthy volunteers and subjects with 
hypercholesterolemia. In these subjects, with normal bile flow and without liver disease, 
tolerability was limited above 10 mg daily by [CONTACT_827176] (GI) AEs. These 
signs and symptoms are believed to be related to increased bile acid excretion and a 
concomitant increase in the concentration of free bile acids in the lower colon. Subjects with 
cholestatic liver disease have reduced bile flow compared to healthy volunteers and 
hypercholesterolemic subjec ts. LUM001 is likely to produce a smaller increase in free bile 
acids in the lower colon. There is also evidence in subjects with cholestasis to suggest that 
ASBT expression may be upregulated and higher LUM001 concentrations may be required to 
achieve the  desired target inhibition of ASBT.  
Dosing in pediatric subjects will be based on subject weight. Earlier studies in healthy 
volunteers and hypercholesterolemic subjects demonstrated that doses of 10 mg daily, 
equivalent to 140 µg/kg/day for a 70 kg subjec t, led to a decrease in serum bile acids by >50% 
following [ADDRESS_1147525] week of 
LUM001 dosing. After 2 to 3 weeks of continuous dosing the observed rates of events was 
similar to those in the placebo group. In a 4 -week dose finding study in healthy volunteers , a 
dose escalation regimen was evaluated to mitigate the risk of loose stools and diarrhea. When 
the LUM001 dose was increased after each 7 -day dosing period, to a m aximum of 5  mg daily, 
the incidence of GI -associated AEs in the LUM001 treated arm was reduced to rates 
comparable to those reported in the placebo group.   
The starting dose in this clinical trial may be as low as 14 µg/kg/day, is equivalent to less than 
the well -tolerated 1 mg dose (~17 µg/kg, 60 kg body weight) used in a previous study (Study 
014), where LUM001 was tested at doses up to 5 mg/day for 14 days in 40 hyperlipi[INVESTIGATOR_827142] (n=5, children ages 10 -11; n=35, adolescents ages 12 -17), A t the 1 mg dose 
in Study 014, only two out of eight subjects reported moderate or severe GI -associated AEs 
during 14 days. On a weight basis, 23 subjects received a dose ≥14 µg/kg/day. The highest 
starting dose in Study 014 was 168 µg/kg/day.  
To reduce the risk of loose stools and diarrhea in the current study, escalation of LUM001 
doses for LUM001 -naïve subjects will occur at 7 -day intervals starting at 14 µg/kg/day and 
increasing to 35 µg/kg/day, 70 µg/kg/day, and 140 µg/kg/day. Thereafter, t he dose of LUM001 
may be adjusted for all study subjects during the dose -optimization period. A minimum period 
of 7-days must elapse between increases in dose. Dose adjustments will be made at the 
investigator’s discretion with the goal of reaching a dose optimized for maximum efficacy and 
tolerability of 35, 70, 140 or 280  μg/kg/day.  
The dose may also be down -titrated, at the investigator’s discretion and in consultation with the 
ChiLDReN protocol chair and the Medical Monitor , for subjects experiencing i ntolerance to a 
given dose.  
Study Visit 
Schedule and 
Procedures  For an individual subject, the study participation period will consist of a [ADDRESS_1147526] dose of LUM001. Study activities will be 
conducted as described in the Schedule of Procedures (Section 16.1). 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 23 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 Study Scheme (as described below):  
Day 0-Week 48  
 
 
Week 49 – Week  96  
 
 
Week  96 – Week 148  
(no in terruption in LUM001 dosing, or interruption ≤7  days between Week 96 and Week 100 ) 
 
 
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 24 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
  
 
 
 
Week  96 – Week 148  
(interruption >7 days between Week 96 and Week 100 )  
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 25 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 Week  144 – Week 220  
 
 
Baseline (Day 0) : Evaluations and procedures completed for the Week 13 Visit of the 
LUM001 -301 study will also serve as the evaluations for the Baseline Visit for the extension 
study. Informed consent and/or assent for participation in the extension study must be obtained 
for all participating subjects and their parents or legal guardians, as appropriate. At the Baseline 
visit (Week 0), subjects will be assessed to confirm continued study eligibility including a 
review of medical history and will undergo a physical examinati on including body weight, 
height, and vital signs. Blood and urine samples will be taken for clinical laboratory testing, 
including a fasting lipid panel and determination of fat -soluble vitamins, bile acids and other 
cholestasis biochemical markers as wel l as for PK analysis (plasma levels of LUM001). The 
clinician scratch scale will be administered, as well as the PedsQL. Female subjects of 
childbearing potential will have a urine pregnancy test and concomitant medications and any 
AEs will be recorded. Th e degree and severity of xanthomatosis will be evaluated for all 
subjects by [CONTACT_827177]. Study drug for Weeks 1 and 2 will be supplied at the 
Baseline visit to eligible subjects.  
Dose Escalation Period (Week 0 to Week 4) : Double -blind dos ing in the dose escalation period 
will be initiated on the morning after the Baseline Visit. Caregivers and age appropriate 
subjects will be instructed to complete their ItchRO electronic diary twice daily (morning and 
evening). Subjects will return to the  clinic at Weeks 2, and 4, and will receive follow -up phone 
calls at Weeks 1 and 3. On  clinic visit days, safety and clinical laboratory evaluations will be 
performed. The clinician scratch scale will be administered, adherence to study drug will be 
assess ed and additional dosing instructions will be supplied. Study diary compliance will be 
assessed and concomitant medications and any AEs will be recorded at clinic visits and at 
scheduled telephone contacts. Additional study drug will be supplied at Weeks 2  and 4.  
Dose Optimization Period (Week 5 to Week 12):  During the dose optimization period, the dose 
for each subject may be increased or decreased at the investigator’s discretion in a double -blind 
manner. The purpose of the dose optimization period is to allow the investigator to adjust the 
subject’s LUM001 dose to a level that is both tolerable to the subject and maximizes the 
potential effect of LUM001 on pruritus. Once an optimal dose is achieved, the dose will be 
fixed for the duration of the study.  
Electronic diaries will be completed twice daily by [CONTACT_654] -appropriate subjects and caregivers 
through Week 12 and then collected. Subjects will return to the clinic at Weeks 8 and 12 and 
will receive follow -up telephone calls at Weeks 6 and 10. At  the clinic visits, safety and clinical 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 26 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 laboratory evaluations will be performed and vital signs, height and weight measurements will 
be collected. The clinician scratch scale will be administered and a review of study diary and 
medication compliance will be completed . Concomitant medications and any AEs will be 
assessed and recorded at each visit and at scheduled telephone contacts. Additional study drug 
will be supplied at Weeks 8 and 12.  
Stable Dosing Treatment Period (Week 13 to Week 48) : Subjects will continue to  receive study 
drug during the stable dosing treatment period according to the dose achieved during the dose 
optimization period. However, if a subject experiences intolerance due to gastrointestinal 
symptoms, the investigator, in consultation with the Chi LDReN protocol chair and Medical 
Monitor , may lower the dose to a previously tolerated dose for the remainder of the study.  
During the stable dosing period, subjects will return to the clinic at Weeks 24, 36, 44 and 48. 
Subjects who undergo a dose change at the Week 12 visit will also return to the clinic at Week 
16 (see below). With the exception of Week 44, safety and clinical laboratory evaluations, 
blood sampling for study drug determination, and a physical exam (including collection of vital 
signs, he ight and weight measurements) will be completed at each clinic visit. In addition, the 
clinician scratch scale and clinician xanthoma scale will be administered and study drug 
compliance will be assessed. The PedsQL will be completed at Weeks 24 and 48 the  Caregiver 
Impression of Change (CIC) will be completed at Week 48. Subjects/caregivers will receive 
follow -up phone calls at Weeks 16, 20, 28, 32 and 40. Concomitant medications and any AEs 
will be evaluated and recorded at all clinic visits and at schedu led telephone contacts.  
Subjects who undergo a dose change at the Week 12 visit will complete an on -site clinic visit at 
Week 16. Subjects who do not undergo a dose change at Week 12 will receive a follow -up 
phone call at Week 16. The study activities tha t will be conducted at the Week 16 clinic visit 
are described in the Schedule of Procedures (Section  16.1). 
Electronic diaries will be completed by [CONTACT_654] -appropriate su bjects and caregivers following the 
Week 24 and Week 44 visits. The diaries will be redistributed at Week  24 and completed twice 
daily for 4 weeks before being collected at Week 28. The diaries will then be redistributed at 
Week 44 and completed twice daily until the end of the study (Week 48). Re -training on the use 
of the diary will occur as appropriate at the Week 24 and Week 44 visits.  
At the physician investigator’s discretion, tapering or withdrawal of concomitant medications 
used for the treatment of pruritus may occur during the stable dosing  period.  
With the exception of Week 44, additional study drug will be supplied at each clinic visit 
during the stable dosing period.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 27 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 Safety Monitoring Period (Week 49 to Week 96) : During the safety monitoring period, subjects 
will return to the clinic ev ery 3  months, at Weeks 60, 72, 84, and 96.  
Safety and clinical laboratory evaluations and a physical exam (including collection of vital signs, 
height, and weight measurements) will be completed at each clinic visit. The clinician scratch 
scale will also be completed at each clinic visit and study drug compliance will be assessed. The 
PedsQL, CIC, and the Clinician Xanthoma scale will also be administered  at Weeks 60, 72, 84, and 
96. Subjects/caregivers will receive follow -up phone calls at Weeks 52, 56, 6 4, 68, 76, 80, 88, 
and 92. Concomitant medications and any AEs will be evaluated and recorded at all clinic visits 
and at scheduled telephone contacts.  
Twice daily completion of the ItchRO electronic diary will be required by [CONTACT_827178] 2 weeks following the Week 60, 72, 84, and 96 clinic visits. 
Review of electronic diary data and assessment of compliance will occu r during scheduled 
telephone contacts at Week 64, 76, and 88 and during the Week 96 clinic visit. Electronic 
diaries will be provided to subjects and caregivers at these visits and re -training on the use of 
the diary will occur, as appropriate.  
At the phy sician investigator’s discretion, withdrawal of concomitant medications used for the 
treatment of pruritus may occur during the safety monitoring period.  
Additional study drug will be supplied at each clinic visit during the follow -up treatment 
period.  
Week 96:  Subjects will be evaluated by [CONTACT_827179] -term, optional follow -up treatment period. This will include a formal 
reassessment of the Protocol Amendment [ADDRESS_1147527] documented consents in 
order to continue in the long -term, optional follow -up treatment period. A physical exam 
(including collection of vital signs, height and we ight measurements) will be performed. Blood 
and urine samples will be taken for clinical laboratory testing, including a fasting lipid panel 
and determination of fat -soluble vitamins, bile acids and other cholestasis biochemical markers, 
as well as for PK analysis (plasma levels of LUM001). The clinician scratch scale and PedsQL 
will be administered and the degree and severity of xanthomatosis will be evaluated for all 
subjects using the clinician xanthoma scale. Review of the ItchRO electronic diary data a nd 
assessment of compliance will occur during the Week [ADDRESS_1147528] dose of 
study drug.  
Follow -up Phone Call ([ADDRESS_1147529] Dose) : For subjects who do not roll over into the 
long-term, optional follow -up treatment period , a safety follow -up phone call w ill be made 
[ADDRESS_1147530] who terminates from the  study early. Concomitant medications 
and any AEs noted during this phone call will be recorded. For subjects who participate in the 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 28 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 long-term, optional follow -up treatment period, this phone call will be replaced by [CONTACT_56421] 
148 end of study (EOS) clinic visit.  For subjects who participate in the long -term, optional 
follow -up treatment period -2, this phone call will be replaced by [CONTACT_56421] 220 (EOS) clinic 
visit.  
Long -term, Optional Follow -up Treatment Period (Week 96 -148):  Once Protocol Amendment 
[ADDRESS_1147531] of the 
following occurs:  
(i) The subjects com plete 48 weeks of additional treatment after Week 96 (safety 
monitoring period)  
(ii) The subjects are eligible and consent to enter another LUM001 study  
Subjects with no LUM001 dosing interruptions or interruptions ≤[ADDRESS_1147532] received during LUM001 -305 (Week  96 dose). Study 
activities will proceed as outlined in Schedule D.  
Subjects with LUM001 dosing interruptions >7 days will be rescreened and dose escalated 
up to 280 µg/kg/day or the highest tolerated  dose over 4 weeks beginning at 35  µg/kg/day (see 
Figure 6). Study activities will proceed as outlined below and in Schedule E.  
• Protocol Amendment (PA) 5 Re -initiating  (RI) Day -2 Clinic Visit:  Consent (and/or 
assent as applicable) are obtained; eligibilit y criteria are confirmed. Physical 
examination (body weight, height, vital signs) is performed; blood and urine samples 
collected for clinical laboratory testing. Female subjects of childbearing potential will 
have a serum pregnancy test. Concomitant medic ations and AEs will be recorded.  
• PA5 RI Day 0 Clinic Visit:  Eligibility criteria are confirmed. Physical examination 
(body weight, height, vital signs) is performed; blood and urine samples collected for 
clinical laboratory testing. Female subjects of chil dbearing potential will have a serum 
pregnancy test. Clinician scratch scale, clinician xanthoma scale, and PedsQL are 
completed. Concomitant medications and AEs will be recorded. Study drug is 
dispensed and subject begins dosing at 35 μg/kg/day dose level . 
• PA5 RI Week [ADDRESS_1147533]:  Concomitant medications and AEs will be 
recorded. Subject escalates to 70 μg/kg/day dose level if prior dose level was tolerated.  
• PA5 RI Week 2 Clinic Visit:  Physical examination (body weight, height, vital signs) is 
performed; blood and urine samples col lected for clinical laboratory testing. Female 
subjects of childbearing potential will have a serum pregnancy test. Clinician scratch 
scale, clinician xanthoma scale, and PedsQL are completed. Concomitant medications 
and AEs will be recorded. Study drug is  dispensed and subject escalates to 
140 μg/kg/day dose, if prior dose level was tolerated.  
• PA5 RI Week [ADDRESS_1147534]:  Concomitant medications and AEs will be 
recorded. Subject escalates to 280 µg/kg/day dose level or previous maximum 
tolerated dose, if prior dose level was tolerated.  
• PA5 RI Week 4 Clinic Visit:  Physical examination (body weight, height, vital signs) is 
performed; blood and urine samples collected for clinical laboratory testing. Female 
subjects of childbearing potential will have a se rum pregnancy test. Clinician scratch 
scale, clinician xanthoma scale, and PedsQL are completed. The ItchRO electronic 
diaries will be provided to subjects and caregivers and re -training on the use of the 
diary will occur, as appropriate. Twice daily compl etion of the electronic diary will be 
required during the [ADDRESS_1147535] continues dosing at 
280 µg/kg/day dose level or on maximum tolerated dose.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 29 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 • PA5 Sch edule D Week [ADDRESS_1147536] (4 weeks after PA5 RI Week 4 Clinic 
Visit):  Concomitant medications and AEs will be recorded. Subjects will then follow 
study activities as outlined in Schedule D.  
Per Schedule D, subjects will return to the clinic every 12 weeks at Weeks 108, 120, 132, 144, 
(end of treatment/early termination [EOT/ET]), and at Week 148 (EOS). During the clinic 
visits, physical exam, body weight and height, vital signs, urine samples, and blood samples for 
clinical laboratory testing inclu ding fasting lipid panel and fat soluble vitamins, bile acids, and 
other cholestasis biochemical markers will be collected. ItchRO compliance will be assessed, 
the electronic diary will be issued, the clinician scratch scale and the clinician xanthoma scal e 
will be assessed at every clinic visit. The PedsQL questionnaire and CIC will be administered at 
Weeks 108, [ADDRESS_1147537] will o ccur at Weeks 100, 104, 112, 116, 124, 128, 136, and 140 where 
collection of concomitant medications and any AEs will be recorded.  
Week 144:  Subjects will be evaluated by [CONTACT_827179] -term, optional follow -up treatment period -2. This will include a formal 
reassessment of the Protocol Amendment [ADDRESS_1147538] documented consents in 
order to continue in the long -term, optional  follow -up treatment period -2. Subjects who 
withdraw from the study prior to completion of the long -term, optional follow -up treatment 
period, should also undergo the procedures specified for the EOT/ET visit (Week  144). These 
procedures include a physical exam (including collection of vital signs, height and weight 
measurements), blood and urine sampling for safety and clinical laboratory evaluations 
(including a fasting lipid panel, determination of fat -soluble vi tamins, bile acids and other 
cholestasis biochemical markers, as well as for PK analysis plasma levels of LUM001). In 
addition, the following assessments should be completed: the clinician scratch scale, the 
PedsQL and the clinician xanthoma scale. The CIC  assessment will be completed. Female 
subjects of childbearing potential will have a urine pregnancy test. Concomitant medications 
and any AEs will be recorded. Study drug compliance will also be assessed and all used and 
unused study drug and study suppli es will be collected. Study drug will be discontinued at this 
visit if the subject chooses not to participate in the long -term, optional treatment period -2. 
Review of the ItchRO electronic diary data and assessment of compliance will occur during the 
Week 144 clinic visit. The electronic diaries will be provided to subjects and caregivers and 
retraining on the use of the diary will occur, as appropriate. Twice daily completion of the diary 
will be required for 2 weeks following the Week 144 clinic visit for  subjects rolling over into 
the long -term, optional follow -up treatment period -2. Subjects not rolling over into long -term, 
optional follow -up treatment period -2 will be asked to complete the diary for 4 weeks following 
Week  144.  
Week 148 : Subjects who ei ther elect not to participate in, or who are not eligible to participate 
in the long -term, optional, follow -up treatment period -[ADDRESS_1147539] dose of study drug and undergo the procedures specified for the EOS visit  
(Week  148). These procedures include a physical exam (including collection of vital signs, 
height and weight measurements), blood and urine sampling for safety and clinical laboratory 
evaluations (including a fasting lipid panel, determination of fat -soluble vitamins, bile acids and 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 30 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 other cholestasis biochemical markers, as well as for PK analysis plasma levels of LUM001). In 
addition, the following assessments should be completed: the clinician scratch scale, the 
PedsQL, the clinician xanthoma scale, and the CIC. Female subjects of childbearing potential 
will have a urine pregnancy test. Concomitant medications and any AEs will be recorded.  
Long -term Optional Follow -up Treatment Period -2 (Week 144 - 220): Once Protocol 
Amendment [ADDRESS_1147540] of the following occurs:  
(i) The subjects complete 72 weeks of additional treatment after We ek 144 (long -term, 
optional follow -up treatment period)  
(ii) The subjects are eligible and consent to enter another LUM001 (SHP625) study  
Subjects rolling over into the long -term optional follow -up treatment period -[ADDRESS_1147541] received during LUM001 -305 (Week 144 dose) (refer 
to Figure 7). Study activities will proceed as outlined in Schedule of Procedures F. Subjects 
with dose interruptions after Week 48 and prior to Week 96 , or who early terminated , may re -
enter the study  with the permission from  the sponsor and the ChiLDReN protocol chair . These 
subjects will initiate dose escalation at visit PA5 RI -2 (per Schedule of Procedures E) and then 
will follow study activities beginning at Week 104 (per Schedule of P rocedures D).  
Per Schedule of Procedures F, subjects will return to the clinic every 12 weeks at Weeks 156, 
168, 180, 192, 204, 216 (EOT/ET visit) and at Week 220 (EOS visit). During the clinic visits, 
physical exam, body weight and height, vital signs, ur ine samples, and blood samples for 
clinical laboratory testing including fasting lipid panel and fat soluble vitamins, bile acids, and 
other cholestasis biochemical markers will be collected. The clinician scratch scale and 
clinician xanthoma scale will be  assessed at every clinic visit. The PedsQL questionnaire and 
the CIC will be administered at Weeks 156, 216 and 220 clinic visits. The ItchRO electronic 
diaries will be provided to subjects and caregivers and retraining on the use of the diary will 
occur,  as appropriate. Caregivers are not required to complete the eDiary (ItchRO[Obs]) if the 
subject is living separately from the ItchRO observer; however, subjects ≥9 years of age will be 
required to complete ItchRO(Pt). Twice daily completion of the electro nic diary will be 
required during the 2 weeks following the Week 144, 156, 168, 180, 192, and 204 clinic visits 
and during the 4 weeks following the Week 216 (EOT/ET) visit. Review of the ItchRO 
electronic diary data and assessment of compliance will occur  during scheduled telephone 
contacts at Week 148, 160, 172, 184, 196, [ADDRESS_1147542] will occur at Weeks 148, 152, 160, 164, 172, 176, 184, 188, 196, 200, 208 
and 212 where collection of concomitant medications and any AEs will be recorded.  
Week 216 (EOT/ET):  Subjects who either complete the long -term optional follow -up treatment 
period -2 or who withdraw from the study prior to completion should undergo the procedures 
specified for the EOT/ET visit (Week 216). These procedures include a physical exam 
(including collection of vital signs, height and weight measurements), blood and urine sampling 
for safety and  clinical laboratory evaluations (including a fasting lipid panel, determination of 
fat-soluble vitamins, bile acids and other cholestasis biochemical markers, as well as for PK 
analysis of LUM001 plasma levels In addition, the following assessments should be completed: 
the clinician scratch scale, the PedsQL, the clinician xanthoma scale, and the CIC. Female 
subje cts of childbearing potential will have a urine pregnancy test. Concomitant medications 
and any AEs will be recorded. Study drug compliance will also be assessed and all used and 
unused study drug and study supplies will be collected. Study drug will be di scontinued at this 
visit.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 31 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 Week 220 (EOS):  All subjects will return to the study site [ADDRESS_1147543] dose of study 
drug and undergo the procedures specified for the EOS visit (Week  220). These procedures 
include a physical exam (including collection  of vital signs, height and weight measurements), 
blood and urine sampling for safety and clinical laboratory evaluations (including a fasting lipid 
panel, determination of fat -soluble vitamins, bile acids and other cholestasis biochemical 
markers, as well  as for PK analysis plasma levels of LUM001). In addition, the following 
assessments should be completed: the clinician scratch scale, the PedsQL, the clinician 
xanthoma scale, and the CIC. Female subjects of childbearing potential will have a urine 
pregna ncy test. Concomitant medications and any AEs will be recorded.  
Drug Level 
Evaluations  Plasma levels of LUM001 will be evaluated at Baseline and Weeks 2, 4, 8, 12, 24, 36, 48, 96, 
216 (EOT/ET) and 220 (EOS). Blood will be drawn approximately [ADDRESS_1147544]-dosing for 
drug level analysis .  
Safety and 
Tolerability 
Evaluations  The safety and tolerability of LUM001 will be assessed by [CONTACT_67484], 
relationship to study drug,  severity and seriousness of treatment -emergent AEs, withdrawals 
due to AEs, and changes in vital signs, laboratory and other safety parameters.  
Alterations in liver parameters assessed for the purposes of safety monitoring will be relative to 
the baseline (Day 0) of the LUM001 -[ADDRESS_1147545] (DSMB) will review SAE data, other key subject safety and 
study data at specified intervals for the duration of the study.  
Efficacy 
Evaluations  The primary evaluation will be the mean change from baseline (Day 0) of LUM0 01-301 and 
baseline (Day 0) of LUM001 -305 to Week 48  in:  
• Fasting serum bile acid level.  
Secondary evaluations will be the mean change from baseline (Day 0) of LUM001 -301 and 
baseline (Day 0) of LUM001 -305 through Week 216/EOT in:  
• Biochemical markers of cholestasis and liver disease (eg, alanine aminotransferase [ALT], 
alkaline phosphate [ALP], gamma -glutamyltransferase [ GGT] and bilirubin [total and 
direct]) . 
• Pruritus as measured by [CONTACT_827180] (ItchRO(Obs)TM, careg iver 
instrument/ItchRO(Pt) TM patient instrument).  
• During the first 12 weeks of the study, the electronic diary (ItchRO) will be completed 
twice daily (AM & PM). During th e stable dosing period (Weeks  13-48), twice daily 
completion of the electronic diary (ItchRO) for 4  consecutive weeks will be required 
following the Week 24 and Week 44 clinic visits. For subjects who continue in the 
safety monitoring period, twice daily completion of the ItchRO will be required for 2 
consecutive weeks following the Week 6 0, 72, and 84 clinic visits. For subjects who 
continue in the long -term optional follow -up treatment period, twice daily completion 
of the ItchRO will be required for 2 consecutive weeks following the Week 96, 108, 
120 and 132 clinic visits and for 4 weeks  following the Week 144 visit. For subjects 
who continue in the long -term optional follow -up treatment period -2, twice daily 
completion of the ItchRO will be required for 2 consecutive weeks following the 
Week 144, 156, 168, 180, 192, and 204 clinic visits , and for 4 weeks following the 
Week 216 visit.  
• Xanthomas as measured by [CONTACT_827181].  
• Clinician scratch scale  
• Fasting serum bile acid levels  
The exploratory evaluation will be the mean change in weight z -score from baseline (Day 0) of 
LUM001 -301 and baseline (Day 0) of LUM001 -305 through Week 216 (EOT/ET).  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 32 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 Exploratory evaluations will include the mean change from baseline in ItchRO, fasting sBA, 
and biochemical markers of cholestasis and liver disease at Week 144, Week 216 (EOT/ET), 
and at Week  220 (EOS).  
Additional exploratory evaluations will be specified in the statistical analysis plan and may 
include analyses between Week 144 (EOT/ET) and Week 148 (EOS) for subjects who 
complete Protocol Amendment 5 and between Week 216 (EOT/ET) and Week 220 (EOS) for 
subjects who complete Protocol Amendment 6.  
Statistical 
Considerations  Sample Size  
Approximately 36 subjects meeting the study’s inclusion and exclusion criteria will be enrolled 
in the study. The number of subjects enrolled in this study will be determi ned by [CONTACT_827182] -over from the LUM001 -[ADDRESS_1147546] one dose of the study drug during the extension study.  
Adverse Events will be examined over the entire treatment period, and for the dose escalat ion 
and optimization periods. Adverse events for each study period will be summarized overall by 
[CONTACT_827183] 
(Study Day 0). Adverse events for the stable dosing period will a lso be summarized overall and 
by [CONTACT_827184].  
 
Other safety measures including clinical laboratory tests, vital signs, physical exams, and 
concomitant medication usage will be summarized descriptively. For quantitative variables, 
descriptive statistics including number of observations, mean, median, standard deviation and 
range will be given for the values themselves and by [CONTACT_827185] -defined 
reference points (see below) at each visit. Qualitative variab les will be summarized using 
counts and percentages by [CONTACT_827186].  
Drug Level Analysis  
Descriptive statistics analysis of LUM001 concentrations will be carried out on the plasma 
concentration data.  
Efficacy  
All efficacy a nalyses will also be performed on the Safety Population, defined as all subjects 
who received at least one dose of the study drug during the extension study.  
Secondary efficacy measures will be analyzed similarly as above. Details of the analysis 
methods w ill be outlined in the SAP.  
All data will be included in data listings.  
 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147547] OF ABBREVIATION S AND TERMS  
Abbreviation  Definition  
μg microgram  
μM micromolar  
7αC4, C4  7α-hydroxy -4-cholesten -3-one; an indirect method of bile acid synthesis  
AE adverse event  
ALGS  Alagille syndrome  
ALP  alkaline phosphatase  
ALT  alanine aminotransferase (SGPT)  
aPTT  activated partial thromboplastin time  
ASBT  api[INVESTIGATOR_14408] -dependent bile acid transporter  
ASBTi  api[INVESTIGATOR_14408] -dependent bile acid transporter inhibitor  
AST  aspartate aminotransferase (SGOT)  
ATC  Anatomic Therapeutic Chemical; classification for drugs  
β-hCG  beta-subunit of human chorionic gonadotropin; pregnancy test  
BA bile acid  
BP blood pressure  
CBC  complete blood count  
CFR  Code of Federal Regulations  
cholesterol 7α -hydroxylase  rate-limiting enzyme in the synthesis of bile acid from cholesterol  
CIC Caregiver Impression of Change  
CMV IgM  cytomegalovirus IgM antibody  
CRF  case report form  
CS clinically significant  
CTCAE  Common Terminology Criteria for Adverse Events  
CV curriculum vitae  
dL deciliter  
DSMB  Data Safety Monitoring Board  
EC Ethics Committee  
eCRF  electronic case report form  
EOS  end of study  
EOT  end of treatment  
ET early termination  
FDA  Food and Drug Administration  
FGF-[ADDRESS_1147548] growth factor 19; regulates carbohydrate, lipid and bile acid 
metabolism  
FGF-[ADDRESS_1147549] growth factor 21; modulates hepatic metabolism  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 34 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 Abbreviation  Definition  
G gram  
GCP  good clinical practices  
GGT  gamma -glutamyltransferase  
GGTP (γGTP)  gamma -glutamyl transpeptidase  
GI gastrointestinal  
HAV IgM  Hepatitis A virus IgM antibody  
HbsAg  surface antigen of the hepatitis B virus  
HCV  Hepatitis C virus  
HDL  high-density lipoprotein  
HDL -C high-density lipoprotein cholesterol  
HR heart rate  
HRQoL  health related quality of life  
IAF informed assent form  
IB Investigator’s Brochure  
IBAT  ileal bile acid transporter  
IBATi  ileal bile acid transporter inhibitor  
ICF informed consent form  
ICH International Conference on Harmonization  
INR international normalized ratio  
IRB institutional review board  
ItchRO ™ Itch Reported Outcome  
ItchRO(Obs) ™ Itch Reported Outcome observer instrument  
ItchRO(Pt) ™ Itch Reported Outcome patient instrument  
IUD intrauterine device  
Kg kilogram  
L liter 
LDL  low-density lipoprotein  
LDL -C low-density lipoprotein cholesterol  
LPA  lysophosphatidic acid  
MCH  mean corpuscular hemoglobin  
MCHC  mean corpuscular hemoglobin concentration  
MCV  mean corpuscular volume  
MedDRA  Medical Dictionary for Regulatory Activities  
mg milligram  
mL milliliter  
mmol  millimole  
MRI  magnetic resonance imaging  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 35 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 Abbreviation  Definition  
NBD  nasobiliary drainage  
NCS  not clinically significant  
ObsRO  observer reported outcome  
PA Protocol amendment  
PBC  primary biliary cirrhosis  
PEBD  partial external biliary diversion  
PedsQL  Pediatric Quality of Life Inventory  
PFIC  progressive familial intrahepatic cholestasis  
PI [INVESTIGATOR_827143]  
q.s. quantity sufficient  
qAM  every morning  
SAE  serious adverse event  
SAP statistical analysis plan  
SD-5613  original designation for LUM001  
Sec second  
SLC10A2  solute carrier family 10 member 2; gene that encodes ASBT protein  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
TG triglycerides  
UDCA  ursodeoxycholic acid  
ULN  upper limit of normal  
US, [LOCATION_003]  [LOCATION_002] of America  
WBC  white blood cell  
WHO  World Health Organization  
WMA  World Medical Association  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 36 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 3. STUDY OBJECTIVES  
The primary objective of the study is to:  
• Evaluate the long -term safety and tolerability of LUM001 in pediatric subjects with 
Alagille syndrome (ALGS).  
Secondary objectives of the study are to:  
• Evaluate the long -term effect of LUM001 on serum bile acid levels associated with 
ALGS.  
• Evaluate the long -term effect of LUM001 on pruritus associated with ALGS.  
• Explore the long -term effect of LUM001 on other biochemical markers of cholestas is and 
liver disease.  
• Evaluate the long -term effect of LUM001 on xanthomas associated with ALGS.  
• Explore an expanded dosing range to identify the doses necessary to achieve the optimal 
benefit -to-risk ratio for this patient population.  
Exploratory objectiv e of the study is to:  
• Evaluate the long -term effect of LUM001 on weight in pediatric subjects with ALGS.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 37 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 4. BACKGROUND AND RATIO NALE  
LUM001 is an inhibitor of the ileal bile acid transporter/api[INVESTIGATOR_14408] -dependent bile acid 
transporter/soluble carrier family 10 member 2 (IBAT/ASBT/SLC10A2), initially developed as a 
lipid lowering agent (SD -5613). At this time, further development for t his indication is not 
planned. By [CONTACT_827187], LUM001 is being developed as a 
therapeutic agent for signs and symptoms of cholestatic liver disease.  
4.1 Therapeutic Rationale  
Alagille syndrome (ALGS) is an example of cholestatic liver disease in children. In patients with 
ALGS, impairment of the egress of bile acids from the liver leads to cholestasis, hepatocellular 
injury and damage, and progressive liver disease that may ult imately lead to the need for liver 
transplantation. Itch is the archetypal symptom of cholestasis, occurring at all stages of 
cholestatic liver disease, with or without jaundice.  
Surgical interruption of the enterohepatic circulation in patients with chol estatic liver disease has 
been shown to be beneficial. However, complications do occur and many patients and their 
families are reluctant to accept a permanent external ostomy in spi[INVESTIGATOR_827144]. 
Pharmacological diversion of bile acids to th e distal gut with an ASBTi/IBATi could be an 
attractive alternative to surgical intervention in ALGS.  
LUM001 is a potent inhibitor of ASBT/IBAT. The ASBT/IBAT is present in the terminal 25% 
of the small intestine. This transporter mediates the uptake of c onjugated bile acids across the 
brush border membrane of the enterocyte. Additional proteins and transporters carry bile acids 
from the enterocyte through the intestinal wall into the blood stream, where they are circulated to 
the liver via the portal vein  and then re -secreted into the intestine in a system known as the 
enterohepatic circulation. Ninety -five percent of bile acids that enter the gut lumen are recycled 
to the gallbladder where they are stored for future release to the duodenum.  
Figure 1: Interruption of Enterohepatic Circulation with an ASBT/IBAT Inhibitor  
 
 
 
 
 
 
 
 
 
 
 
 
ASBT  
 
 
Preventing recycling, 
lowers bile acid (BA) 
levels in liver, preventing 
liver damage  
X 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 38 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 ASBT/IBAT expression is under negative feedback regulation by [CONTACT_5086]; thus in the setting of 
cholestasis, ASBT/IBAT is maladaptively upregulated ( Neimark et al., 2004 ) (Hofmann, 2003 ). 
Therefore, inhibiting the reuptake of bile acids may represent an ideal treatment for cholestatic 
disease. In the current study, ALGS will serve as models for generalized cholestasis. By 
[CONTACT_827188], LUM001 could interrupt the enterohepatic 
circulation and mimic the effects of partial external biliar y diversion (PEBD) or ileal exclusion. 
The current e xtension study will test this hypothesis.  
4.2 Alagille Syndrome  
Alagille syndrome (ALGS) is an autosomal dominant with variable penetration multisystem 
disorder. The clinical diagnosis is based on the presen ce of intrahepatic bile duct paucity on liver 
biopsy in association with at least three of the major clinical features: chronic cholestasis, cardiac 
disease, skeletal abnormalities, ocular abnormalities and characteristic facial features. Fewer than 
200 pa tients with ALGS are born each year in the [LOCATION_002]. The estimated prevalence in 
Europe is 1.4/100,000 ( Orphanet: The portal for rare diseases and orphan drugs ). Elevations of 
serum bilirubin up to [ADDRESS_1147550] damage, including gamma -glutamyltransferase 
(GGTP or GGT) and alkaline phosphatase (ALP), usually are significantly elevated. Cholesterol 
levels may  exceed 25.9 –51.7 mmol/L. Multiple xanthomas are com mon sequelae of severe 
cholestasis. The pruritus seen in patients with this condition i s among the most severe of any 
chronic liver disease and it is present in most children by [CONTACT_308128]. Al though surgical 
interruption of the enterohepatic circulation has been successfully employed in the treatment of 
cholestasis and hypercholesterolemia in ALGS ( Emerick and Whitington, 2002 ) (Modi et al., 
2007 ), the management of cholestasis in ALGS remains largely supportive at this time. As 
cholestasis  tends to improve over the first 5 to 10  years of life, therapi[INVESTIGATOR_827145], without a commitment to liver transplantation, are particularly 
attractive ( Emerick et al., 1999 ).  
4.3 Pruritus  
Patients with cholestatic liver disease frequently present with pruritus, w hich can be severe, even 
in the absence of jaundice. Elevation of serum bile acids is frequently accompanied by [CONTACT_99407], 
and a causal association between pruritus and bile acids is suggested by [CONTACT_716]:  (1) 
pruritus can been induced in volunteers by  [CONTACT_290537][INVESTIGATOR_827146], 
deoxycholate and chenodeoxycholate to the skin; and (2) pruritus can be relieved by [CONTACT_827189], which dramatically lowers serum bile acids. 
Nevertheless, the correlation  between the levels of serum and skin bile acids and the degree of 
pruritus is poor.  
Intractable and pharmacologically recalcitrant pruritus is one of the major morbidities afflicting 
children with ALGS or progressive familial intrahepatic cholestasis (PF IC). Treatment with 
antipruritics and bile salt resins may provide partial relief of itching for children with ALGS, but 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 39 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 currently available pharmacologic approaches are of limited value. It has been shown that 
removing bile with surgical procedures such a s partial external biliary diversion and nasal biliary 
drainage (NBD) substantially reduces pruritus in ALGS ( Emerick and Whitington, 2002 ), PFIC, 
and primary biliary cirrhosis (PBC). Almost complete resolution of  pruritus has been observed in 
children with PFIC disease in a period of as little as two to four weeks following the procedure. 
The rapid resolution of itch in response to therapy can be seen in Figure 2 extracted from the 
original description of this procedure by [CONTACT_827190] ( 1988 ). Rapid lowering of 
bile acids, bilirubin and ALT has also been observed ( Table  1). 
Figure 2: Serum Bile Salt Concentration and Degree of Itch  
 
Patient SR - serum bile salt concentration and degree of itch over a 4 -yr course. Nasoduodenal drainage (D) resulted 
in reduced serum bile salt concentration and itch. When medical management failed, a cholecystostomy tube was 
placed (S 1), resulting in a re duction in serum bile salt concentration to normal and the disappearance of itching. 
When the cholecystostomy tube was accidentally pulled out (A), the serum bile salt concentration and itching 
increased rapi[INVESTIGATOR_375]. The construction of a permanent cholecystos tomy (S 2) resulted in a quick return to normal, a state 
that has been maintained since. ( Whitington and Whitington, 1988 ). 
 
Table  1: Improvement in Biochemical Markers and Pruritus After Partial External 
Biliary Diversion in PFIC Disease and Alagille Syndrome Subjects  
 
Diagnosis  Age at  
Surgery  
(yrs)  Pruritus Score  
(0-4 Scale)*  Serum Bile 
Acids  
(µM)  Conjugated  
Bilirubin  
(µM)  Alanine  
Aminotransferase  
(IU/L)  
Pre Post Pre Post Pre Post Pre Post 
PFIC  3 4 0 226 2 24 0 140 30 
PFIC  9 4 0 225 3 80 0 193 13 
PFIC  3 4 0 275 9 17 0 155 69 
PFIC  3 4 0 218 5 68 10 141 64 
Alagille  12 4 1 - 2 153 37 164 77 198 168 
Alagille  6 4 1 317 25 50 15 248 305 
* 0 = no itching; 4 = itching with cutaneous mutilation and bleeding ( Whitington and Whitington, 1988 ) 
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 40 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 4.4 LUM001  
4.4.1 Nonclinical Studies  
[IP_ADDRESS]  Pharmacology  
LUM001 is a potent selective inhibitor of the ileal api[INVESTIGATOR_14408] -dependent bile transporter, a 
transmembrane protein localized on the luminal surface of ileal enterocytes, commonly referred 
to as ASBT/IBAT. The drug is a competitive inhibitor for bile acid substrate with a high affinity 
for the transporter. Nonclinical studies indicate that selectiv e inhibition of ASBT by [CONTACT_827191]001 
results in increased fecal bile acid excretion, inhibition of the postprandial rise in serum bile 
acids, and decrease in serum total cholesterol. It also increases the activity of hepatic cholesterol 
7α-hydroxylase and 3 -hydroxy-3-methyl -glutaryl -CoA (HMG -CoA) reductase, consistent with 
inhibition of bile acid reabsorption as the mechanism of action.  
[IP_ADDRESS]  Pharmacokinetics  
Because of its large molecular weight and the presence of a quaternary nitrogen atom, LUM001 
is poorly absorbed  from the gut. In rats and dogs, oral bioavailability was <  0.4% at all doses 
tested. LUM001 is metabolically stable after oral administration. After intravenous 
administration, the majority of drug is excreted in the feces, with approximately 5% excretion  in 
the urine.  
[IP_ADDRESS]  Toxicology  
A comprehensive assessment of LUM001 has been conducted in vitro and in animals. LUM001 
is not toxic at doses far higher than those that are pharmacologically active in mice, rats, dogs, 
and monkeys. The most significant effect ob served in rodents is a prolongation of coagulation 
time considered secondary to malabsorption of vitamin K, which in turn is related to inhibition of 
bile acid absorption, the pharmacologic effect of LUM001. Reversible prolongation of 
coagulation times was  observed primarily in male rats that are especially sensitive to agents that 
alter vitamin K absorption and may not be an appropriate model for predicting vitamin K 
malabsorption in humans. Acute oral doses up to 200 mg/kg LUM001 were well tolerated in 
dogs, with emesis as the primary dose -limiting toxicity. There was no evidence of mutagenic 
activity in vitro and no clastogenic activity in vitro or in vivo. Results from rat and rabbit 
embryo/fetal development studies with doses up to 1000 and 250 mg/kg/da y, respectively, 
showed no adverse effects on fetal growth and development. Additional toxicology information 
can be found in the Investigator’s Brochure (IB).  
4.4.2 Previous Clinical Experience  
Detailed information concerning the clinical studies conducted with  LUM001 can be found in 
the Investigator’s Brochure. A summary is included below.  
The overall objective of the initial clinical development plan was to evaluate the safety and 
efficacy of chronic, oral administration of LUM001 (tablet and capsule formulati ons) for the 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147551] been evaluated in a total 
of 12 clinical studies, including 2 studies that also tested sustained release formulations. Phase 1 
studies included a single and two multiple dose tolerability studies, an adsorption, distribution, 
metabolism, and excretion (ADME) study, a statin co -administration study, a statin interaction 
study, and a food composition st udy. Phase [ADDRESS_1147552] been exposed to LUM001 (immediate 
release) for up to [ADDRESS_1147553] increases in high -density lipoprotein 
cholesterol (HDL -C) and total triglycerides relative to placebo.  
Administration of LUM001 at doses up to [ADDRESS_1147554] commonly reported adverse drug reactions in 
LUM001 -treated subjects were abdo minal crampi[INVESTIGATOR_007] (pain) and diarrhea and loose stools. With 
the exception of a single serious adverse event (SAE) of cholecystitis no other SAEs possibly 
related or related to LUM001 have been reported, (over 1,400 subjects exposed).  
The majority of orally administered LUM001 was excreted intact in the feces along with a few 
minor metabolites. LUM001 exposure in adolescents and children (Study  014) was low and 
consistent with a drug that is minimally absorbed. Pharmacokinetic parameter s in adolescent and 
children subjects did not significantly differ from those seen in adult subjects.  
No clinically significant laboratory abnormalities were documented in LUM001 -treated subjects. 
LUM001 was associated with mild, often transient elevation s of serum ALT in a small 
percentage of subjects. Clinically significant (CS) reductions of serum fat -soluble vitamin levels 
were not observed with LUM001 treatment in humans; however, levels of the carotenoid 
-carotene were mildly reduced. No alterations  in coagulation parameters were observed, 
indicating no functional changes in vitamin K status. Fecal  fat excretion was not increased 
compared to placebo after four weeks of LUM001 treatment at doses up to 100  mg. 
One Phase 2 randomized, double -blind, plac ebo-controlled study has been completed in pediatric 
subjects from 12 months to 18 years with ALGS (LUM001 -302 – IMAGO). Thi s study 
evaluated the safety and efficacy of maralixibat in the treatment of cholestatic liver disease. All 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 42 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 subjects suffered from i ntractable pruritus explainable only by [CONTACT_142125]. The primary 
efficacy endpoint for this study, the change from baseline to Week 13/ET in fasting serum bile 
acid levels for maralixibat treatment in comparison with placebo treatment, was not met. Despi [INVESTIGATOR_827147], there were no significant differences in 
the serum bile acid level from baseline values to Week 13/ET in either the 140 μg/kg/day or the 
280 μg/kg/day treatment groups. Nominally significant improveme nts in Observer ItchRO 
average daily itch scores from baseline values to the Week 13/ET visit were noted in the  
140 μg/kg/day treatment group and in the overall maralixibat treatment group. Additionally, the 
Peds QL Scale (Parent) score compared with plac ebo treatment showed a significant 
improvement at Week 13/ET in the maralixibat 140 ug/kg/day and in the overall maralixibat 
treatment groups. There were no SAEs or deaths reported during the conduct of the study. 
Generally similar percentages of subjects experienced TEAEs in the active treatment groups (in 
the maralixibat 140 μg/kg/day treatment group, 6/6 subjects [100.0%] and in the maralixibat  
280 μg/kg/day treatment group, 7/8 subjects [87.5%]) versus 4/6 subjects (66.7%) who 
experienced a TEAE in the  placebo group. The majority of TEAEs reported in the overall 
maralixibat group were mild or moderate in severity (9/14 subjects [64.3%] and 4/14  subjects 
[28.6%], respectively). Reported events were generally consistent with the expected TEAEs 
including G I events and conditions associated with liver deterioration.  
4.[ADDRESS_1147555] in healthy volunteers and subjects with hypercholesterolemia and in 
the completed Phase 2 study completed in pediatric subjects with ALGS (LUM001 -302, see 
Section  4.4.2 ). In these subjects, with normal bile flow and without liver disease, tolerability was 
limited above [ADDRESS_1147556] been reported in the literature. Weaver, Austin, & Cole 
(1991 ) provided data indicating that the average length of the small intestine increases with age 
from birth through 20 years; this relationship followed a curve that is similar to t he height and 
weight growth curves. However, a plateau had not been reached at the maximum age examined 
(20 years), precluding predictions of intestinal length for older adults and thus scaling to infants 
and children based on estimated intestinal length . An analysis of intestin al length as a function of 
age, weight, and height in adult cadavers was conducted by [CONTACT_827192], Destrieux, Desme, 
Bertrand, & Velut ( 2002 ). Their analysis demonstrated that age had a negative and body weight a 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147557] mg/kg scaling.  For reference in an average adult subject, weighing 70 kg, a 
10 mg daily dose is equivalent to 140  µg/kg/day.  
Sample daily exposure (mg/day) across proposed dose levels for subjects ranging in weight from 
10-30 kg is depi[INVESTIGATOR_28071]  2. 
Table  2: Sample Daily Exposure (mg/day) in Pediatric Subjects  
Weight  
(kg) Dose Level 1 
(14 µg/kg/day)  Dose Level 2 
(35 µg/kg/day)  Dose Level 3 
(70 µg/kg/day)  Dose Level 4 
(140 µg/kg/day)  Dose Level 5 
(280 µg/kg/day)  
10 0.1 0.4 0.7 1.4 2.8 
15 0.2 0.5 1.1 2.1 4.2 
20 0.3 0.7 1.4 2.8 5.6 
25 0.4 0.9 1.8 3.5 7.0 
30 0.4 1.1 2.1 4.2 8.4 
 
In a previous study (Study 014), LUM001 was administered to 40 hyperlipi[INVESTIGATOR_827148] (n=5, children ages 10 -11; n=35, adolescents ages 12 -17), up to a maximum tested dose 
of 5 mg/day for [ADDRESS_1147558] weight in Study  014 was 60 kg and a 5  mg/day 
dose of LUM001 was approxim ately equivalent to 83  µg/kg/day. Plasma LUM001 exposure in 
adolescents and children was low (non -detectable <0.25cng/mL to 1.13 ng/mL) and consistent 
with a drug that is minimally absorbed. Detection of LUM001 in plasma samples was sporadic, 
both within a nd among subjects. In addition there does not appear to be a relationship with either 
subject age or gender. These data do not differ from the extensive pharmacokinetic data collected 
in adults to date. Although the bioavailability of LUM001 has not yet be en characterized in 
children younger than 10 years of age, the GI systems are functionally mature in children by 
[CONTACT_2902] 1 year of age ( Walthall et al., 2005 ) (van den Anker et al., 2011 ). This study will enroll 
children ages [ADDRESS_1147559] frequently reported AEs in all treatment groups (LUM001 and placebo) were diarrhea, 
abdominal pain, loose stools and nausea. Most AEs were assessed with a probable or uncertain 
relationship to study medicati on and were generally characterized as mild or moderate in 
severity, except for those in six subjects who experienced severe nausea, diarrhea or abdominal 
pain. These GI events usually resolved during continued treatment. Thirty -nine (39) out of [ADDRESS_1147560] seven days of LUM001 dosing, and observed at a four -fold lower 
frequency from Days 8 to 14. This is consistent with the extensive adult dosing experience, 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 44 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 where GI events were observed at levels similar to those i n the placebo group after two weeks of 
continuous dosing.  
To assess the effects of dose titration to mitigate dose -limiting adverse effects, LUM001 was 
evaluated in a 28 -day once -daily dosing study in healthy volunteers (Study 003). In one arm, the 
dose w as increased after each 7 -day dosing period, to a maximum of 5  mg daily (equivalent to a 
dose of 67 µg/kg/day, using the average subject weight). Using this dosing regimen, the 
incidence of GI -associated AEs was lower than those observed in the placebo gro up (Table  3) 
and in other treatment arms with constant dosing above and below 5 mg daily.  
Table  3: GI-associated Adverse Events in Study 003  
 GI Adverse Events  Placebo  
(n=20)  1 mg qAM  
(n=8)  2.5 mg qAM  
(n=25)  5 mg qAM  
(n=26)  0.5-5 mg qAM*  
(n=16)  
Abdominal pain  2 (10%)  3 (37%)  4 (16%)  5 (17%)  1 (6.3%)  
Constipation  2 (10%)  0 3 (12%)  0 0 
Diarrhea  1 (5%)  1 (12%)  5 (20%)  2 (7%)  0 
Nausea  0 0 1 (4%)  1 (4%)  0 
Pruritus Ani  0 0 6 (24%)  4 (15%)  0 
*Escalation regimen: 0.5 mg qAM (7 µg/kg/day) on Days 1 -7, 1 mg qAM (13 µg/kg/day) on Days 8 -14, 2.5 mg 
qAM (33 µg/kg/day) on Days 15 -21, 5 mg qAM (67 µg/kg/day) on Days 22 -28. Average body weight 75 kg.  
The appropriate efficacious dose of LUM001 for the lowering of bile acid concentrations and the 
reduction of pruritus in cholestatic populations is not known. However, earlier studies 
demonstrated that doses of 10 mg daily (equiv alent to 140  µg/kg/day for a [ADDRESS_1147561]) led to a 
decrease in serum bile acids in healthy volunteers by >50%. In the PFIC population, there is 
some evidence that ASBT is upregulated, suggesting that higher doses may be required to 
saturate transporters and reach the desired effect in PFIC disease.  
In the current LUM001 development program, the safety, tolerability and efficacy of LUM001 is 
being assessed for the first time in children with cholestatic liver disease associated with ALGS, 
12 months to 18 years. The starting dose in these clinical trials, 14  µg/kg/day, is equivalent to 
less than the well -tolerated 1 mg dose (~17 µg/kg, 60  kg body weight) used in Study 014, where 
LUM001 was tested at doses up to 5 mg/day for 14  days in 39 hyperlipi[INVESTIGATOR_827149]. 
At the 1 mg dose in Study014, only two out of eight subjects reported moderate or severe GI -
associated AEs during 14 days. On a weight basis, 23 subjects received a dose ≥14 µg/kg/day. 
The highest starting dose in Study 014 was 168 µg/kg/da y.  
To reduce the risk of loose stools and diarrhea in the current study, escalation of LUM001 doses 
for LUM001 -naïve subjects will occur at 7 -day intervals starting at 14  µg/kg/day and increasing 
to 35  µg/kg/day, 70 µg/kg/day, and 140 µg/kg/day. Thereafte r, the dose of LUM001 may be 
adjusted for all study subjects during the dose -optimization period. A minimum period of [ADDRESS_1147562] elapse between increases in dose. Dose adjustments will be made at the investigator’s 
discretion with the goal of reaching a d ose optimized for maximum efficacy and tolerability of 
either 35, 70, 140 or 280 μg/kg/day.  
The dose may also be down -titrated, at the investigator’s discretion and in consultation with the 
ChiLDReN protocol chair and the Medical Monitor , for subjects expe riencing intolerance to a 
given dose.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 46 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 5. INVESTIGATIONAL PLAN  
5.1 Study Design  
This is a multicenter, double -blind study of LUM001 in children >[ADDRESS_1147563] completed participation in the LUM001 -301 protocol. All subjects will 
receive active drug (LUM001) in the study. The study is divided into 6 parts: a dose escalation 
period, a dose optimization period, a stable dosing period, a safety monitoring period, and 2 long 
term, optional treatment periods.  
Dose Escalation Period  
All subjects entering the extension study will participate in a 4 -week double -blind dose 
escalation period during which:  
• Subjects randomized to receive placebo during the LUM001 -301 protocol will receive 
weekly dose increases of LUM001 up to a target dose of 1 40 μg/kg/day.  
• Subjects randomized to active drug during the LUM001 -[ADDRESS_1147564] and up to a maximum daily dose of 280 μg/kg LUM001 or [ADDRESS_1147565] on pruritus. Reductions in dose will be based on tolerability. At the 
investigator’s discretion, the doses for subjects who were previously down -titrated may be  
re-challenged during the dose optimization period. Each subject will receive one of the following 
dose levels:  
• LUM001 35 μg/kg/day.  
• LUM001 70 μg/kg/day.  
• LUM001 140 μg/kg/day.  
• LUM001 280 μg/kg/day.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147566] of the study.  
Long -term Optional Follow -up Treatment Period  
The long -term, optional follow -up treatment period is for eligible subjects w ho choose to remain 
on treatment with LUM001 following the initial 96 weeks. During this long -term, optional 
follow -up treatment period, subjects with dosing interruptions ≤7 days will remain on the same 
dose they were taking at Week 96 . Subjects with LUM0 01 dosing interruptions >[ADDRESS_1147567]’s previously achieved highest tolerated dose. 
Study drug for each subject wil l remain blinded and will be prepared by [CONTACT_827175]’s specified dose -escalation regimen. Subjects’ participation 
in the long -term, optional follow -up treatment period will continue until the first of the foll owing 
occur: (i) subjects complete 48 weeks of additional treatment (after Week 96 [safety monitoring 
period]), or (ii) the subjects are eligible to enter another LUM001 study.  
Long -term Optional Follow -up Treatment Period -[ADDRESS_1147568] according to the protocol’s specified dose -escalation regimen. 
Subjects’ participation in the long -term optional follow -up treatment period will continue unt il 
the first of the following occur: (i) subjects complete 72 weeks of additional treatment (after 
Week 144 [Long -term Optional Follow -up Treatment Period]), or (ii) the subjects are eligible to 
enter another LUM001 (SHP625) study.  
5.[ADDRESS_1147569] (DMB) will review adverse event (AE) data, other key subject safety 
and study data at specified intervals for the duration of the study. The  DMB will be composed of 
at least [ADDRESS_1147570] of the study: one or more 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147571] one biostatistician. The  DMB’s primary responsibility is to review the 
progress of the study, particularly with regard to safety and risk/benefit, and make 
recommendations to Sponsor to stop or modify the tria l if safety concerns are identified. Further 
details regarding the structure, function and operation of the DMB will be detailed in the DMB 
charter.  
5.3 Number of Study Centers  
This will be a multicenter study in approximately 12 clinical centers that partici pated in Study 
LUM001 -301. 
5.4 Number of Subjects  
Approximately 36 subjects meeting the study’s inclusion and exclusion criteria may be enrolled 
in the study.  
5.[ADDRESS_1147572] dose of LUM001.   
Study activities will be conducted as described in the Schedule of Procedures (Section  16.1).  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 49 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 Figure 3: Study Design for LUM001 -305 (Day 0 -Week 48)  
 
 
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 50 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 Figure 4: Safety Monitoring Period (Week  49-Week  96)  
*for subjects not rolling over into Protocol Amendment 5  
 
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 51 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 Figure 5: Long -term Optional Follow -up Treatment Period (Week 96 -Week  148)  
Applies to the following population:  
• Subjects w ith no interruption in LUM001 dosing or interruption ≤7  days between Week 
96 and Week 100 ) 
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 52 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 Figure 6: Long -term Optional Follow -up Treatment Period (Week 96 -Week  148)  
Applies to the following population:  
• Subjects who experienced an interruption in LUM001 dosing >7 consecutive days 
between  Week 96 and Week 100  

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 53 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 Figure 7: Long -term Optional Follow -up Treatment Period -2 (Week 144 -Week  220)  
 
 
5.5.1 Treatment  
The Week 13 Visit from the LUM001 -301 protocol will also serve as the Baseline Visit for the 
extension protocol. Eligible subjects will be enrolled in the extension study at the Baseline Visit 
(Day 0). Dosing with study drug will begin on Day 1, following the Baseline Visit on (Day 0).  
Study drug will be prepare d by a central pharmacy based on the subject’s weight. During the 
study, weight will be monitored at each visit. A change from Baseline in a subject’s weight that 
is greater than 10% will require a dose adjustment. Each subsequent 10% increase in weight wi ll 
be considered the new baseline for determination of future dose adjustments. The central 
pharmacy will make weight -based dose adjustments at the time of the subject’s next LUM001 
preparation.  
Diluent will be added by [CONTACT_827193][INVESTIGATOR_827150]. 
Study drug will be dispensed to subjects/caregivers at the study site. The  appropriate amount of 
study drug will be dispensed at the Study Day [ADDRESS_1147573] (qAM, ac). Study drug should be administered 
approximately at the same time every day.  

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 54 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 [IP_ADDRESS]  Dose Escalation Period  
For subjects ran domized to placebo in the LUM001 -[ADDRESS_1147574] 
4 weeks of the study will be increased at weekly intervals to 140  μg/kg/day, or to a max imum 
tolerated dose below 140 μg/kg/day (10  mg maximum total dose). For subjects who were 
randomized to receive active drug in the LUM001 -[ADDRESS_1147575] according to a specified 
dose-escalation regimen. This regimen will represent a real dose escalation for subjects 
previously randomized to placebo and a mock dose escalation for subjects previously 
randomized to active study treatment.  
The dosing regimen for each treatment group during the dose escalation period is summarized in 
Table  4.  
 
Table  4: Dose Escalation Regimens  
LUM001 -301 
Protocol  Extension Study Protocol LUM001 -305 
Dose Escalation Period  
Week 13  
(μg/kg/day)  Week 1  
Days 1 - 7 
(μg/kg/day)  Week 2  
Days 8 - 14 
(μg/kg/day)  Week 3  
Days 15 - 21 
(μg/kg/day)  Week 4  
Days 22 - 28 
(μg/kg/day)  
Placebo [ADDRESS_1147576] 4 weeks of the study will be increased at weekly 
intervals to 140 μg/kg/day, or to a maximum tolerated dose below 140 μg/kg/day (10  mg maximum total dose) . 
2 LUM001 doses for subjects whose stable dose upon completion of the LUM001 -301 protocol was 35  μg/kg/day will 
remain stable at 35 μg/kg/day, or to a maximum daily dose of 2.5 mg/day.  
3 LUM001 doses for subjects whose stable dose upon co mpletion of the LUM001 -301 protocol was 70  μg/kg/day will 
remain stable at 70 μg/kg/day, or to a maximum daily dose of 5 mg/day.  
4 LUM001 doses for subjects whose stable dose upon completion of the LUM001 -301 protocol was 140  μg/kg/day will 
remain stable at 140 μg/kg/day, or to a maximum daily dose of 10 mg/day.  
5 LUM001 doses for subjects whose stable dose upon completion of the LUM001 -301 protocol was 280  μg/kg/day will 
remain stable at 280 μg/kg/day, or to a maximum daily dose of 20 mg/day.  
The primary anticipated adverse reaction or intolerance is gastrointestinal in nature (eg,  diarrhea, 
abdominal pain, crampi[INVESTIGATOR_007], etc.). In the absence of GI intolerance, escalation to the next dose 
level for an individual subject may occur at the investigator’s discretion, following a scheduled 
phone call or visit (see Schedule of Procedures, Section  16.1). 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147577]/caregiver.  
[IP_ADDRESS]  Dose Optimization Period  
Following the dose escalation period, the LUM001 dose for each subject may be increased or 
decreased by [CONTACT_827194] a dose level that is tolerated by [CONTACT_423]. Dose optimization will occur in a blinded, 
titrated manner with four dose levels available as treatment options: 35, 70, 140 or 280 
μg/kg/day. Adjustments m ay occur at weekly intervals. Once an optimal LUM001 dose is 
achieved, the dose will be fixed for the duration of the study.  
The maximum daily dose of LUM001 in this study is 280 μg/kg/day, up to a maximum daily 
dose of [ADDRESS_1147578] 
further escalation if there are safety or tolerability concerns. Doses of LUM001 will not be 
increased above 280 μg/kg/day or 20  mg per day at any time.  
[IP_ADDRESS]  Stable Dosing and Safety Monitoring Periods  
At the e nd of the Dose Optimization Period, subjects will continue dosing to complete the stable 
dosing and safety monitoring periods for up to 96  weeks of cumulative LUM001 exposure in this 
study.  
Subjects who completed the 48 -week study prior to the implementat ion of Protocol 
Amendment  #[ADDRESS_1147579] (DMB) will 
review SAE data, other key subject safety and study data at specified intervals for the duration of 
the study.  
[IP_ADDRESS]  Long -term, Optional Follow -up Treatment Period  
At Week 96, all subjects will be assessed by [CONTACT_827171] -term, optional follow -up treatment period. Following the 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 56 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 completion  of the Week 96 study visit, subjects who choose to participate in the long -term, 
optional follow -up treatment period will be maintained at the same Week  96 dose level. Subjects 
with dose interruptions >[ADDRESS_1147580]’s previously tolerated dose under 
Protocol Amendment 4. Subjects who do not wish to enter  the long term, optional follow -up 
treatment period will be contact[CONTACT_827195] [ADDRESS_1147581] received permission from the ChiLDReN protocol chair and the Medical 
monitor , may be recontact[CONTACT_827173] -term optional follow -
up treatment period of the study.  
Study drug administration under Protocol Amendment 5 will not change from Protocol 
Amendment 4.  
[IP_ADDRESS]  Long -term, Optional Follow -up Treatment Period -[ADDRESS_1147582] r eceived permission from the ChiLDReN protocol chair and the Medical 
Monitor , may be recontact[CONTACT_827173] -term, optional follow -
up treatment period -2 of the study.  
Study Drug Administration under Protocol Amendment 6 wil l not change from Protocol 
Amendment 5.  
5.5.2 Dosing Interruptions  
[IP_ADDRESS]  Dose Escalation Following Dose Interruption  
Subjects with interruptions in LUM001 dosing of more than [ADDRESS_1147583]’s previously achieved highest tolerated dose. Study drug for each 
subject will remain blind ed and will be prepared by [CONTACT_827196]’s specified dose -escalation regimen ( Table  5).  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 57 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 Table  5: Dose Escalation Regimen for Re -initiation of LUM001 Dosing When 
Dosing Interruption is Greater than 7 Consecutive Days  
 Study Week  
Week 1  
(μg/kg/day)  Week 2  
(μg/kg/day)  Week 3  
(μg/kg/day)  Week 4  
(μg/kg/day)  
LUM001 Dose  [ADDRESS_1147584]’s LUM001 dosing interruption 
is reached.  
 
[IP_ADDRESS]  Visit Schedule Following Dose Interruption for Stable Dosing and Safety 
Monitoring Periods  
Upon re -initiation of study drug, subjects who undergo a dosing interruption of greater than 7 
consecutive days will follow the same visit schedule and procedures that are specified for the 
Baseline Day 0 Visit (Section 8.1.1 ) and during Dose Escalation Treatment Period (Section 
8.1.2 ). Completion of the ItchRO electronic diary, however, will not be required during this time. 
The visit schedule upon re -initiation of LUM001 dosing is shown in Figure 8. 
Figure 8: Visit Schedule for Re -initiation of LUM001 when Dosing Interruption is 
Greater than 7 Consecutive Days  
 
 
 
Subjects with dosing interrupt ions of greater than 7 consecutive days will require reintegration in 
the study to ensure that 1) their resumed visit schedule aligns with the protocol, and 2) their total 
LUM001 exposure during the study does not exceed [ADDRESS_1147585] visit upon dose 
re-initiation (“RI Day 0” in Figure 8) should be assigned to that same Clinic Visit. If the decision 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147586] visit upon dose re -initiation (“RI Day 
0”) should be assigned to the next Clinic Visit. Table  [ADDRESS_1147587] study 
visit upon dose re -initiation based on when the dosing interruption occurred.  
Table  6: Dosing Interruptions: Reintegration to Study Visit Schedule  
Dosing Interruption  Assignment of  
First Dose Re -initiation Study Visit  
Between Weeks 13 - 24 Week 24  
Between Weeks 25 - 36 Week 36  
Between Weeks 37 - 48 Week 48  
Between Weeks 49 - 60 Week 60  
Between Weeks 61 - 72 Week 72  
Between Weeks 73 - 84 Week 84  
 
After Week 84  To be managed on a case -by-case basis in consultation with 
the Medical Monitor and ChiLDReN Protocol Chair  
 
[IP_ADDRESS]  Visit Schedule Following Dose Interruption for Long -term, Optional 
Follow -up Treatment Period  
Upon re -initiation of study drug into the long-term optional follow -up treatment period s, subjects 
who undergo a dosing interruption of greater than [ADDRESS_1147588] who 
terminates from the study early. Concom itant medications and any AEs noted during this phone 
call will be recorded. For subjects who participate in the long -term, optional follow -up treatment 
period, this phone call will be replaced by [CONTACT_56421] 148 end of study (EOS) clinic visit. For 
subjects who participate in the long -term, optional follow -up treatment period -2, this phone call 
will be replaced by [CONTACT_56421] 220 (EOS) clinic visit.  
5.[ADDRESS_1147589] completed the study period(s) based on the version of the 
protoc ol they participated under. For subjects who consent to the long -term, optional follow -up 
treatment period or the long -term, optional follow -up treatment period -2, the subject is 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147590] completed the study if they participated in the Week  144 e nd of treatment 
(EOT) or Week 216 (EOT) visit, respectively.  
The end of study for the purposes of regulatory reporting and EDC entry is the point of last 
contact [CONTACT_827197] -specified scheduled follow -up period or the EOS 
visit as specified in Schedule of Procedures F  . 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147591] ENROLLMENT  
6.1 Enrollment  
Before subjects may be enrolled to participate in the study, the Sponsor, or designe e, requires a 
copy of the appropriate written Independent Ethic Committee (IEC) or Institutional Review 
Board (IRB) approval of the protocol, informed consent/assent form(s) (ICF), and all other 
applicable subject information.  
Following informed consent/assent, the subject will be considered enrolled into the study. The 
unique [ADDRESS_1147592]’s 
identification number must remain constant and must be used on all study documentation related 
to that subject.  
Subjects will be enrolled in the long -term, optional fo llow-up treatment period based on the 
investigator’s determination of meeting eligibility criteria outlined in Section 7. A subject will be 
consider ed enrolled in either the long -term, optional follow -up period under Protocol 
Amendment [ADDRESS_1147593] who consents to Protocol Amendment 5 or 6 and does not meet criteria per the 
investigator is considered a screen failure for the long -term, optional fo llow-up period under 
Protocol Amendment 5 or 6, as appropriate. Final consent and eligibility determined for subjects 
rescreened will be collected in the case report form (CRF).  
6.[ADDRESS_1147594] who 
prepares the study drug and the pharmacy monitor who monitors the pharmacy records and 
procedures, will remain  blinded to all subjects’ treatment assignments until after the study 
database for Mirum ’s LUM001 -305 protocol has been locked. Sponsor personnel and CRO 
personnel will remain blinded to all subjects’ dose levels until after the study databases for the 
LUM 001-[ADDRESS_1147595] at any time by [CONTACT_827198]’s central 
pharmacy.  If a subject is unblinded by [CONTACT_74169], the Sponsor must be informed of the 
unblinding within [ADDRESS_1147596] 
be determined prior to submitting a regulatory safety report for a SAE (as defined in 
Section  11.2.3 ). 
Any unblinding event carried out in connection with submission of a regulatory safety report will 
be conducted by [CONTACT_1034] (see Section  11.1). 
Every reasonable attempt should be made to complete the early termination study procedures and 
observations (see Schedule of Procedures, Section  16.1) prior to unblinding, as knowledge of the 
treatment arm could influence subject assessment.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147597] meet the following eligibility criteria 
before being dispensed study drug treatment.  
Original Inclusion and Exclusion Criteria (through Protocol Amendment 4)  
7.[ADDRESS_1147598] meet all of the following criteria:  
1. Male or female, 12 months to 18 years of age.  
2. Competent to provide informed consent and assent (per IRB/EC), as appropriate.  
3. Completed participation in the LUM001 -[ADDRESS_1147599] [ β human 
chorionic gonadotropin (β -hCG)] at the Baseline Visit.  
5. Sexually active females must  be prepared to use an effective method (≤ 1% failure rate) of 
contraception during the trial. Effective methods of contraception are considered to be:  
6. Hormonal (eg, contraceptive pi[INVESTIGATOR_4382], patch, intramuscular implant or injection); or  
7. Barrier method, eg, (a)  condom with spermicide, or (b) diaphragm, with spermicide; or  
8. Intrauterine device (IUD).  
9. Subjects above the age of assent and caregivers and children must be able to read and 
understand English or Spanish.  
10. Caregivers (and age appropriate subjects) must ha ve access to phone for scheduled calls from 
study site.  
11. Caregivers (and age appropriate subjects) must be willing and able to complete a daily 
electronic diary (ItchRO) during the first consecutive 12 weeks of the study and then for 4 
consecutive weeks fol lowing the Week 24 and Week 44 visits.  
12. Caregivers (and age appropriate subjects) must digitally accept the licensing agreement in the 
ItchRO electronic diary software at the outset of the study.  
13. Eligible subjects must be able to adhere to local Ethics Com mittee or Institutional Review 
Board (IRB) blood volume limits for laboratory testing.  
Protocol Amendment 5 Inclusion Criteria: Eligible subjects for the long -term optional 
follow -up treatment period  
Subjects will be considered eligible for the long -term o ptional follow -up treatment period if they 
meet the following criteria:  
1. The subject has completed the protocol either through Week 96, or the ET visit, or has 
received permission from the sponsor and the ChiLDReN protocol chair  to re-enter the study 
in the  long-term, optional follow -up treatment period.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147600] 
(β-human chorionic gonadotropin [β -HCG]) at the time of entry into the long -term optional 
follow -up treatment period.  
3. Male and female subjects of child -bearing potential who are sexually active, or are not 
currently sexually active, but become sexually active during the study or for [ADDRESS_1147601] agree to use acceptable contraception dur ing the 
study.  
4. Informed consent and assent (per IRB/EC) as appropriate.  
5. Caregivers (and age appropriate subjects) must have access to phone for scheduled calls from 
study site.  
6. Caregivers (and age appropriate subjects) must be willing and able to use an eDiary device 
during the study.  
Protocol Amendment 6 Inclusion Criteria: Eligible subjects for the long -term optional 
follow -up treatment period -[ADDRESS_1147602] (β -
human chorionic gonadotropin [β -HCG]) at the time of entry into the long -term optional 
follow -up treatment period -2. 
3. Males and females of child -bearing potential who are sexually active, or are not currently 
sexually active, but become sexually active during the study or for [ADDRESS_1147603] agree to use acceptable contraception during the study.  
4. Informed consent and assent (per IRB/EC) as appropriate.  
5. Caregivers (and age appropriate subjects) must have access to phone for scheduled calls from 
study site.  
6. Caregivers (and age appropriate subjects) must be willing to follow the rules of eDiary 
completion  (see Section  8.4.1 ). 
7.2 Exclusion Criteria  
Subjects will be exclude d from the study if they meet any of the following criteria:  
1. Experienced an AE or SAE related to the study drug during the LUM001 -[ADDRESS_1147604] from the core study.  
2. Any conditions or abnormalities (including laboratory abnormalities ) which, in the opi[INVESTIGATOR_15960], Medical Monitor or ChiLDReN Protocol Chair, may compromise the safety 
of the subject, or interfere with the subject participating in or completi ng the study . 
3. History or known presence of gallstones or kidney stones.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147605]’s participation in the LUM001 -301 protocol. 
Non-adherence is defined by [CONTACT_827199]1 of less than 80% in the LUM001 -301 
protocol.  
5. Unlikely to comply with the study protocol, or unsuitable for any other reason, as judged by 
[CONTACT_093].  
Protocol Amendment 5 Exclusion Criteria: Eligible subjects for the long -term optional 
follow -up tre atment period  
All exclusion criteria for the original LUM001 -305 study apply upon re -entry into the long -term, 
optional follow -up treatment period.  
Protocol Amendment 6 Exclusion Criteria: Eligible subjects for the long -term optional 
follow -up treatment pe riod-2 
All exclusion criteria for the original LUM001 -305 study apply upon re -entry into the long -term 
optional follow -up treatment period -2. 
                                                 
 
1. Dosing compliance is calculated by [the total number of doses that were actually taken by [CONTACT_423]] divided by [the 
total number of doses that should have been taken by [CONTACT_423]] multiplied by 100.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147606] ug, and descriptions of AEs should be recorded 
in the appropriate source documents and CRFs.  
8.1.1 Baseline (Day 0)  
Evaluations and procedures completed for the Week 13 Visit of the LUM001 -301 study will also 
serve as the evaluations for the Baseline Visit for t he extension study. I nformed consent (and/or 
assent when appropriate) for participation in the extension study must be obtained for all 
participating subjects and their parents or legal guardians, as appropriate. At the Baseline visit 
(Week 0), subjects wi ll be assessed to confirm continued study eligibility including a review of 
medical history and will undergo a physical examination including body weight, height, and vital 
signs. Blood and urine samples will be taken for clinical laboratory testing, inclu ding a fasting 
lipid panel and determination of bile acids and other cholestasis biochemical markers as well as 
for PK analysis (plasma levels of LUM001). The clinician scratch scale will be administered, as 
will the PedsQL. Female subjects of childbearing potential will have a urine pregnancy test and 
concomitant medications and any AEs will be recorded. The degree and severity of  
xanthomatosis will be evaluated for all subjects by [CONTACT_827177]. Study drug for 
Weeks 1, and 2 will be supplied at the Baseline visit to eligible subjects.  
8.1.2 Dose Escalation Treatment Period (Week 0 to Week 4)  
Double -blind dosing in the do se escalation period will be initiated on the morning after the 
Baseline Visit. Caregivers and age appropriate subjects will be instructed to complete their 
ItchRO electronic diary (eDiary) twice daily (morning and evening). Subjects will return to the 
clinic at Weeks 2, and 4, and will receive follow -up phone calls at Weeks 1 and 3. On clinic visit 
days, vital signs (including height and weight measurements) will be collected and blood and 
urine samples will be taken for clinical laboratory testing, includ ing a fasting lipid panel and 
determination of fat -soluble vitamins, bile acids and other cholestasis biochemical markers. The 
clinician scratch scale will be administered, adherence to study drug will be assessed and 
additional dosing instructions will be  supplied. Study diary compliance will be assessed and 
concomitant medications and any AEs will be recorded at clinic visits and at scheduled telephone 
contacts. Additional study drug will be supplied at Week 2 and Week 4.  
Clinic visits and follow -up phone  calls during the dose escalation period are allowed a ±2  day 
scheduling window.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 66 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 8.1.3 Dose Optimization Period (Week 5 to Week 12)  
During the dose optimization period, the dose for each subject may be increased or decreased at 
the investigator’s discretion in a  double -blind manner. The purpose of the dose optimization 
period is to allow the investigator to adjust the subject’s LUM001 dose to a level that is both 
tolerable to the subject and maximizes the potential effect of LUM001 on pruritus. Once an 
optimal do se is achieved, the dose will be fixed for the duration of the study.  
Electronic diaries will be completed twice daily by [CONTACT_654] -appropriate subjects and caregivers 
through Week 12 and then collected. Subjects will return to the clinic at Weeks 8 and 12 and will 
receive follow -up telephone calls at Weeks 6 and 10. At the clinic visits, vital signs (including 
height and weight measurements) will be collected and blood and urine samples will be taken for 
clinical laboratory testing, including a fasting lipid pa nel and determination of fat -soluble 
vitamins, bile acids and other cholestasis biochemical markers. The clinician scratch scale will 
be administered and a review of study diary and medication compliance will be completed. 
Concomitant medications and any A Es will be assessed and recorded at each visit and at 
scheduled telephone contacts. Additional study drug will be supplied at Weeks 8 and 12.  
Clinic visits and follow -up phone calls during the dose optimization period are allowed a ±5  day 
scheduling windo w. 
8.1.4 Stable Dosing Period (Week 13 to Week 48)  
Subjects will continue to receive study drug during the stable dosing treatment period according 
to the dose achieved during the dose optimization period. However, if a subject experiences 
intolerance due to gas trointestinal symptoms the investigator, in consultation with the 
ChiLDReN protocol chair and Medical Monitor , may lower the dose to a previously tolerated 
dose for the remainder of the study.  
During the stable dosing period, subjects will return to the c linic at Weeks 24, 36, 44 and 48. 
Subjects who undergo a dose change at the Week 12 visit will also return to the clinic at Week 
16 (see below). With the exception of Week 44, safety and clinical laboratory evaluations, blood 
sampling for study drug determ ination, and a physical exam (including collection of vital signs, 
height and weight measurements) will be completed at each clinic visit. In addition, the clinician 
scratch scale and clinician xanthoma scale will be administered and study drug compliance will 
be assessed. The PedsQL will be completed at Weeks 24 and 48 and the Caregiver Impression of 
Change (CIC) will be completed at Week 48. Subjects/caregivers will receive follow -up phone 
calls at Weeks 16, 20, 28, 32 and 40. Concomitant medications and any AEs will be evaluated 
and recorded at all clinic visits and at scheduled telephone contacts.  
Subjects who undergo a dose change at the Week 12 visit will complete an on -site clinic visit at 
Week 16. Subjects who do not undergo a dose change at Week 12 will receive a follow -up phone 
call at Week 16. The study activities that will be conducted at th e Week 16 clinic visit are 
described in the Schedule of Procedures (Section  16.1). 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 67 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 Electronic diaries will be completed by [CONTACT_654] -appropriate subjects and caregivers following the 
Week 24 and Week 44 visits. The diaries will be redistributed at Week 24 and completed twice 
daily for 4 weeks before being collected at Week 28. The diaries will then be redistributed at 
Week 44 and completed twice daily until  the end of the study (Week  48). Re -training on the use 
of the diary will occur as appropriate at the Week 24 and Week 44 visits.  
At the physician investigator’s discretion, tapering or withdrawal of concomitant medications 
used for the treatment of prurit us may occur during the stable dosing period.  
With the exception of Week 44, additional study drug will be supplied at each clinic visit during 
the stable dosing period.  
Clinic visits and follow -up phone calls during the stable dosing period are allowed a  ±14 day 
scheduling window.  
8.1.5 Safety Monitoring Period (Week 49 to Week 96)  
During the safety monitoring period, subjects will return to the clinic every 3 months, at Weeks 
60, 72, 84, and 96.  
Safety and clinical laboratory evaluations and a physical exam ( including collection of vital 
signs, height, and weight measurements) will be completed at each clinic visit. The clinician 
scratch scale will also be completed at each clinic visit and study drug compliance will be 
assessed. The PedsQL, CIC, and the Clini cian Xanthoma scale will also be administered at 
Weeks 60, 72, 84, and 96. Subjects/caregivers will receive follow -up phone calls at Weeks 52, 
56, 64, 68, 76, 80, 88, and 92. Concomitant medications and any AEs will be evaluated and 
recorded at all clinic visits and at scheduled telephone contacts.  
Twice daily completion of the ItchRO electronic diary will be required by [CONTACT_827178] 2 weeks following the Week 60, 72, 84, and 96 clinic visits. 
Review of electronic diary data and assessment of compliance will occu r during scheduled 
telephone contacts at Week 64, 76, and 88 and during the Week 96 clinic visit. Electronic diaries 
will be provided to subjects and caregivers at these visits and re -training on the use of the diary 
will occur, as appropriate.  
At the phy sician investigator’s discretion, withdrawal of concomitant medications used for the 
treatment of pruritus may occur during the safety monitoring period.  
Additional study drug will be supplied at each clinic visit during the follow -up treatment period.  
8.1.[ADDRESS_1147607] documented consents in order to continue 
in the long -term, optional follow -up treatment period. A physical exam (including collection of 
vital signs, height and we ight measurements) will be performed. Blood and urine samples will be 
taken for clinical laboratory testing, including a fasting lipid panel and determination of fat -
soluble vitamins, bile acids and other cholestasis biochemical markers as well as for PK a nalysis 
(plasma levels of LUM001). The clinician scratch scale and PedsQL will be administered and the 
degree and severity of xanthomatosis will be evaluated using the clinician xanthoma scale. 
Review of the ItchRO electronic diary data and assessment of c ompliance will occur during the 
Week [ADDRESS_1147608] dose of study drug.  
8.1.7 Follow -up Phone Call ([ADDRESS_1147609] Dose)  
For subjects who do not roll over into the long -term, optional follow -up treatment period, a 
safety follow -up phone call will be made [ADDRESS_1147610] who terminates from the 
study early. Concomitant medications and any AEs noted during this phone call will be recorded. 
For subjects w ho participate in the long -term optional follow -up treatment period, this phone call 
will be replaced by [CONTACT_56421] 148 (EOS) clinic visit.  
8.1.8 Long -term, Optional Follow -up Treatment Period (Week 96 -148) 
Once Protocol Amendment [ADDRESS_1147611] of the following occurs:  
i.The subjects complete 48 weeks of additional treatment after Week 96 (safety monitoring 
 period)  
ii.The subjects are eligible and consent to enter another LUM001 study  
 
Subjects with no LUM001 dosing interruptions or interruptions ≤[ADDRESS_1147612] received during LUM001 -305 (Week 96 dose)  (refer to 
Figure 5). Study activities will proceed as outlined in Schedule of Procedures D  .  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 69 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 Subjects with LUM001 dosing interruptions >7 days will be rescreened and require dose 
escalation upon resumption of study drug. The dose of LUM001 will be increased at weekly 
intervals up to 280 µg/kg/day or the sub ject’s previously tolerated dose under Protocol 
Amendment 4 (refer to Figure 6). Study activities will proceed as outlined below and in Schedule 
of Procedures E . 
• Protocol A mendment (PA) 5 Re -initiating  (RI) Day -2 Clinic Visit : Consent (and/or assent as 
applicable) are obtained; eligibility criteria are confirmed. Physical examination (body 
weight, height, vital signs) is performed; blood and urine samples collected for clin ical 
laboratory testing. Female subjects of childbearing potential will have a serum pregnancy 
test. Concomitant medications and AEs will be recorded.  
• PA5 RI Day 0 Clinic Visit:  Eligibility criteria are confirmed. Physical examination (body 
weight, height,  vital signs) is performed; blood and urine samples collected for clinical 
laboratory testing. Female subjects of childbearing potential will have a serum pregnancy 
test. Clinician scratch scale, clinician xanthoma scale, and PedsQL are completed. 
Concomit ant medications and AEs will be recorded. Study drug is dispensed and subject 
begins dosing at 35  μg/kg/day dose level.  
• PA5 RI Week [ADDRESS_1147613]:  Concomitant medications and AEs will be recorded. 
Subject escalates to 70  μg/kg/day dose level or previous maximum tolerated dose as 
established under Protocol Amendment 4.  
• PA5 RI Week 2 Clinic Visit:  Physical examination (body weight, height, vital signs ) is 
performed; blood and urine samples collected for clinical laboratory testing. Female subjects 
of childbearing potential will have a serum pregnancy test. Clinician scratch scale, clinician 
xanthoma scale, and PedsQL are completed. Concomitant medicati ons and AEs will be 
recorded. Study drug is dispensed and subject escalates to 140  μg/kg/day dose or previous 
maximum tolerated dose as established under Protocol Amendment 4.  
• PA5 RI Week [ADDRESS_1147614]:  Concomitant medications and AEs will be recorde d. 
Subject escalates to 280  µg/kg/day dose level or previous maximum tolerated dose as 
established under Protocol Amendment 4.  
• PA5 RI Week 4 Clinic Visit:  Physical examination (body weight, height, vital signs) is 
performed; blood and urine samples collect ed for clinical laboratory testing. Female subjects 
of childbearing potential will have a serum pregnancy test. Clinician scratch scale, clinician 
xanthoma scale, and PedsQL are completed. The ItchRO electronic diaries will be provided 
to subjects and care givers and retraining on the use of the diary will occur, as appropriate. 
Twice daily completion of the electronic diary will be required during the [ADDRESS_1147615] continues dosing at 280  µg/kg/day dose level or previous maximum tolerated dose as 
established under Protocol Amendment 4.  
• PA5 Schedule D Week [ADDRESS_1147616] (4 weeks after PA5 RI Week 4 Clinic Visit):  
Concomitant medications and AEs will b e recorded. Subjects will then follow study activities 
as outlined in Schedule of Procedures D  , Week  104. 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 70 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 Per Schedule of Procedures D  , subjects will return to the clinic every 12  weeks at Wee ks 108, 
120, 132, 144 (EOT/ET visit) and at Week 148 (EOS visit). During the clinic visits, physical 
exam, body weight and height, vital signs, urine samples, and blood samples for clinical 
laboratory testing including fasting lipid panel and fat soluble v itamins, bile acids, and other 
cholestasis biochemical markers will be collected. ItchRO compliance will be assessed, the 
electronic diary will be issued, and the clinician scratch scale and clinician xanthoma scale will 
be assessed at every clinic visit. The PedsQL questionnaire and the CIC will be administered at 
Weeks 108, [ADDRESS_1147617] documented 
consents in order to continue in the long -term, optional  follow -up treatment period -2. Subjects 
who withdraw from the study prior to completion of the long -term, optional follow -up treatment 
period , should also undergo the procedures specified for the EOT/ET visit (Week 144). These 
procedures include a physical exam (including collection of vital signs, height and weight 
measurements), blood and urine sampling for safety and clinical laboratory eval uations 
(including a fasting lipid panel, determination of fat -soluble vitamins, bile acids and other 
cholestasis biochemical markers, as well as for PK analysis plasma levels of LUM001). In 
addition, the following assessments should be completed: the clin ician scratch scale, the PedsQL 
and the clinician xanthoma scale. The CIC assessment will be completed. Female subjects of 
childbearing potential will have a urine pregnancy test. Concomitant medications and any AEs 
will be recorded. Study drug compliance will also be assessed and all used and unused study 
drug and study supplies will be collected. Study drug will be discontinued at this visit if the 
subject chooses not to participate in the long -term, optional treatment period -2. Review of the 
ItchRO elect ronic diary data and assessment of compliance will occur during the Week [ADDRESS_1147618] 
dose of study drug and undergo the procedures specified for the EOS visit (Week 148). These 
procedures include a physical exam (including collection of vital signs, height and weight 
measurements), blood and urine sampling for safety and clinical laboratory evaluations 
(including a fasting lipid panel, determination of fat -soluble vitamins, bile acids and other 
cholestasis biochemical markers, as well as for PK analysis plasma levels of LUM001). In 
addition, the following assessments should be completed: the clinician scratch scale, the PedsQL, 
the clinician xanthoma scale, and the CIC. Female subjects of childbearing potential will have a 
urine pregnancy test. Concomitant medications and any AEs will be recorded.  
8.1.11  Long -term, Optional Follow -up Treatment Period -2 (Week 144 -220) 
Once Protocol Amendment [ADDRESS_1147619] of the following occurs:  
i.The subjects complete 72 weeks of additional treatment after Week 144 (long -term, 
 optional follow -up treatment period  
ii.The subjects are eligible and consent to enter another LUM001  (SHP625)  study  
 
Subjects rolling over into the long -term optional follow -up treatment period -[ADDRESS_1147620] received during LUM001 -305 (Week 144 dose) (refer 
to Figure 7). Study activities will proceed as outlined in Schedule of Procedures F  . Subjects with 
dose i nterruptions after Week 48 and prior to Week 96 , or who early terminated , may re -enter the 
study with the permission from the sponsor and the ChiLDReN protocol chair . These subjects 
will initiate dose escalation at visit PA5 RI -2 (per Schedule of Procedures E  ) and then will 
follow study activities beginning at Week 104 (per Schedule of Procedures D ). 
Per Schedule of Procedures F  , subjects will return to the clinic every 12  weeks at Weeks 156, 
168, 180, 192, 204, 216 (EOT/ET visit) and at Week 220 (EOS visit). During the clinic visits, 
physical exam, body weight and heigh t, vital signs, urine samples, and blood samples for clinical 
laboratory testing including fasting lipid panel and fat soluble vitamins, bile acids, and other 
cholestasis biochemical markers will be collected. The clinician scratch scale and clinician 
xanthoma scale will be assessed at every clinic visit. The PedsQL questionnaire and the CIC will 
be administered at Weeks 156, 216 and 220 clinic visits. The ItchRO electronic diaries will be 
provided to subjects and caregivers and retraining on the use of the  diary will occur, as 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 72 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 appropriate. Caregivers are not required to complete the eDiary (ItchRO[Obs]) if the subject is 
living separately from the ItchRO observer; however, subjects ≥9 years of age will be required to 
complete ItchRO(Pt). Twice daily complet ion of the electronic diary will be required during the 
2 weeks following the Week 144, 156, 168, 180, 192, and 204 clinic visits and during the 
4 weeks following the Week 216 (EOT/ET) visit. Review of the ItchRO electronic diary data and 
assessment of com pliance will occur during scheduled telephone contacts at Week 148, 160, 172, 
184, 196, [ADDRESS_1147621] will occur at Weeks 148, 152, 160, 164, 172, 176, 184, 188, 196, 200, 208 
and 212 where collection of concomitan t medications and any AEs will be recorded.  
8.1.12  Week 216 (EOT or ET)  
Subjects who either complete the long -term, optional follow -up treatment period -2 or who 
withdraw from the study prior to completion should undergo the procedures specified for the 
EOT/early termination (ET) visit (Week 216). These procedures include a physical exam 
(including collection of vital signs, height and weight measurements), blood and urine sampling 
for safety and clinical laboratory evaluations (including a fasting lipid panel, det ermination of 
fat-soluble vitamins, bile acids and other cholestasis biochemical markers, as well as for PK 
analysis plasma levels of LUM001). In addition, the following assessments should be completed: 
the clinician scratch scale, the PedsQL, the clinicia n xanthoma scale, and the CIC. Female 
subjects of childbearing potential will have a urine pregnancy test. Concomitant medications and 
any AEs will be recorded. Study drug compliance will also be assessed and all used and unused 
study drug and study suppli es will be collected. Study drug will be discontinued at this visit.  
8.1.13  Week 220 (EOS)  
All subjects will return to the study site [ADDRESS_1147622] dose of study drug and undergo the 
procedures specified for the EOS visit (Week 220). These procedures in clude a physical exam 
(including collection of vital signs, height and weight measurements), blood and urine sampling 
for safety and clinical laboratory evaluations (including a fasting lipid panel, determination of 
fat-soluble vitamins, bile acids and oth er cholestasis biochemical markers, as well as for PK 
analysis plasma levels of LUM001). In addition, the following assessments should be completed: 
the clinician scratch scale, the PedsQL, the clinician xanthoma scale, and the CIC. Female 
subjects of chil dbearing potential will have a urine pregnancy test. Concomitant medications and 
any AEs will be recorded.  
8.[ADDRESS_1147623] who terminates 
from the study early at the Early Termination Visit. For subjects who enter into  the safety 
monitoring period, physical examinations will be conducted at Weeks 60, 72, 84, and 96. For 
subjects who enter into the long -term, optional follow -up treatment period, physical 
examinations will be conducted at Weeks 108, 120, 132, 144 (EOT/ET)  and Week 148 (EOS). 
For subjects who enter into the long -term, optional follow -up treatment period -2, physical 
examinations will be conducted at Weeks 156, 168, 180, 192, 204, 216 (EOT/ET) and Week 220 
(EOS).  
Body weight, height, and vital signs, including body temperature, blood pressure (BP), 
respi[INVESTIGATOR_34403], will be determined at every study clinic visit. A change in weight greater 
than 10% of the weight used to calculate the subject’s current LUM001 dose will result in a dose 
adjustment. Each subsequent 10% increase in weight will be considered the new baseline for 
determination of future dose adjustments. This dose adjustment will be made by [CONTACT_827200]’s next LUM001 preparation.  
8.[ADDRESS_1147624] of planned tests is 
compi[INVESTIGATOR_827151]  16.2. 
The Investigator is responsi ble for reviewing and signing all laboratory reports. The clinical 
significance of each value outside of the reference range will be assessed and documented as 
either not clinically significant (NCS) or clinically significant (CS). See  Section  11.4.1  regarding 
laboratory abnormalities.  
8.4 Pruritus and Quality of Life Assessments  
8.4.1 Itch Reported Outcome (ItchRO™)  
Pruritus will be assessed using a newly deve loped Itch caregiver/patient reported outcome 
measure (ItchROTM) administered as a twice daily electronic diary as described in Section  16.3. 
Caregivers for all subjects will complete the Observer instrument: ItchRO(Obs) ™. Children 
≥9 years of age will complete the patient instrument: ItchRO(Pt) ™. Children between the ages of 
5 and 8 years of age will complete the patient instrument with the ass istance of their caregiver: 
ItchRO (Pt). Subjects and caregivers will be trained on the use of the electronic diary during their 
participation in LUM001 -301 protocol.  
During the dose escalation and dose optimization periods (Week 0 - Week 12), 
subjects/ca regivers will be required to submit twice daily assessments using the electronic diary.  
During the stable dosing period, daily completion of the diary will be required by [CONTACT_827201] 4 consecutive weeks that follow  the Week 24 and Week 44 clinic 
visits. At Week 24 and Week 44, subjects/caregivers will be provided with the electronic diary 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 74 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 and re -trained on its use, as needed. At the Week 24 visit, subjects/caregivers will also be 
provided with prepaid/pre -labeled mailing supplie s that should be used to return the electronic 
diary to the study center immediately after they have completed the 4 weeks of diary entries. At 
the Week 44 visit, subjects/caregivers will be instructed to bring their electronic diary with them 
when they re turn for the Week [ADDRESS_1147625] not to participate in the long -term, 
optional follow -up treatment period -2 (Protocol Amendment 6) will also be asked to complete 
the ItchRO during the 4 weeks that follow the Week 144 (EOT) visit. During the long -term, 
optional follow -up treatment period -2, twice daily completion of the ItchRO will be required for 
2 consecutive weeks following the Week 144, Week 156, Week 168, Week 180, Week 192, and 
Week 204 clinic visits and during the 4 weeks that follow the Week 216 (EOT) visit. At these 
visits, subjects/caregivers will be provided with the electronic diary and re -trained on its use, as 
needed. In cases where an ItchRO observer can no longer observe the subject (eg, no longer 
living with the subject ), the ItchRO(Obs) will not need to be completed; however, ItchRO(Pt) 
will need to be completed  by [CONTACT_130690] ≥9 years of age. Subjects/caregivers will be 
instructed to bring their electronic diary with them when they return for their next clinic visit. 
The electronic diary will be collected at Week  148 for subjects who do not participate in the 
long-term, optional follow -up treatment period -2 (Protocol Amendment 6), and at Week 220 for 
subjects who do participate in the long -term, optional follow -up treatment period -2. 
8.4.2 Clinician Scratch Scale  
A clinician’s assessment of pruritus will be made by t he principal investigator [INVESTIGATOR_11637] -investigator 
using the clinician scratch scale  (Section  16.4). This assessment will be completed at Baseline 
(Day 0) and at all clinic visits thereafter (Weeks 2, 4, 8, 12, 24, 36, 48, 60, 72, 84, and 96). For 
subjects who enter into the long -term, optional follow -up treatment period, the clinician scratch 
scale will be administered at Weeks 108, 120, 132, 144 (EOT/ET ). Subjects who elect not to 
participate in the long -term, optional follow -up treatment period -2 (Protocol Amendment 6) will 
also have the clinician scratch scale administered at  Week 148 (EOS). For subjects who enter 
into the long -term, optional follow -up treatment period -2, the clinician scratch scale will be 
administered at Weeks 156, 168, 180, 192, 204, 216 (EOT/ET) and Week 220 (EOS).  
The clinician’s assessment of the subject’s pruritus is focused on scratching and visible damage 
to the skin as a resul t of scratching as observed by [CONTACT_099]. The  clinician scratch scale uses 
a 5-point scale, in which [ADDRESS_1147626] visits.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 75 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 8.4.3 Clinician Xanthoma Scale  
A clinician’s assessment of xanthomatosis will be made by [CONTACT_458] [INVESTIGATOR_827152]  (Section  16.5). This assessment will be 
completed at Baseline (Day 0) and at Weeks 24, 36, 48, 60, 72, 84, and 96. For subjects who 
enter into the long -term, optional follow -up treatment period, the clinician’s assessment of 
xanthomatosis will be administered  at Weeks 108, 120, 132, 144 (EOT/ET).  Subjects who elect 
not to participate in the long -term, optional follow -up treatment period -2 (Protocol Amendment 
6) will also have the clinician’s assessment of xanthomatosis administered at Week  148 (EOS). 
For subje cts who enter into the long -term, optional follow -up treatment period -2, the clinician’s 
assessment of xanthomatosis will be administered at Weeks 156, 168, 180, 192, 204, 216 
(EOT/ET) and Week 220 (EOS).  
The clinician’s assessment of the subject’s xanthom atosis is focused on the number of lesions 
present and the degree to which the subject’s lesions interfere or limit his or her activities. The  
clinician xanthoma scale uses a 5 -point scale, in which 0 represents no evidence of 
xanthomatosis, 1 represents f ewer than 20 scattered individual lesions, 2  represents more than 20 
lesions that do not interfere with or limit activities, 3  represents large numbers of lesions that by 
[CONTACT_827202], and 4 repres ents 
xanthomas that interfere with function (such as hand use or ability to walk) because of excess 
size or number ( Emerick and Whitington, 2002 ). 
8.4.4 Pediatric Quality of Life Inventory (PedsQL)  
The PedsQL™ is a one -page questionnaire that will be administered to subjects and or caregivers 
at the Baseline (Day 0) and Week 24 and Week 48 clinical visits using the age -appropriate 
PedsQL module (Section  16.6). For subjects who enter into the long -term, optional follow -up 
treatment period, the PedsQL will be administered at Weeks 108, 144 (EOT/ET). Subjects who 
elect not to participate in the long -term, optional follow -up treatment period -2 (Protocol 
Amendment 6) will also have the PedsQL  administered at Week 148 (EOS). For subj ects who 
enter into the long -term, optional follow -up treatment period -2, the PedsQL will be administered 
at Weeks 156, 216 (EOT/ET) and Week 220 (EOS). The PedsQL is a validated, modular 
instrument designed to measure health -related quality of life (HRQoL ) in children and 
adolescents ( Varni et al., 2001 ).  
In addition to the core generic PedsQL module, the multidimensional fatigue and family impact 
questionnaires will also be administered at the Baseline (Day 0) and Weeks 24, 48, 60, 72, 84, 
and [ADDRESS_1147627] questionnaires will be administered at Weeks 108 and 144 (EOT/ET). Subjects who elect 
not to participate in the long -term, optional follow -up treatment period -2 (Protocol 
Amendment  6) will also have the multidimensional fatigue and family impact questionnaires 
administered at Week 148 (EOS). For subjects who enter into the long -term, optional follow -up 
treatment period -2, the multidimensional fatigue and family impact questionnaires will be 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 76 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 administered a t Weeks 156, 216 (EOT/ET) and Week 220 (EOS). Age at the LUM001 -301 
baseline visit will be used as the age for the determination of the appropriate questionnaire to be 
used for the study. This same module will be used for the duration of the study regardle ss of 
subsequent birthdays throughout the study.  
8.4.5 Caregiver Impression of Change  
The Caregiver Impression of Change (CIC) is designed to assess the caregiver’s perception of 
the subject’s xanthoma severity at the end of study drug treatment compared to his/ her xanthoma 
severity prior to the start of treatment with study drug. The CIC will be completed by [CONTACT_827203] 48, 60, 72, 84, and 96 visits , see Section  16.1. For subjects who enter 
into the long -term, optional follow -up treatment period, the CIC will be administered at Weeks 
108, 144 (EOT/ET). Subjects who elect not to participate in the long -term, optional follow -up 
treatment peri od-2 (Protocol Amendment 6) will also have the CIC  administered at Week 148 
(EOS). For subjects who enter into the long -term, optional follow -up treatment period -2, the CIC 
will be administered at Weeks 156, 168, 180, 192, 204, 216 (EOT/ET) and Week 220 (E OS). 
8.[ADDRESS_1147628] continue to use appropriate 
contraception with their partners, or refrain from sexual activity, from the time of enrollm ent 
until the end of the study. Acceptable methods of contraception are condoms with contraceptive 
foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, 
diaphragm with spermicidal gel, or a sexual partner who is su rgically sterilized.  
8.5.2 Fasting Requirements  
On study days in which blood samples are collected for the lipid panel and/or cholestasis 
biomarkers, all subjects will be required to fast for at least 4 hours (only  water is permitted) 
before blood sample collect ion. On these visit days study drug should be administered as usual (1 
mL or 0.5 mL qAM,  ac), in the morning [ADDRESS_1147629] fat soluble vitamin levels monitored; blood samples for the analysis of fat 
soluble vitamins should be obtained before the daily dose of vitamins is administered, and 
approximately 4 hours after any food or formula.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 77 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 9. STUDY DRUG  
9.1 Study Drug Description  
9.1.1 LUM001  
LUM 001 is a powder that is to be dissolved with an appropriate diluent in order to administer the 
study drug as an oral solution. The composition of LUM001 study drug oral solution is described 
in Table  7. The composition of LUM001 study drug 0.5 mL oral solution is described in Table  8. 
Table  7: Composition of LUM001 1.0 mL Oral Solution  
Component  Function  Quantity per 1.0  mL 
LUM001  Active Ingredient  0.02 to 20 mg  
Propylene Glycol  Co-solvent  250 mg  
Sucralose  Sweetener  7.5 mg  
Grape Flavoring Agent  Taste Masking Agent  5 mg  
Water, q.s. to  Vehicle  1.0 mL  
 
Table  8: Composition of LUM001 0.[ADDRESS_1147630] syringes will be provided by [CONTACT_827204].  
9.3 Drug Accountability  
The central pharmacy and all study staff are required to docume nt the receipt, dispensing and 
return/destruction of study drug supplies provided by [CONTACT_1034].  
At the conclusion of the study, any unused drugs, as well as original containers (even if empty), 
will be returned to the Sponsor or handled according to wri tten instructions from the Sponsor, 
following approval by [CONTACT_1034].  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147631]’s weight 
will be monitored at each visit. A change in weight greater than 10% of the weight used to 
calculate the subject’s current LUM001 dose will result in a dose adjustment. Each subsequent 
10% increase in weight will be considered the new baseline for determination of future dose 
adjustments . This dose adjustment will be made by [CONTACT_827205]’s next LUM001 preparation.  
Study drug (LUM001 with diluent) will be prepared by a central pharmacy based on the 
subject’s last recorded weight from the LUM001 -[ADDRESS_1147632] prior to shippi[INVESTIGATOR_827150]. Study drug will be dispensed to 
subjects/caregivers at the study site.  
Each subject dose for subjects who weigh 10 kg or more  will be administered orally as  a 1.0  mL 
solution containing study drug (LUM001) using the syringe provided. Each  subject dose for 
subjects who weigh less than 10 kg will be administered orally as a 0.5  mL solution containing 
study drug (LUM001)using the syringe provided. Study drug sho uld be taken at least [ADDRESS_1147633] meal of the day ( qAM, ac) and should be administered approximately at the 
same time each day for the duration of the treatment period. See  Sections [IP_ADDRESS] , [IP_ADDRESS] , and 
[IP_ADDRESS]  for information regarding dosing during the dose escalation and stable dosing periods, 
respectively.  
Please refer to the Study Drug Manual provided by [CONTACT_827206], administration and storage.  
10.2 Treatment Compliance  
Compliance with treatment dosing will be monitored and recorded by [CONTACT_217961]. 
Subjects and/or guardians will be asked to complete a paper diary indicating when they took 
their study me dication and when they ate breakfast.  
10.3 Concomitant Medications  
A concomitant medication is any non -protocol specified drug or substance (including over -the-
counter medications, herbal medications and vitamin supplements) administered during 
participation in  the study (from baseline/Day [ADDRESS_1147634] -treatment follow -up visit). 
Concomitant medications should not be recorded prior to informed consent, or during gap 
periods when the subject is not participating in the study.  
All medications (other tha n study drug) taken by [CONTACT_827207] (PI)/Investigator’s designee. Concomitant 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 79 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 medication will be coded using the World Health Organization (WHO) Drug Dictionary (release  
date 01 September 2008 , or more recent version if available). AEs related to administration of 
these medications must also be documented.  
At the physician investigator’s discretion, tapering or withdrawal of concomitant medications 
used for the treatment of pruritus may occur during stable dosing period. With the exception of 
vitamin supplementation and anti -pruritic medications, the dosage and dosing regimen of other 
concomitant medications should not change during the course of the study except  for dose 
adjustments due to weight increase. All modifications to concomitant medications must be 
carefully documented in the relevant CRFs.  
Concomitant use of bile acid or lipid binding resins or any investigational drug product other 
than LUM001 is not allowed during the study.  
10.[ADDRESS_1147635] abnormal liver enzyme 
levels (eg, A LT, ALP) total bilirubin, cholesterol and serum bile acids prior to their exposure to 
study drug in the lead -in study. If an individual subject exhibits a Common Terminology Criteria 
for Adverse Events ( CTCAE) Grade 3 treatment emergent  laboratory abnormal ity, with the 
exception of the specific rules outlined below (Sections  10.5) dosing can be suspended or 
continued as per the investigator’s judgeme nt and following discussion with the ChiLDReN 
protocol chair and the medical monitor . If suspended, the investigator, the ChiLDReN protocol 
chair, and the medical monitor  will evaluate the subject’s safety data and make a decision to 
either restart dosing at the same level, restart dosing at a lower dose level, or discontinue dosing.  
10.5.[ADDRESS_1147636] monitoring of clinical safety parameters, the following guidelines are 
provided for the monitoring of selected parameters c hosen based on preclinical and clinical 
observations.  
Confirmation Guidance : At any time during the study, the initial clinical laboratory results 
exceeding the safety monitoring criteria presented below must be confirmed by [CONTACT_827208] (in the central laboratory that performed the initial measurement) on new 
specimen s. Of note: the INR retest should be conducted by [CONTACT_827209], Inc.  CONFIDENTIAL  Page [ADDRESS_1147637] be available prior 
to the next scheduled clinic visit or phone follow -up.  
Stoppi[INVESTIGATOR_86556] : If any of the stoppi[INVESTIGATOR_37466] (refer to Section  10.5.1 ) 
are confirmed, the physician investigator in consultation with the ChiLDReN protocol chair and 
the medical monitor  or appropriately qualified designee(s), will permanently discontinue the 
subject from further treatment with study drug. The subject will be evaluated as outlined below 
and will be encouraged to complete the early termination study procedures. Subjects wh o do not 
meet the stoppi[INVESTIGATOR_827153], the ChiLDReN 
protocol chair, and the medical monitor  (or appropriately qualified designee) should confer as to 
whether additional close monitoring of the subject is appropriate. The investigator should also 
assess the need to capture an AE, its severity according to the CTCAE directives and potential 
causality. These assessments should also include an evaluation of whether criteria for an SAE are 
fulfilled (see Sectio n 11.2.3 ). 
[IP_ADDRESS]  Safety Monitoring for Liver Chemistry Tests  
Safety monitoring criteria take into consideration the subject’s historical baseline ALT and total 
bilirubin levels. Historical baseline levels will be defined as the values reported for each subject 
at their baseline visit for the LUM001 -[ADDRESS_1147638]’s historical baseline level, the initial measurement(s) should be 
confirmed within 48 to 72 hours of the initial report.  
Historical Baseline1 ALT  ALT  
< ULN  > [ADDRESS_1147639]  
> ULN  > 3 x historical baseline and > [ADDRESS_1147640]  
 
Historical Baseline1 Total Bilirubin  Total Bilirubin  
Total Bilirubin 1 -10 mg/dL  
(17.10 – 171.04 μmol/L)  3 mg increase over historical baseline level  
Total Bilirubin >10 mg/dL  
(>171.04 μmol/L)  5 mg increase over historical baseline level  
1 Historical baseline values are those reported at baseline of the LUM001 -301 protocol.  
 
Frequency of Repeat Measurements:  Subjects with a confirmed ALT or total bilirubin level that 
is continuing to rise should have their liver chemistry tests (ALT, ALP, IN R and total bilirubin) 
retested as clinically indicated, until levels stabilize or begin to recover.  
Further Investigation into Liver Chemistry Elevations:  Based on the inclusion/exclusion criteria 
for this study, the population to be enrolled, will have p re-existing baseline liver disease and will 
be closely monitored by [CONTACT_827210], Inc.  CONFIDENTIAL  Page 81 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 diseases. For subjects with a confirmed elevation in ALT or total bilirubin level, as described 
above, the followin g evaluations should be performed as clinically indicated:  
• Close and frequent monitoring of liver enzyme and serum bilirubin tests as clinically 
indicated.  Frequency of retesting can decrease if abnormalities stabilize or the trial drug 
has been discontinued and the subject is asymptomatic. If the appropriate frequency of 
monitoring is not feasible study drug administration will be suspended.  
• Obtain a detailed history of symptoms and prior and concurrent diseases.  
• Obtain comprehensive history for concomitant drug use (including nonprescription 
medications, herbal and dietary supplement preparations), alcohol use, recreational 
drug use, and special diets.  
• Obtain a history for exposure to environmental chemical agents and travel  
• Serology for viral h epatitis (HAV IgM, HBsAg, HCV antibody, CMV IgM, and EBV 
antibody panel).  
• Serology for autoimmune hepatitis (eg, antinuclear antibody [ANA]).  
Additional liver evaluations, including gastroenterology/hepatology consultations, hepatic CT or 
MRI scans, may be  performed at the discretion of the Investigator, in consultation with the 
ChiLDReN protocol chair and the Medical monitor .  
[IP_ADDRESS]  Stoppi[INVESTIGATOR_81748], and the event is 
without an alternative explanation as discussed with the ChiLDReN protocol chair , and 
medical monitor , discontinuation of dosing of a subject with study drug will  be considered if:  
 
Historical Baseline Tests  Change Observed  
ALT (any level)  ALT  [ADDRESS_1147641]  
Total Bilirubin 1-10 mg/dL  (17.10 – 171.04 μmol/L)  5 mg increased and a 2 x increase over historical 
baseline level  
Total Bilirubin >10 mg/dL (>171.04 μmol/L)  2 x increase over historical baseline level  
1 Historical Baseline values are those reported at baseline of the LUM001 -301 protocol.  
 
 
[IP_ADDRESS]  Safety Monitoring for Triglycerides  
In the event of a confirmed laboratory result for fasting total triglyceride >500 mg/dL (>5.65 
mmol/L), the Investigator, the ChiLDReN protocol chair, and the medical monitor  may consider 
a temporary interruption of study drug. Dosing may resume when the t riglyceride level returns to 
<300 mg/dL (3.39 mmol/L) or to the subject’s baseline level.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 82 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 [IP_ADDRESS]  Safety Monitoring for Fat Soluble Vitamins  
Vitamin status will be assessed per the schedule of procedures (see Section  16.1), blood samples 
will be obtained at the study visits before the daily dose of vitamins is administered. In the event 
of a confirmed laboratory result that falls either below or above the no rmal range for a vitamin 
(25-hydroxy vitamin  D, retinol, retinol binding protein, tocopherol (α), total lipi[INVESTIGATOR_805]), or for an 
elevated INR (as a proxy for vitamin K status), the investigator should make the appropriate 
modification to the subject’s vitamin su pplementation regimen.  
The response to the change in regimen will be assessed by [CONTACT_827211] -up blood work one 
month later. Changes will continue to be made until the levels are in the desired range. 
Adjustments may be discontinued outside of the desi red range if there is agreement between the 
Investigator, the ChiLDReN protocol chair, and medical monitor  that vitamin sufficiency 
cannot be reasonably expected.  
[IP_ADDRESS]  Monitoring/Stoppi[INVESTIGATOR_827154] a confirmed laborator y result for INR >1.5 (unresponsive to vitamin K therapy), 
the Investigator, the ChiLDReN protocol chair, and the medical monitor  may consider a 
temporary interruption of study drug. Dosing may resume when the INR falls below 1.[ADDRESS_1147642]’ s baseline level.  
10.6 Adjustment of Dose  
Gastrointestinal intolerance, as evidenced by [CONTACT_16651]/loose stools, abdominal pain/crampi[INVESTIGATOR_827155], is expected to be the most frequent manifestation of a lack of tolerability to study drug. If 
an individual subjec t exhibits a treatment emergent CTCAE Grade 2 or greater drug -related GI 
toxicity, study drug dose may be lowered to a previously well tolerated dose. This decision 
should be made in consultation with the ChiLDReN protocol chair and medical monitor . A 
requirement for intravenous fluids as treatment for diarrhea (without an alternative explanation) 
will lead to discontinuation of study drug.  
If a subject experiences an acute illness requiring temporary discontinuation of study drug, they 
may continue their participation in the study and resume study treatment as long as the period of 
discontinuation does not exceed [ADDRESS_1147643] who 
withdraws consent to participate in the study will be removed from further treatment and/or 
study observation immediately upon the date of the request.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147644] of the legal guardian, Investigator or Sponsor before completion of the protocol -
specified treatment period, and has received >1 dose of study drug, every effort should be made 
to complete the assessments scheduled for the Early Termination visit (see Schedule of 
Procedures, Section  16.1), provided the subject has not withdrawn full conse nt. The Early 
Termination visit should be scheduled within [ADDRESS_1147645] follow -up visit(s) until the AE has resolved or stabilized.  
Subjects must be withdrawn from the study for any of the following reasons:  
• Withdrawal of consen t/assent by [CONTACT_168377].  
• Pregnancy.  
• An AE (including disease progression) that leads the Investigator to decide that the 
subject should be withdrawn.  If a subject suffers an AE that, in the judgment of the 
Investigator or the Sponsor, pre sents an unacceptable consequence or risk to the 
subject, the subject must be discontinued from the study.  
• Significant protocol deviation (eg, medication or treatment that is prohibited by [CONTACT_12695]).  
• At the discretion of the Investigator if deemed not medically acceptable to continue 
study treatment.  
• Noncompliance, including failure to adhere to the study requirements as stated in the 
study protocol.  
• Administrative decision by [CONTACT_9304].  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147646]’s caregiver, 
from laboratory findings, or other means, will be recorded on the AE eCRF and medical record.  
Safety information will be collected, reviewed, and evaluated by [CONTACT_827212].  
11.1 Regulatory Requirements  
The Sponsor or designee is responsible for regulatory submissions and reporting to the 
Investigators of SAEs including suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) per 
the International Conference on Harmonization (ICH) guidelines E2A and ICH E6. Country -
specific regulatory requirements will be followed in accordance with local country regulations 
and guidelines.  
The Investigator should immediately  report all SAEs to the Sponsor or designee. It is essential to 
report SAEs in a timely manner to the Sponsor, or designee, along with completed 
documentation of AEs to allow the Sponsor, or designee, to identify potential study -related, 
study drug - or dos e-related AEs.  
The Sponsor is responsible for reporting any suspected adverse reaction that is both serious and 
unexpected to the applicable regulatory authorities. The  Sponsor  or designee  will evaluate the 
available information and decide if there is a reasonable possibility that the study drug caused the 
AE and, therefore, meets the definition of a S[LOCATION_003]R.  
Additionally, Independent Ethics Committees (IEC)/Institutional Review Boards (IRB) will be 
notified of any SAE according to applicable regulations.  The Data Monitoring Board (DMB) will 
be notified of any SAE as specified in the DMB charter.  
Appropriate personnel at the Sponsor  or designee  will unblind S[LOCATION_003]Rs for the purposes of 
regulato ry reporting. T he Sponsor or designee  will submit S[LOCATION_003]Rs to regulatory agencies in 
blinded or unblinded fashion according to local law. The Sponsor  or designee  will submit 
S[LOCATION_003]Rs to Investigators in a blinded fashion.  
11.2 Definitions  
11.2.1  Adverse Event  
An AE is any  unfavorable and unintended sign (including a clinically significant abnormal 
laboratory finding, for example), symptom, or disease temporally associated with the study or 
use of investigational drug product, whether or not the AE is considered related to the 
investigational drug product.  
An AE does not  include the following:  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 85 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 • Continuous persistent disease/symptom present before the start of study drug, which 
does not unexpectedly progress, or change in severity following drug administration.  
• Disease being s tudied and/or signs and symptoms associated with the disease, such as 
jaundice or itching, or abnormalities in liver enzymes already present at the baseline 
visit.  
• Treatment failure or lack of efficacy.  
 
11.2.2  Adverse Reaction and Suspected Adverse Reaction  
An adverse reaction  is any AE caused by [CONTACT_5257].  
A suspected adverse reaction  is any AE for which there is a reasonable possibility that the drug 
caused the AE. A suspected adverse reaction implies a lesser degree of certainty about causality 
than an ad verse reaction.  
11.2.3  Serious Adverse Event (SAE)  
A serious AE is any AE that in the view of either the Investigator or Sponsor, meets any of the 
following criteria:  
• Results in death.  
• Is life threatening: that is, poses an immediate risk of death at the time of the event.  
• An AE or suspected adverse reaction is considered “life -threatening” if, in the view of 
either the Investigator or Sponsor, its occurrence places the subject at immediate risk 
of death. It does not include an AE or suspected adverse reaction tha t, had it occurred 
in a more severe form, might have caused death.  
• Requires inpatient hospi[INVESTIGATOR_1081].  
• Hospi[INVESTIGATOR_37480] 24 hours to a medical facility 
and does not always qualify as an AE. Hospi[INVESTIGATOR_139538] a pre -
existing condition that did not worsen during the clinical investigation is not considered 
an AE. Hospi[INVESTIGATOR_827156].  
• Complications that occur during hospi[INVESTIGATOR_1084], and if a complication 
prolongs hospi[INVESTIGATOR_059], the event is considered seri ous. Treatment in a hospi[INVESTIGATOR_827157] a hospi[INVESTIGATOR_059]. Admission to the hospi[INVESTIGATOR_827158] “serious”, not the duration of hospi[INVESTIGATOR_4408].  
• Results in a persistent or significant incapacity or substantial disruption of the a bility 
to conduct normal life functions.  
• Results in congenital anomaly or birth defect in the offspring of the subject (whether 
the subject is male or female).  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 86 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 • Important medical events  that may not result in death, are not life -threatening, or do 
not requi re hospi[INVESTIGATOR_10462], based upon 
appropriate medical judgment, they may jeopardize the subject and may require 
medical or surgical intervention to prevent one of the outcomes listed in this definition. 
Examples of such med ical events include  allergic bronchospasm requiring intensive 
treatment in an emergency room or at home, blood dyscrasias or convulsions that do 
not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug 
abuse.  
 
11.3 Monitoring and R ecording Adverse Events  
Any pre -existing conditions or signs and/or symptoms present in a subject prior to the start of the 
study (ie, before informed consent) should be recorded as Medical History and not recorded as 
AEs unless the pre -existing condition worsened. In addition, AEs that occur while the subject is 
not enrolled in the study during a gap period (ie, prior to enrollment in Protocol Amendment 5), 
will be collected as medical history unless the AE started within [ADDRESS_1147647]’s 
medical records, in accordance with the Investigator’s normal clinical practice, and on the AE 
eCRF. Each AE is to b e evaluated for seriousness, causal relationship to the study drug, 
intensity, action taken, any treatment given, outcome, and duration. It should be noted that the 
term “severe” used to grade intensity is not synonymous with the term “serious.”  
11.3.[ADDRESS_1147648] safety, and in order to fulfill regulatory requirements, all SAEs 
(regardless of their relationship to study drug) should be reported to the Sponsor or designee  
within 24 hours of the study center’s first knowledge o f the event. The collection of SAEs will 
begin after the subject signs the informed consent form and stop [ADDRESS_1147649]’s last protocol -specified follow -up visit will be evaluated by 
[CONTACT_10552]. If  the Investigator and Sponsor agree the subject’s condition is 
unlikely to resolve, the Investigator and Sponsor will determine the follow -up requirement.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147650] all 
observed or volunteered AEs on the Adverse Event Case Report Form.  
11.3.3  Evaluation of Adverse Events (Serious and Non -Serious)  
The following should be documented on the Adverse Event Case Report Form . 
[IP_ADDRESS]  Relationship to the Study Drug  
The Investigator will document his/her opi[INVESTIGATOR_827159]:  
• Related:  There is clear evidence that the event is related to the use of study drug (eg, 
confirmation by [CONTACT_38000] -challenge test).  
• Possible:  The event cannot be explained by [CONTACT_423]’s medical condition, 
concomitant therapy, or other causes, and there is a plausible temporal relationship 
between the event and study drug administration.  
• Unlikely/Remote:  An event for w hich an alternative explanation is more likely 
(eg, concomitant medications or ongoing medical conditions) or the temporal 
relationship to study drug administration and/or exposure suggests that a causal 
relationship is unlikely (For reporting purposes, Un likely/Remote will be grouped 
together with Not Related).  
• Not Related:  The event can be readily explained by [CONTACT_19578]’s underlying medical 
condition, concomitant therapy, or other causes, and therefore, the Investigator believes 
no relationship exists between the event and study drug.  
 
[IP_ADDRESS]  Severity  
The CTCAE grade of the event should be reported according to CTCAE Version 4.0 
(Section  16.8). If the CTCAE does not have a grading for a particular AE, the severity of the 
event should be reported based on the following:  
• Mild (Grade 1):  The event is easily tolerated by [CONTACT_827213]’s usual daily activities.  
• Moderate (Grade 2):  The event causes the subject more discomfort and interrupts the 
subject’s usual daily activities.  
• Severe (Grade 3):  The event is incapacitating and causes considerable interference with 
the subject’s usual daily activities.  
 
Specific definitions will be provided for designated GI events expected to occur in this study, in 
order to aid Investigators with determination of event severity.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147651] be in dicated (criteria listed in 
Section  11.2.3 ).  
[IP_ADDRESS]  Action Taken with Study Drug  
Action taken with study drug due to the event is characterized by [CONTACT_080]:  
• None: No changes were made to study drug administration and dose.  
• Permanently Discontinued:  Study drug was discontinued and not restarted.  
• Temporarily Interrupted, restarted – same dose:  Dosing was temporarily interrupted or 
delayed due to t he AE and restarted at the same dose.  
• Reduced dose:  Dosing was reduced, temporarily interrupted or delayed due to the AE 
and restarted at the next lower dose.  
 
[IP_ADDRESS]  Treatment Given for Adverse Event  
Any treatment (eg, medications or procedures) given for the AE  should be recorded on the AE 
eCRF ( treatment should also be recorded on the concomitant treatment or ancillary procedures 
CRF as appropriate).  
[IP_ADDRESS]  Outcome of the Adverse Event  
If the event is a non -serious AE then the event’s outcome is characterized by [CONTACT_31806] o f the 
following:  
• AE Persists:  Subject terminates from the trial and the AE continues.  
• Recovered:  Subject recovered completely from the AE.  
• Became Serious:  The event became serious (the date that the event became serious 
should be recorded as the Resolution Date of that AE and the Onset Date of the 
corresponding SAE).  
• Change in Severity (if applicable):  AE severity changed.  
 
If the event is a SAE then the event’s outcome is characterized by [CONTACT_080]:  
• Ongoing:  SAE continuing.  
• Recovered:  Subject recovered completely from the SAE (the date of recovery should 
be entered as the SAE resolution date).  
• Fatal:  Subject died (the date of death should be entered as the SAE resolution date).  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147652] be reported within 24 hours.  
• SAE (see Section  11.3.1 ). 
• Pregnancy.  
• Dosing errors.  
• Treatment unblinding for any reason (see Section  6.3). 
 
11.4.[ADDRESS_1147653] learning of the occurrence o f 
pregnancy. Follow -up information including delivery or termination should be reported within 
24 hours.  
If pregnancy is suspected during the study (including follow -up), a pregnancy test will be 
performed. The subject with a confirmed pregnancy will be im mediately withdrawn from 
treatment with study drug. However, the subject will be encouraged to complete the Early 
Termination procedures to the extent that study procedures do not interfere with the pregnancy. 
Regardless of continued study participation, t he study physician will assist the subject in getting 
obstetrical care and the progress of the pregnancy will be followed until the outcome of the 
pregnancy is known (ie, delivery, elective termination, or spontaneous abortion). If the 
pregnancy results in  the birth of a child, the study center and Sponsor may require access to the 
mother and infant’s medical records for an additional follow -up after birth.  
Payment for all aspects of obstetrical care, child or related care will be the subject’s 
responsibili ty.  
11.4.[ADDRESS_1147654] was symptomatic (list 
symptoms) or asymptomatic, and the event accidental or intentional.  
Dosing d etails should be captured on the appropriate eCRF and paper subject diaries. If the 
subject  takes a dose of study drug that exceeds protocol specifications and the subject  is 
symptomatic, then the symptom(s) should be documented as an AE and be reported pe r 
Section  11.3. 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 90 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 Should an overdose occur, the Investigator or designee should refer to the Guidance to 
Investigator’s section of the Investigator’s Brochure and contact [CONTACT_10557] 
[ADDRESS_1147655] results may, in the opi[INVESTIGATOR_689], 
constitute or be associated with an AE. Examples of these incl ude abnormal laboratory results 
that are associated with symptoms, or require treatment (eg, bleeding due to thrombocytopenia, 
tetany due to hypocalcemia, or cardiac arrhythmias due to hyperkalemia). Whenever possible, 
the underlying diagnosis should be li sted in preference to abnormal laboratory values as AEs. 
Clinically significant abnormalities will be monitored by [CONTACT_827214], the 
ChiLDReN proto col chair, and the medical monitor . Laboratory abnormalities deemed not 
clinically significant (NCS) by [CONTACT_37723]. Similarly, 
laboratory abnormalities reported as AEs by [CONTACT_368166].  
The Investigator is responsible for reviewing and signing all laboratory reports. The  signed 
clinical laboratory reports will serve as source documents.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 91 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 12. STATISTICAL CONSIDER ATIONS  
This section presents a summary of the planned statistical  analyses. A statistical analysis plan 
(SAP) will be written for the study that contains detailed descriptions of the analyses to be 
performed. The SAP will be written prior to database lock.  
Approximately 36 subjects meeting the study’s inclusion and excl usion criteria will be enrolled 
in the study. The number of subjects enrolled in this study will be determined by [CONTACT_827182] -over from the LUM001 -[ADDRESS_1147656] one dose of the study drug during the extension study.  
Adverse Events will be examined over the entire treatment period, and for the dose escalat ion 
and optimization periods. Adverse events for each study period will be summarized overall by 
[CONTACT_827183] 
(Study Day 0). Adverse events for the stable dosing period will a lso be summarized overall and 
by [CONTACT_827184].  
Other safety measures including clinical laboratory tests, vital signs, physical exams, and 
concomitant medication usage will be summarized descriptively. For quantitative v ariables, 
descriptive statistics including number of observations, mean, median, standard deviation and 
range will be given for the values themselves and by [CONTACT_827185] -defined 
reference points (see below) at each visit. Qualitative variabl es will be summarized using counts 
and percentages by [CONTACT_827186].  
Drug Level Analysis  
Descriptive statistics analysis of LUM001 concentrations will be carried out on the plasma 
concentration data.  
Efficacy  
All efficacy an alyses will also be performed on the Safety Population, defined as all subjects 
who received at least one dose of the study drug during the extension study.  
Secondary efficacy measures will be analyzed similarly as above. Details of the analysis methods 
will be outlined in the SAP.  
All data will be included in data listings.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 92 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 12.1 Sample Size Considerations  
Approximately 36 subjects meeting the study’s inclusion and exclusion criteria may be enrolled 
in the study. Because this is an extension study for subjects who participated in the LUM001 -[ADDRESS_1147657] one dose of 
the study drug. The Safety Population will be used for all safety analyses. Subjects will be 
analyzed by [CONTACT_82153].  
12.2.2  Siblings  
At the start of the LUM001 -301 study, siblings enrolled in the study will be assigned in a blinded 
manner to the same treatment arm. The data from all enrolled participants (including siblings) 
will be used for the safety analysis. For the efficacy analysis, data from only one of the siblings 
will be used. The choice of which subject’s data to use in the efficacy analysis will be done in a 
random fashion before the LUM001 -[ADDRESS_1147658] on the results. Additional methodological detail will be included in 
the protocol’s SAP.   
12.2.3  Demographic and Baseline Characteristics  
[IP_ADDRESS]  Subject Disposition  
Subject disposition will be summarized descript ively. The number and percentage of subjects 
enrolled, completed, and withdrawn, along with reasons for withdrawal, will be tabulated 
overall, and by [CONTACT_827215]001 -305 study entry.  
The number and percentage of subjects receiving study  drug following the protocol specified 
dose escalation procedure, stable dosing, safety monitoring, and long -term optional follow -up 
dosing regimens will be tabulated overall and by [CONTACT_827216] 
(LUM001 -301). Line listings wil l be prepared for all subjects not following the planned dosing 
schedule, showing all doses and dose changes occurring.  
Other disposition and study conduct information, including major protocol violations will be 
listed. In addition, for subjects who had dose gaps or re -initiated to all protocol amendments, the 
number of days of the off -drug period will be summarized. Duration of the follow -up period will 
be tabulated.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 93 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 [IP_ADDRESS]  Baseline Data  
The following baseline data will be used to describe the study population:  
• Demographic variables, including age, gender and race/ethnicity.  
• Medical history.  
• Baseline disease characteristics (eg, pruritus scores, liver biochemistries).  
• Prior medications of interest (eg, ursodiol [UDCA], rifampi[INVESTIGATOR_2513]) and concomitant 
medications.  
Demographic and baseline characteristics will be summarized overall and descriptively by 
[CONTACT_827216] (LUM001 -301).  
Baseline for this study will be considered Day 0 in the study.  
Medical history information will be presented in  listings.  
12.2.4  Efficacy Analyses  
[IP_ADDRESS]  Efficacy Variables  
The primary evaluation will be the mean change from baseline (Day 0) of LUM001 -301 and 
baseline (Day 0) of LUM001 -305 baseline to Week 48 in:  
• Fasting serum bile acid level.  
Secondary evaluations will be the mean change from baseline (Day 0) of LUM001 301 and 
baseline (Day 0) of LUM001 -305 through Week  216/EOT in:  
• Biochemical markers of cholestasis and liver disease (eg, ALT, ALP, GGT and bilirubin 
[total and direct]).  
• Pruritus as measured by [CONTACT_827217] (ItchRO(Obs)TM, caregiver 
instrument/ItchRO(Pt) TM patient instrument).  
• During the first 12 weeks of the study, the electronic diary (ItchRO) will be 
completed twice daily (AM & PM). During the stable dosing period (Weeks  13-48), 
twice d aily completion of the electronic diary (ItchRO) for 4  consecutive weeks will 
be required following the Week 24 and Week 44 clinic visits. For subjects who 
continue in the safety monitoring period, twice daily completion of the ItchRO will be 
required for 2 consecutive weeks following the Week 60, 72, and 84 clinic visits. For 
subjects who continue in the long -term, optional follow -up treatment period, twice 
daily completion of the ItchRO will be required for 2 consecutive weeks following 
the Week 96, 108, 120, and 132 clinic visits, and for 4 weeks following the Week 144 
visit. For subjects who continue in the long -term optional follow -up treatment period -
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 94 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 2, twice daily completion of the ItchRO will be required for 2 consecutive weeks 
following the Week 144 , 156, 168, 180, 192, 204 clinic visits, and for 4 weeks 
following the Week 216 visit.  
• Xanthomas as measured by [CONTACT_827181].  
• Clinician scratch scale  
• Fasting serum bile acid level  
The exploratory evaluation will be the mean change in weight z -score from baseline Day  0 of 
LUM001 -301 and baseline (Day 0) of LUM001 -305 through Week 216 (EOT/ET).  
Exploratory evaluations will include the mean change from baseline in ItchRO, fasting sBA, and 
biochemical markers of cholestasis and liver disease at Week  144, Week 216, (EOT/ET) and  at 
Week 220 (EOS). The exploratory evaluation will be the mean change in weight z -score from 
baseline (Day  0) of LUM001 -301 and baseline (Day 0) of LUM001 -305 through Week 216 
(EOT/ET).  
Additional exploratory evaluations will be specified in the SAP and may include analyses 
between Week 144 (EOT/ET) and Week 148 (EOS) for subjects who complete Protocol 
Amendment 5 and between Week 216 (EOT/ET) and Week 220 (EOS) for subjects who 
complete Protocol Amendment 6.  
[IP_ADDRESS]  Primary Efficacy A nalysis  
The change from baseline to Week 48 in the serum bile acid will be tabulated overall and by 
[CONTACT_827216] (LUM001 -301), using summary statistics including 
the number of observations, the mean, median, standard deviation , minimum and maximum. 
Differences from baseline will be calculated and summarized as above, with a 95% confidence 
interval for the mean.  
[IP_ADDRESS]  Secondary, Exploratory and Other Efficacy Analyses  
Secondary Analyses  
Secondary efficacy variables that are continuous  measures will be analyzed similarly to the 
primary efficacy analyses.  
Change from baseline in Xanthoma scale will be categorized as improved, stable or worsened.  
Exploratory Analyses  
Exploratory efficacy variables that are continuous measures will be ana lyzed similarly to the 
primary efficacy analyses.  
Additional exploratory analyses may be performed and will be defined  in the SAP.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 95 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 Other Analyses  
Analyses of PedsQL and the CIC will be performed and will be defined in the SAP.  
12.2.5  Safety Analyses  
Safety analy ses will be performed on the Safety Population.  
[IP_ADDRESS]  Safety Assessments  
The following assessments will be used to monitor safety:  
• AEs and SAEs.  
• Clinical laboratory results.  
• Vital signs.  
• Physical exam findings, including body weight and height.  
• Concomitant medication usage.  
 
12.2.[ADDRESS_1147659] listings will be prepared for all safety data.  
[IP_ADDRESS]  Adverse Events  
Frequencies (number and percentage) of subjects with one or more treatment emergent AEs will 
be summarized overall, and by [CONTACT_22058] t group assigned in the core study (LUM001 -301), by 
[CONTACT_827218] (MedDRA™) terminology. All treatment emergent AEs, all treatment emergent AEs 
potentially related to stu dy drug, all treatment emergent SAEs and all treatment emergent SAEs 
potentially related to study drug will be summarized. Specific AEs of special interest, 
particularly GI related AEs, will be outlined in the SAP and summarized. AEs will be 
summarized ove rall and then separately for the dose escalation/optimization, stable dose, safety 
monitoring and long -term, optional follow -up treatment periods of the study.  
The incidence of AEs, and their severity, as well as the incidence of subjects who withdraw due  
to an AE will be tabulated. A subject listing of all treatment emergent AEs, and AEs causing 
study discontinuation will be presented.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 96 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 [IP_ADDRESS]  Laboratory Tests  
Clinical laboratory (chemistry panel, complete blood count (CBC) with differential, coagulation, 
lipid panel, cholestasis biomarkers, fat soluble vitamins, and urinalysis parameters) test 
parameters will be listed for individual subjects and summarized overall, and by [CONTACT_827219] (LUM001 -301) for each study visit. Change from baseline will also be 
presented over time, as appropriate. Percent change from baseline will be added for laboratory 
values as outlined in the SAP.  
A separate listing will present laboratory values of all subjects who change from normal to 
abnormal or fro m abnormal to normal during the course of the study. Changes within a treatment 
group for selected safety measures will be assessed at Weeks 8, 12, 24, 36, 48, 96, and at 
additional time points during the long -term, optional follow -up treatment periods.  
The effect of LUM001 on fat soluble vitamin levels will be assessed. These laboratory values 
will be summarized as above and listed for individual subjects. A separate listing will present 
laboratory values of all subjects who change from sufficient to insuf ficient or from insufficient to 
sufficient during the course of the study.  
[IP_ADDRESS]  Physical Exams, Vital Signs and Weight/Height Measurements  
Changes in physical exam findings after baseline will be listed for individual subjects.  
Vital signs, weight and height ( both weight and height are to be measured as an absolute number 
and as a z -score for age and gender) will be listed for individual subjects and summarized 
overall, and by [CONTACT_827216] (LUM001 -301) for each study visit. 
Changes  from baseline for all visits after the baseline visit will be included in the summary table. 
Baseline for vital signs will be defined as the last evaluation before dosing with study drug. This 
will include the LUM001 -301 baseline visit (Day 0) and the LUM 001-305 baseline (Day 0) visit.  
[IP_ADDRESS]  Concomitant Medications  
Concomitant medications will be coded using the World Health Organization (WHO) Drug 
Dictionary and summarized descriptively by [CONTACT_236820] (ATC) class, using 
counts and percentages.   
[IP_ADDRESS]  Study Drug Exposure  
Due to poor absorption of LUM001, very low systemic exposure and plasma drug levels are 
expected. The key measurement will be the pharmacodynamic effect on serum bile acid levels. 
However, exposure to study drug will be measured at specified study visits approximately [ADDRESS_1147660] days of exposure to study 
medication will b e summarized descriptively by [CONTACT_1570].  
 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 97 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 12.2.7  Additional Analyses  
Additional analyses may be performed to explore both safety and efficacy measures collected in 
this study. The precise methods and analyses will be determined after the database is locked and 
the blind is broken. Thus all such analyses will be interpreted cautiously and not used for formal 
inference, although inferential statistics may be used as part of the data summary.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 98 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 13. INVESTIGATOR’S REGUL ATORY OBLIGATIONS  
13.1 Informed Consent  
The written i nformed consent/assent document(s) should be prepared in the language(s) of the 
potential patient population, on an English version provided by [CONTACT_16015].  
The Investigator is responsible for obtaining written informed consent/assent from the subject 
and/or their legally acceptable representative(s). Before any tests or assessments are performed, 
an adequate explanation of the aims, methods, anticipated benefits, and potential hazards of the 
study will be provided to the subject and/or legally acceptable representative. The subject and/or 
legally acceptable representative must be given sufficient time to consider whether to participate 
in the study and be assured that withdrawal from the study may be requested at any time without 
jeopardizing me dical care related to or required as a result of study participation.  
Subjects and/or their legally acceptable representative(s) will be required to read, sign, and date 
an IEC approved informed consent/ascent form (ICF/IAF) summarizing the discussion pri or to 
enrollment. Since this is a pediatric study, in addition to the written informed consent, the assent 
of the child must also be obtained, as required by [CONTACT_180443]’s governing IRB. The person 
who conducted the informed consent discussion (not n ecessarily an Investigator) should also sign 
and date the ICF/IAF. The original signed ICF/IAF should be retained in accordance with 
institutional policy. Subjects and/or their legally acceptable representative(s) will be given a 
copy of their ICF, and IAF .  
The subject’s and/or legal representative’s agreement and the acquisition of informed consent 
should be documented in the subject’s medical record. When the study is completed and the CRF 
has been monitored, the ICF will be kept in the Investigator’s ce ntral study file. Regulatory 
authorities may check the existence of the signed ICF in this central study folder if not having 
done so during the performance of the study.  
Over the course of the study, the ICF/IAF may be modified, as appropriate (eg, due to  protocol 
amendment or significant new safety information). The resulting IEC -approved ICF/IAF will be 
used for all subjects subsequently entering the study or those already enrolled and still actively 
participating in the trial.  
13.[ADDRESS_1147661] of the Stu dy 
The Guidelines of the World Medical Association (WMA) Declaration of Helsinki dated October 
2008, the applicable regulations and guidelines of current Good Clinical Practice (GCP) as well 
as the demands of national drug and data protection laws and othe r applicable regulatory 
requirements will be strictly followed.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 99 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 13.3 Independent Ethics Committee/Institutional Review Board  
A copy of the protocol, proposed informed consent/assent forms, other written subject 
information, and any proposed advertising materia l must be submitted to the IEC/IRB for written 
approval. A copy of the written approval of the protocol and informed consent/assents form(s) 
must be received by [CONTACT_827220] g. A copy of the written approval of any other items/materials that must be 
approved by [CONTACT_827221]/IRB must also be received by [CONTACT_827222]. The Investigator’ s 
Brochure must be submitted to the IEC/IRB for acknowledgement.  
The Investigator must submit and, where necessary, obtain approval from the IEC/IRB for all 
subsequent protocol amendments and changes to the informed consent/assent documents. The 
Investigat or should notify the IEC/IRB of deviations from the protocol in accordance with ICH 
GCP Section  4.5.2. The Investigator should also notify the IEC/IRB of serious AEs occurring at 
the study center and other AE reports received from the Sponsor or designee, in accordance with 
local procedures.  
The Investigator will be responsible for obtaining annual IEC/IRB approval/renewal throughout 
the duration of the study. Copi[INVESTIGATOR_5699]’s reports, all IEC/IRB submissions and the 
IEC/IRB continuance of appro val must be sent to the Sponsor or designee.  
13.[ADDRESS_1147662]’s confidentiality is maintained. On the CRFs or 
other documents submitted to the Sponsor or designee, subjects should be identified by [CONTACT_827223] s and a subject study number only. Documents that are not for submission to the Sponsor 
or designee (eg, signed informed consent/assent forms) should be kept in strict confidence by [CONTACT_3786].  
In compliance with federal and local regulations/ICH GCP Guidelines, it is required that the 
Investigator and institution permit authorized representatives of the company, regulatory 
agency(ies), and the IEC/IRB direct access to review the subject’s original medical records for 
verification o f study -related procedures and data. Direct access includes examining, analyzing, 
verifying, and reproducing any records and reports that are important to the evaluation of the 
study. The Investigator is obligated to inform and obtain the consent of the su bject  to permit 
named representatives to have access to his/her study -related records without violating the 
confidentiality of the subject.  
All information concerning this study and which was not previously published is considered 
confidential information.  This confidential information shall remain the sole property of Mirum 
Pharmaceuticals, Inc.; it shall not be disclosed to others without written consent of Mirum  
Pharmaceuticals, Inc.; and shall not be used except in the performance of this study.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147663] of this clinical study is also considered 
confidential and may be disclosed and/or used only Mirum  Pharmaceuticals, Inc., as they deem 
necessary. To allow the use of the information derived from this clinical study and to ensure 
compliance to current federal regulations, the Investigator is obliged to furnish Mirum  
Pharmaceuticals, Inc., with the complete test results and all data compi[INVESTIGATOR_11134].  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147664] of 
the names of the Investigator(s) for the study and other possible participants, their professional 
background (eg, Investigator, coordinator, technician) and their role  in the study. The 
Investigator should ensure that all appropriately qualified persons to whom he/she has delegated 
trial duties are recorded on a Sponsor -approved Delegation of Site Responsibilities Form.  
14.[ADDRESS_1147665] provide the Sponsor or designee with the following documents (copi[INVESTIGATOR_827160]’s regulatory document binder):  
• Signed and dated Protocol Signature [CONTACT_3490].  
• Completed and signed statement of Investigator (Form FDA 1572/financial disclosure form) 
(where applicable).  
• Curriculum vitae (CV) of the Investigator and sub -investigators (where  applicable, all 
persons listed on Form FDA 1572).  
• Letter of approval from the IEC/IRB for both protocol and c onsent/assent forms.  
• Copy of the IEC/IRB -approved written informed consent/assent forms, and any other written 
information and/or advertisement to be used.  
• IEC/IRB membership list or compliance certification letter.  
• Name [CONTACT_272757], and other facilities 
conducting tests, including a copy of the laboratory certificate (where  applicable).  
• In case a laboratory certification is not available, a written statement as to how the laboratory 
complies with quality a ssurance should be provided. The  Sponsor's monitor must be notified 
if the laboratory is changed.  
• List of normal laboratory values (where applicable).  
In addition, in advance of enrolment of subjects, study staff is required to complete all required 
training. 
14.[ADDRESS_1147666] be obtained for all protocol amendments and amendments 
to the informed consent/assent documents. The reg ulatory authority and IEC/IRB must be 
informed of all amendments and give approval for any amendments likely to affect the safety of 
the subjects or the conduct of the trial. The Investigator must send a copy of the approval letter 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 102 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 from the IEC/IRB to the Sponsor or designee. Amendments to the protocol will not be 
implemented until written IEC/IRB approval has been received.  
14.4 Study Termination  
Both the Sponsor or designee and the Investigator reserve the right to terminate the study the 
Investigator’s site, according to the terms of the study contract. The Investigator/Sponsor or 
designee should notify the IEC/IRB in writing of the trial’s completion or early termination and 
send a copy of the notification to the Sponsor or designee.  
The Sponsor or designee r eserves the right to terminate the study overall.  
14.[ADDRESS_1147667]’s CRF data 
are obtained. These include but are not limited to hospi[INVESTIGATOR_1097], clinical and  office charts, 
laboratory and pharmacy records, diaries, imaging, and correspondence. All original source 
documents supporting entries in the CRFs must be maintained and be readily available.  
The Investigator and the study center staff are responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation in accordance with 
Section  8 of the ICH Guidelines (E6), suitable for inspection at any  time by [CONTACT_368151]/or applicable regulatory authorities. The clinical site’s regulatory 
document binder  essential elements should include:  
• Subject files containing completed CRFs (eCRFs), informed consents/assents, an d supporting 
copi[INVESTIGATOR_10467].  
• Study files containing the protocol with all amendments, Investigator’s Brochure, copi[INVESTIGATOR_648442]-study documentation and all correspondence to and from the IEC/IRB and the Sponsor or 
designee.  
• If drug supplies ar e maintained at the study center, documentation for proof of receipt, study 
drug accountability records, return of study drug for destruction, final study drug product 
reconciliation statement, and all drug -related correspondence.  
 
No study document should  be destroyed without prior written agreement between the Sponsor or 
designee and the Investigator. Should the Investigator wish to assign the study records to another 
party or move them to another location, he/she must notify the Sponsor or designee.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 103 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 14.5.1  Parent Report for Teenagers (ages 13 -18 years)  
 
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147668], inspecting 
the various records of the trial (eg, CRFs and other pertinent data) provided that subject 
confidentiality is respected. Quality control audits may be performed at the Sponsor’s discretion.  
Throughout the  course of the study, a study monitor will make frequent contacts with the 
Investigator and/or study staff. This will include telephone calls and on -site visits. During the 
on-site visits, the CRFs will be reviewed for completeness and adherence to the pro tocol, 
accuracy, consistency of the data, and adherence to local regulations on the conduct of clinical 
research. The monitor will need access to subject medical records and other study -related records 
needed to verify the entries on the CRFs. The study mo nitor will also perform drug 
accountability checks and review the clinical site’s regulatory document binder to assure 
completeness of documentation in all respects of clinical study conduct. On completion of the 
study, the study monitor will arrange for a  final review of the study files after which the files 
should be secured for the appropriate time period.  
The Investigator or appointed delegate will receive the study monitor during these on -site visits 
and will cooperate in providing the documents for in spection and respond to inquiries. In 
addition, the Investigator will permit inspection of the study files by [CONTACT_827224].  
14.[ADDRESS_1147669] use 
vocabulary and language that are c learly understood.  
14.8 Compensation for Injury  
The Sponsor maintains appropriate insurance coverage for clinical trials and will follow 
applicable local compensation laws. Subjects will be treated and/or compensated for any study -
related illness/injury in acco rdance with the information provided in the Informed Consent 
document.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 106 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 15. REFERENCES  
Orphanet [Online]. Available: www.orpha.net [Accessed].  
Emerick, K. M., Rand, E. B., Goldmuntz, E., Krantz, I. D., Spi[INVESTIGATOR_228582], N. B. & Pi[INVESTIGATOR_77613], D. A. 1999. 
Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. 
Hepatology,  29, 822 -9. 
Emerick, K. M. & Whitington, P. F. 2002. Partial exte rnal biliary diversion for intractable 
pruritus and xanthomas in Alagille syndrome. Hepatology,  35, 1501 -6. 
Hofmann, A. F. 2003. Inappropriate ileal conservation of bile acids in cholestatic liver disease: 
homeostasis gone awry. Gut, 52, 1239 -41. 
Hounnou, G., Destrieux, C., Desme, J., Bertrand, P. & Velut, S. 2002. Anatomical study of the 
length of the human intestine. Surg Radiol Anat,  24, 290 -4. 
Modi, B. P., Suh, M. Y., Jonas, M. M., Lillehei, C. & Kim, H. B. 2007. Ileal exclusion for 
refractory symptomat ic cholestasis in Alagille syndrome. J Pediatr Surg,  42, 800 -5. 
Neimark, E., Chen, F., Li, X. & Shneider, B. L. 2004. Bile acid -induced negative feedback 
regulation of the human ileal bile acid transporter. Hepatology,  40, 149 -56. 
van den Anker, J., Schwab , M. & Kearns, G. 2011. Developmental Pharmacokinetics. In: 
SEYBERTH, H., RANE, A. & SCHWAB, M. (eds.) Pediatric Clinical Pharmacology  
Varni, J. W., Seid, M. & Kurtin, P. S. 2001. PedsQL 4.0: reliability and validity of the Pediatric 
Quality of Life Inven tory version 4.0 generic core scales in healthy and patient 
populations. Medical care,  39, 800 -12. 
Walthall, K., Cappon, G. D., Hurtt, M. E. & Zoetis, T. 2005. Postnatal development of the 
gastrointestinal system: a species comparison. Birth Defects Res B Dev Reprod Toxicol,  
74, 132 -56. 
Weaver, L. T., Austin, S. & Cole, T. J. 1991. Small intestinal length: a factor essential for gut 
adaptation. Gut, 32, 1321 -3. 
Whitington, P. F. & Whitington, G. L. 1988. Partial external diversion of bile for the treatment of 
intractable pruritus associated with intrahepatic cholestasis. Gastroenterology,  95, 130 -6. 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 107 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May 2019  
 
 16. APPENDICES  
 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 108 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May  2019  
 
 16.1 Schedule of Procedures  
Schedule of Procedures A: Baseline – Week 12  
Study Period  Baseline  Treatment Period  
Dose Escalationc Dose Optimization  
Study Week   1 2 3 4 6 8 10 12 
Study Day  Day 01 7 14 21 28 42 56 70 84 
Window (in days)   (±2)  (±2)  (±2)  (±2)  (±5)  (±5)  (±5)  (±5)  
Informed Consent  X         
Eligibility Assessment / Medical History  X         
Physical Exam  X         
Body Weight & Height  X  X  X  X  X 
Vital Signs2 X  X  X  X  X 
CBC with Differential3 X  X  X  X  X 
Coagulation3 X  X  X  X  X 
Chemistry Panel3 X  X  X  X  X 
Lipid Panel3,[ADDRESS_1147670] eDiary / Caregiver eDiary (ItchRO) Xb Xb Xb Xb Xb Xb Xb Xb Xb 
Clinician Scratch Scale  X  X  X  X  X 
Clinician Xanthoma Scale  X         
PedsQL  X         
Enrollment  X         
Study Drug Supplied  X  X  X  X  X 
Assess Study Drug Compliance    X  X  X  X 
Review Study Diaries & Assess Compliance  X  X  X  X  X 
Concomitant Medications  X X X X X X X X X 
Adverse Events  X X X X X X X X X 
Phone Contact6  X  X  X  X  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 109 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May  2019  
 
 Schedule of Procedures A: Baseline – Week 12  
Study Period  Baseline  Treatment Period  
Dose Escalationc Dose Optimization  
Study Week   1 2 3 4 6 8 10 12 
Study Day  Day 01 7 14 21 28 42 56 70 84 
Window (in days)   (±2)  (±2)  (±2)  (±2)  (±5)  (±5)  (±5)  (±5)  
1 Evaluations and procedures completed for the Week 13 Visit of the LUM001 -301 protocol  will also serve as 
the evaluations for the Baseline Visit for this extension study.  
2 Blood pressure (BP), heart rate (HR), temperature, respi[INVESTIGATOR_1487].   
[ADDRESS_1147671] 4 hrs. (only water permitted prior to collection).  
[ADDRESS_1147672] 12 weeks of the study, the eDiary 
(ItchRO) will be completed twice daily (AM & PM). 
Compliance will be assessed at each visit/phone contact.  
c Subjects should be dosed for at least [ADDRESS_1147673] -dosing for drug level analysis.  
 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 110 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May  2019  
 
 Schedule of Procedures B - Stable Dosing: Week 16 – Week 48  
Study Period  Treatment Period (cont’d)  
Stable Dosing  
Study Week  166 20 24 28 32 36 40 44 Week 48  
 
Study Day  112 140 168 196 224 252 280 308 336 
Window (in days)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  
Physical Exam  X6  X   X   X 
Body Weight & Height  X6  X   X   X 
Vital Signs1 X6  X   X   X 
CBC with Differential2 X6  X   X   X 
Coagulation2 X6  X   X   X 
Chemistry Panel2 X6  X   X   X 
Lipid Panel2,[ADDRESS_1147674] eDiary/Caregiver eDiary  
(ItchRO)    Xb Xb 
to Week 28     Xb Xb 
to Week 48  
PedsQL    X      X 
Caregiver Impression of Change 
(CIC)          X 
Study Drug Supplied    X   X   X 
Assess Study Drug Compliance    X   X  X X 
Review Study Diaries & Assess 
Compliance    X   X  X X 
Concomitant Medications  X X X X X X X X X 
Adverse Events  X X X X X X X X X 
Phone Contact5 X X  X X  X   
1 Blood pressure (BP), heart rate (HR), temperature, respi[INVESTIGATOR_1487].   
[ADDRESS_1147675] 4 hrs. (only water permitted prior to collection).  
[ADDRESS_1147676] be available to receive a phone call from study staff.  
6  A Week 16 Clinic Visit will be completed for all subjects who undergo a change in dose at Week 12; 
Subjects who do not undergo a dose change at Week 12 will be contact[CONTACT_635182] 16.  a At the indicated visits, oxalate will  be part of the urinalysis.  
b During the stable dosing period, twice daily completion of 
the eDiary (ItchRO) for [ADDRESS_1147677] -
dosing for drug level analysis  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 111 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May  2019  
 
 Schedule of Procedures B - Stable Dosing: Week 16 – Week 48  
Study Period  Treatment Period (cont’d)  
Stable Dosing  
Study Week  166 20 24 28 32 36 40 44 Week 48  
 
Study Day  112 140 168 196 224 252 280 308 336 
Window (in days)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  
 
  Clinic Visit  
 Phone Contact  
[CONTACT_108467], Inc.  CONFIDENTIAL  Page 112 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May  2019  
 
  
Schedule of Procedures C - Safety Monitoring Period: Week 52 – Week 96/Early Termination Schedule of Procedures  
Study Period  Treatment Period (cont’d)  
Study Termination  Follow -Up Safety Monitoring Period  
Study Week  52 56 60 64 68 72 76 80 84 88 92 Week 96  
(or Early Term7) 30 days after 
final dose8 Study Day  364  392  420  448  476  504  532  560  588  616  644  672  
Window (in days)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±5) 
Informed Consent / 
Eligibility Assessment 
for PA51            X  
Physical Exam    X   X   X   X  
Body Weight & Height    X   X   X   X  
Vital Signs2   X   X   X   X  
CBC with Differential3   X   X   X   X  
Coagulation3   X   X   X   X  
Chemistry Panel3   X   X   X   X  
Lipid Panel3,[ADDRESS_1147678] 
eDiary/Caregiver eDiary 
(ItchRO)    Xb Xb 
to 
Week 
62  Xb Xb 
to 
Week 
74  Xb Xb 
to 
Week 
86  Xb Xb 
to Week 98  
PedsQL    X   X   X   X  
Caregiver Impression of 
Change (CIC)    X   X   X   X  
Study Drug Supplied    X   X   X   X  
Assess Study Drug 
Compliance    X   X   X   X  
Review Study Diaries & 
Assess Compliance     Xc   Xc   Xc    
Concomitant 
Medications  X X X X X X X X X X X X X 
Adverse Events  X X X X X X X X X X X X X 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 113 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May  2019  
 
 Schedule of Procedures C - Safety Monitoring Period: Week 52 – Week 96/Early Termination Schedule of Procedures  
Study Period  Treatment Period (cont’d)  
Study Termination  Follow -Up Safety Monitoring Period  
Study Week  52 56 60 64 68 72 76 80 84 88 92 Week 96  
(or Early Term7) 30 days after 
final dose8 Study Day  364  392  420  448  476  504  532  560  588  616  644  672  
Window (in days)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±5) 
Phone Contact6 X X  X X  X X  X X  X 
1 Subjects can consent to roll over into the long -term optional follow -up treatment period, per Schedule D.  
2 Blood pressure (BP), heart rate (HR), temperature, respi[INVESTIGATOR_1487]  
[ADDRESS_1147679] 4 hrs. (only water permitted prior to collection).  
[ADDRESS_1147680] be available to receive a phone call from study staff.  
7 Subjects who withdraw early during the follow -up treatment period should complete all evaluations at this 
visit.  
8 Visit not required for subjects with ≤7 days LUM001 dose interruption who roll over into the long -term 
optional follow -up treatment period (Schedule D) or for subjects with >7 days but less than 30 days 
LUM001 dose interruption who roll over into the long -term optional follow -up treatment period (Schedule 
E). a At the indicated visits, oxalate will be part of the 
urinalysis.  
b During the follow -up period, twice daily completion of 
the eDiary (ItchRO) for [ADDRESS_1147681]  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 114 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May  2019  
 
 Schedule of Procedures D – Long -term, Optional Treatment Period:  Week 96  – Week 148  
for those subjects with ≤[ADDRESS_1147682] dose of LUM001 applicable as follows:  
• If another study becomes available for subjects prior to completion of Protocol Amendment 5, the subject will complete EOT 
assessments as outlined for Week 144.  
• Subjects who complete 48 weeks of additional treatment and who are not eligible for another study will complete EOS assessments as 
outlined for Week 148.  
Schedule of Procedures D – Long -term, Optional Treatment Period: Week 96 – Week 148  
Study Period  Treatment Period (cont’d)  
EOT Visit/ET  EOS Visit9 Long -term, Optional Follow -up Treatment Period  
Study Week  100 104 108 112 116 120 124 128 132 136 140  
 Week 1448 
Week 148  Study Day  700  728  756  784  812  840  868  896  924  952  980  1008  
Window (in days)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±5) 
Informed Consent / 
Eligibility Assessment 
for PA61,10            X  
Physical Exam    X   X   X   X X 
Body Weight2 & Height    X   X   X   X X 
Vital Signs3   X   X   X   X X 
CBC with Differential4   X   X   X   X X 
Coagulation4   X   X   X   X X 
Chemistry Panel4   X   X   X   X X 
Lipid Panel4,[ADDRESS_1147683] 
eDiary/Caregiver eDiary 
(ItchRO)  Xb 
to 
Week 
98  Xb Xb 
to 
Week 
110  Xb Xb 
to 
Week 
122  Xb Xb 
to 
Week 
134  Xb Xb 
to Week 148  
PedsQL    X         X X 
Caregiver Impression of 
Change (CIC)    X         X X 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 115 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May  2019  
 
 Schedule of Procedures D – Long -term, Optional Treatment Period: Week 96 – Week 148  
Study Period  Treatment Period (cont’d)  
EOT Visit/ET  EOS Visit9 Long -term, Optional Follow -up Treatment Period  
Study Week  100 104 108 112 116 120 124 128 132 136 140  
 Week 1448 
Week 148  Study Day  700  728  756  784  812  840  868  896  924  952  980  1008  
Window (in days)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±5) 
Study Drug Supplied    X   X   X   X11  
Assess Study Drug 
Compliance    X   X   X   X  
Review Study Diaries & 
Assess Compliance  Xc   Xc   Xc   Xc  Xc Xc 
Concomitant 
Medications  X X X X X X X X X X X X X 
Adverse Events  X X X X X X X X X X X X X 
Phone Contact7 X X  X X  X X  X X    
1 Subjects can consent to roll over into the long -term optional follow -up treatment period -2, per Schedule 
F. 
2 Increases of 10% or more in a subject’s weight from baseline will require a dose adjustment, per 
Section  10.1. 
3 Blood pressure (BP), heart rate (HR), temperature, respi[INVESTIGATOR_1487].
  
[ADDRESS_1147684] 4 hrs. (only water permitted prior to collection).  
[ADDRESS_1147685] not to participate in the long -term, optional follow -up treatment period -2 (Protocol 
Amendment 6) should return to the study site [ADDRESS_1147686] dose of study drug and complete all 
evaluations at this visit  
10 Eligibiility should only be assessed at Week 144 for subjects that complete PA5 (Week 144) and rollover 
directly to PA6. Subjects who did not consent to PA5 and who re -enter in PA6 from IPA5 or earlier will 
not be re­assessed for eligibility at Week 144  
11. Subjects should continue dosing at Week 144 if entering PA6  
 a At the indicated visits, oxalate will be part of the 
urinalysis.  
b During the follow -up period, twice daily completion of 
the eDiary (ItchRO) for [ADDRESS_1147687]  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 116 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May  2019  
 
 Schedule of Procedures E – Re-Entry into Long -term Optional Treatment Period/Long -term Optional Treatment Period -2: applicable as 
follows:  
• Subject s either previously completed the follow -up period up to Week 96 , or has received permission from the sponsor and the 
ChiLDReN protocol chair to re -enter the study .  
Schedule of Procedures E – Re-entry into  Long -term, Optional Treatment Period / Long -term, Optional Treatment Period -2 
Study Period  Dose Escalation Treatment Period  
PA5 DE Study 
Week  PA5 
RI -2h PA5 
RI 
Day 0 PA5 
RI 
Week 1  PA5 
RI 
Week 2  PA5 
RI 
Week 3  PA5 
RI 
Week 4  PA5 
 Schedule D - Week 
104 
Scheduling 
Considerations   
0      
Window (in 
days)   
(±14)  (±2) (±2) (±2) (±2) (±2)  
(±2) 
Informed 
Consent/Assent  X       
Assess Eligibility 
for study re-entry  X X      
Physical Exam  X X  X  X  
Body Weight & 
Height  X X  X  X  
Vital Signsa X X  X  X  
CBC with 
Differentialb X X  X  X  
Coagulationb X X  X  X  
Chemistry Panelb X X  X  X  
Lipid Panelb,c  X  X  X  
Cholestasis 
Biomarkersb,c  X  X  X  
Fat Soluble 
Vitaminsb,c,d  X  X  X  
Urinalysisb  X  X  X  
Serum Pregnancy 
Test (if 
indicated)e X X  X  X  
Clinician Scratch 
Scale   X  X  X  
Clinician 
Xanthoma Scale   X  X  X  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 117 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May  2019  
 
 Schedule of Procedures E – Re-entry into  Long -term, Optional Treatment Period / Long -term, Optional Treatment Period -2 
Study Period  Dose Escalation Treatment Period  
PA5 DE Study 
Week  PA5 
RI -2h PA5 
RI 
Day 0 PA5 
RI 
Week 1  PA5 
RI 
Week 2  PA5 
RI 
Week 3  PA5 
RI 
Week 4  PA5 
 Schedule D - Week 
104 
Scheduling 
Considerations   
0      
Window (in 
days)   
(±14)  (±2) (±2) (±2) (±2) (±2)  
(±2) 
Caregiver 
ItchRO/  
Patient ItchRO       X  
(collected for 2 -week 
period following this 
visit)   
PedsQL   X      
Study Drug 
Suppliedf  X  X  X  
Caregiver 
ItchRO/  
Patient ItchRO 
Device Supplied       X  
Assess Study 
Drug Compliance     X  X  
Concomitant 
Medications  X X X X X X X 
Adverse Events  X X X X X X X 
Follow -up Phone 
Contactg   X  X  X 
a Blood pressure (BP), heart rate (HR), temperature, respi[INVESTIGATOR_1487].   
b See Section 16.[ADDRESS_1147688] 4 hrs (only water permitted) prior to collection.  
d Blood samples must be drawn before administration of vitamin supplementation.  
e Females of childbearing potential, result must be reviewed prior to dispensing study drug.  
f Study drug may be dispensed at unscheduled clinic visits.  
g Subjects must be available to receive a phone call from st udy staff.  
h Subjects with dose interruptions prior to Week [ADDRESS_1147689]  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 118 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May  2019  
 
 Schedule of Procedures F – Long -term, Optional Treatment Period -2: Week 144  – 220 (Study Completion/Termination), applicable as 
follows:  
• If another study becomes available for subjects prior to completion of Protocol Amendment 6, the subject will complete EOT 
assessments as outlined for Week 216.  
• Subjects who complete 72 weeks of additional treatment and who are not eligible for another study will complete EOS assessmen ts as 
outlined for Week 220.  
Schedule of Procedures F – Long -term, Optional Treatment Period -2: Week 144 – Week 220 (Study Completion/Termination)  
Study Period   
Long -term, Optional Follow -up Treatment Period -2 EOT/ET 
Visit  EOS 
Visit  
Study Week  148 152 156 160 164 168 172 176 180 184 188 192 196 200 204 208 212  
 Week 
2167 Week 
220 
Study Day                     
Wind ow  
(in days)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±5) 
Phys ical Exam    X   X   X   X   X   X X 
Body W eight1 
& Height    X   X   X   X   X   X X 
Vital Signs2   X   X   X   X   X   X X 
CBC with 
Differential3   X   X   X   X   X   X X 
Coagul ation3   X   X   X   X   X   X X 
Chemis try 
Panel3   X   X   X   X   X   X X 
Lipid Panel3,4   X   X   X   X   X   X X 
Choles tasis 
Biomarkers3,4   X   X   X   X   X   X X 
Fat So luble 
Vitamins3,4    X   X   X   X   X   X X 
Plasma  
Sample for 
LUM001                   X X 
Urinal ysis3   X   X   X   X   X   Xa Xa 
Urine 
Pregnancy 
Test5   X   X   X   X   X   X X 
Clinic ian 
Scratch Scale    X   X   X   X   X   X X 
Clinician 
Xanthoma 
Scale    X   X   X   X   X   X X 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 119 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May  2019  
 
 Schedule of Procedures F – Long -term, Optional Treatment Period -2: Week 144 – Week 220 (Study Completion/Termination)  
Study Period   
Long -term, Optional Follow -up Treatment Period -2 EOT/ET 
Visit  EOS 
Visit  
Study Week  148 152 156 160 164 168 172 176 180 184 188 192 196 200 204 208 212  
 Week 
2167 Week 
220 
Study Day                     
Wind ow  
(in days)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±5) 
Subjec t 
eDiary/  
Caregiver 
eDiary 
(ItchRO)  Xb 
to 
Week 
146  Xb Xb 
to 
Week 
158  Xb Xb 
to 
Week 
170  Xb Xb 
to 
Week 
182  Xb Xb 
to 
Week 
194  Xb Xb 
to 
Week206  Xb Xb 
to Week 
220 
PedsQL    X               X X 
Caregi ver 
Impression of 
Change (CIC)    X               X X 
Study Drug 
Supplied    X   X   X   X   X     
Assess  Study 
Drug 
Compliance    X   X   X   X   X   X  
Review  Study 
Diaries & 
Assess 
Compliance  Xc   Xc   Xc   Xc   Xc   Xc    
ItchRO /Patient 
ItchRO 
Device 
Returned                    X 
Concom itant 
Medications  X X X X X X X X X X X X X X X X X X X 
Adverse 
Events  X X X X X X X X X X X X X X X X X X X 
Phone 
Contact6 X X  X X  X X  X X  X X  X X   
1 Increases of 10% or more in a subject’s weight from baseline will require a dose 
adjustment, per Section  10.1. 
2 Blood pressure (BP), heart rate (HR), temperature, respi[INVESTIGATOR_1487].
  
[ADDRESS_1147690] 4 hrs. (only water permitted prior to collection).  
[ADDRESS_1147691] be available to receive a phone call from study staff.  a At the indicated visits, oxalate will be part of the urinaly sis. 
b During the follow -up period, twice daily completion of the eDiary (ItchRO) for [ADDRESS_1147692] no longer lives with an ItchRO observer, the 
ItchRO(Obs) will not need to be completed; however, ItchRO(Pt) will need to be 
completed by [CONTACT_130690] ≥9 years of age  
c Study staff will review ItchRO diary data from the prior period and assess 
compliance.  
 Clinic Visit  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 120 
LUM001 -305 Protocol Amendment 6. 2 
SHP625  13 May  2019  
 
 Schedule of Procedures F – Long -term, Optional Treatment Period -2: Week 144 – Week 220 (Study Completion/Termination)  
Study Period   
Long -term, Optional Follow -up Treatment Period -2 EOT/ET 
Visit  EOS 
Visit  
Study Week  148 152 156 160 164 168 172 176 180 184 188 192 196 200 204 208 212  
 Week 
2167 Week 
220 
Study Day                     
Wind ow  
(in days)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±14)  (±5) 
[ADDRESS_1147693] of Laboratory Analytes  
 
CBC with Differential  
Red blood cells  
Hemoglobin  
Hematocrit  
MCV, MCH, MCHC  
Platelets  
White blood cells  
WBC Differential  
(% and absolute)  
• Neutrophils  
• Eosinophils  
• Basophils  
• Lymphocytes  
• Monocytes  
 
Coagulation  
Activated partial 
thromboplastin time (aPTT) 
(sec)  
Prothrombin time (PT) (sec)  
INR Clinical Chemistry  
Sodium  
Potassium  
Chloride  
Bicarbonate  
Total protein  
Albumin  
Calcium  
Phosphate  
Glucose  
Blood urea  nitrogen 
(BUN)  
Creatinine  
Uric Acid  
Total bilirubin  
Direct bilirubin 
(conjugated)  
Indirect bilirubin 
(unconjugated)  
Alkaline 
phosphatase (ALP)  
AST (SGOT)  
ALT (SGPT)  
GGT  Lipid Panel1 
Total cholesterol  
LDL -C (direct)  
HDL -C 
Triglycerides (TG)  
 
Cholestasis 
Biomarkers1 
Serum bile acids  
7α hydroxy -4-
colesten -3-one 
(C4) 
 
Fat Soluble 
Vitamins1 
25-hydroxy 
vitamin  D 
Retinol  
Retinol binding 
protein  
Tocopherol (α)  
Total lipi[INVESTIGATOR_827161]2 
Oxalate3 
 
LUM001 Drug Levels  
LUM001 in plasma 
1 Blood samples for the analysis of fat soluble vitamins should be drawn prior to administration of vitamin 
supplementation and approximately 4 hours after food or formula. Other biomarkers [eg,  autotaxin, 
lysophosphatidic acid (LPA), FGF -19, FGF -21] may be measured. At the discretion of the Sponsor, samples 
will be collected and approp riately stored for subsequent analysis, as needed.  
2 Will be performed on abnormal findings unless otherwise specified.  
3 At the specified time points on the Schedule of Procedures (Section  16.1), oxalate will be part of the urinalysis.  
 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 122 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 16.3 Itch Reported Outcome Instrument (ItchRO™)  
Many of the ALGS subjects in this study are expected to be between the ages of 12 months and 
10 years, necessitating reliance upon an observer -reported outcome instrument (ObsRO) to 
evaluate a pruritus endpoint.  
The ItchRO instrument is being developed both as a patient reported outcome measure (PROM) 
for pediatric subjects (9 years of age and older) and an ObsRO for caregivers/parents. The 
ItchRO will be completed using an electronic diary (eDiary) twice daily (m orning and evening) 
for both the PROM and ObsRO.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 123 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 16.3.1  Patient Itch Reported Outcome Instrument, ItchRO(Pt)™  
A screen shot from the ItchRO(Pt) morning report  is show below. The score associated with 
each response option is indicated in red text (these wil l not be shown on the eDiary). The 
minimum ItchRO(Pt) morning report score is 0 and the maximum score is 4.  
 
 
 
0 
1 
2 
3 
4 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 124 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 If the patient selects “I didn’t feel itchy at all” the morning diary is complete, if not the following 
screens will be shown on t he eDiary:  
   
A screen shot from the ItchRO(Pt) evening report  is shown below. The score associated with 
each response option is indicated in red text (these will not be shown on the eDiary). The 
minimum ItchRO(Pt) evening report score is 0 and the maximum score is 4.  
 
 
0 
1 
2 
3 
4 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 125 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 If the patient selects “I didn’t feel itchy” the evening diary is complete, if not the following 
screen will be shown on the eDiary:  
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 126 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 16.3.2  Observer Itch Reported Outcome Instrument, ItchRO(Obs)™  
A screen shot from the ItchRO(Obs) morning report is shown below. The score associate d with 
each response option is indicated in red text (these will not be shown on the eDiary). The 
minimum ItchRO(Obs) morning report score is 0 and the maximum score is 4.  
 
 
If the caregiver selects “None observed or reported” the morning di ary is complete, if not the 
following screen will be shown on the eDiary:  
 
 
0 
1 
2 
3 
4 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 127 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 All caregivers will also be required to answer the following question on the ItchRO(Obs) 
morning report : 
 
 
A screen shot from the ItchRO(Obs) evening report  is shown below. The s core associated with 
each response option is indicated in red text (these will not be shown on the eDiary). The 
minimum ItchRO(Obs) evening report score is 0 and the maximum score is 4.  
 
 
0 
1 
2 
3 
4 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 128 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 If the caregiver selects “None observed or reported” the evening diary is complete, if not the 
following screen will be shown on the eDiary:  
 
 
 
All caregivers will also answer the following question on the ItchRO(Obs) evening report : 
 
 
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 129 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 16.4 Clinician Scratch Scale  
This scoring scale was originally d eveloped to assess pruritus before and after surgical 
intervention in children with ALGS and PFIC ( Whitington and Whitington, 1988 ). 
The clinician will rate the subject’s pruritus, as evidenced by [CONTACT_117891], according to the 
following scale:  
Score  Description  
0 None  
1 Rubbing or mild scratching when undistracted  
2 Active scratching without evident skin abrasions  
3 Abrasion evident  
4 Cutaneous mutilation, hemorrhage and scarring evident  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 130 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 16.5 Clinician Xanthoma Scale  
The Clinician Xanthoma scoring scale was originally developed to assess xanthomas before and 
after surgical intervention in children with ALGS ( Emerick a nd Whitington, 2002 )  
The clinician will rate the subject’s degree of xa nthomatosis according to the following scale:  
Score  Description  
0 None  
1 Minimal  
2 Moderate  
3 Disﬁguring  
4 Disabling  
 
In the study in which this scale was used to assess xanthomas before and after surgical 
intervention in children with ALGS, “minimal” xanthomas represented fewer than 20  scattered 
individual lesions, “moderate” represented more than 20 lesions that did not interfere with or 
limit activities, “disﬁguring” represented large numbers of lesions that by [CONTACT_827225] c aused distortion of the face or extremities, and “disabling” represented xanthomas that 
interfered with function (such as hand use or ability to walk) because of excess size or number.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 131 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 16.6 Pediatric Quality of Life Inventory (PedsQL™)  
The PedsQL Generic Cores Scale is composed of 23 items to assess pediatric HRQoL 
measurements across 4 domains: Physical Functioning (8 items), Emotional Functioning 
(5 items), Social Functioning (5 items), and School Functioning (5 items). Each item consists of 
a 5-level Li kert item survey (0 -4). Each PedsQL™ age -appropriate form should take less than 
four minutes to complete.  
Pediatric HRQoL measurement instruments must be sensitive to cognitive development and must 
include both child self -report and parent proxy -report. A ccordingly, the PedsQL consists of 
developmentally appropriate forms for children ages 1 -12 months, 13 - 24 months, 2 -4, 5-7, 8-12, 
and 13 -18 years. Pediatric self -report is measured in children and adolescents ages 5 -18 years, 
and parent proxy -report of ch ild HRQOL is measured for children and adolescents ages 12 
months to 18 years.  
Quality of life will be assessed using the appropriate PedsQLTM module(s) provided below.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 132 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 16.6.1  Parent Report for Infants (ages 1 -12 months)  
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 133 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
  
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 134 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
  

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 135 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 16.6.2  Parent Report for Infants (ages 13 to 24 months)  
 
 
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 136 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
  

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 137 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
  

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 138 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 16.6.3  Parent Report for Toddlers (ages 2 -4 years)  
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 139 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
  

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 140 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 16.6.4  Parent Report for Young Children (ages 5 -7 years)  
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 141 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
  

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 142 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 16.6.5  Parent Report for Children (ages 8 -12 years)  
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 143 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 144 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
  
16.6.6  Pediatric Quality of Life Inventory v 4.0 for Young Children (ages 5 -7 years)  
 
 
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 145 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
  

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 146 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
  

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 147 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 16.6.7  Pediatric Quality of Life Inventory for Children (ages 8 -12 years)  
 
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 148 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 149 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
  
16.6.8  Pediatric Quality of Life Inventory for Teenagers (ages 13 -18 years)  
 
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 150 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
  

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 151 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 16.6.9  Multidimensional Fatigue Scale Parent Report for Toddlers (ages 2 -4 years)  
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 152 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
  

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 153 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 16.6.10  Multidimensional Fatigue Scale Parent Report for Young Children 
(ages  5-7 years)  
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 154 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
  

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 155 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 16.6.11  Multidimensional Fatigue Scale Parent Report for Children (ages 8 -12 years)  
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 156 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 157 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 16.6.12  Multidimensional Fatigue Scale Parent Report for Teenagers  
(ages 13 -18 year s) 
 
 
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 158 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
  
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 159 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 16.6.13  Multidimensional Fatigue Scale Young Child Report (ages 5 -7 years)  
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 160 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
  

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 161 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
  

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 162 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 16.6.14  Multidimensional Fatigue Scale Child Report (ages 8 -12 years)  
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 163 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 164 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
  
16.6.15  Multidimensional Fatigue Scale Teen Report (ages 13 -18 years)  
 
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147694] Module v 2.0 
 
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 167 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
  
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 168 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
  

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 169 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 16.7 Caregiver Impression of Change (CIC)  
The Caregiver Impression of Change (CIC) is designed to assess the caregiver’s perception of 
the subject’s xanthoma severity at the end of study drug treatment compared to his/her xanthoma 
severity pri or to the start of treatment with study drug. The CIC will be completed by [CONTACT_827226] 48, 60, 72, 84, and [ADDRESS_1147695] not to participate in the long -term, optional follow -up treatment period -2 (Protocol 
Amendment 6) will also have the CIC administered at Week 148 (EOS). For subjects who enter 
into the long -term, optional follow -up treatment period -2, the CIC will be administered at Weeks 
156, 168, 180, 192, 204, 216 (EOT/ET) and Week 220 (EOS).  
The questionnaire is designed for self -administration and uses a [ADDRESS_1147696] outcome.  
CIC 
 
How would you rate the change in your child’s xanthoma severity since the start of the study?  
 
 Much better (1) 
Better (2) 
A little better (3) 
No change (4) 
A little worse (5) 
Worse (6) 
Much worse (7) 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 170 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 16.8 Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0  
Adverse events should be graded by [CONTACT_827227] 4.0 (Published:  May 
28, 2009 [v4.03: June 14, 2010]).  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 171 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 16.9 Protocol History  
Document  Date  Global/Country/Site Specific  
Original Protocol  14 Apr 2014   
Amendment 1  29 Jan 2015  Global  
Amendment 2  12 Feb 2015  Global  
Amendment 3  
Note: no summary of 
changes included for 
Protocol Amendment 3 as 
this protocol version was 
never operationalized.  27 Apr 2016  Global  
Amendment 4  27 Apr 2016  Global  
Amendment 5  13 Nov 2017  Global  
Amendment 6  25 Jun  2018  Global  
Amendment 6.1  08 Feb 2019  Global  
 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 172 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 16.9.1  Protocol Amendment 6.1 Summary of Changes  
 
Protocol Number:  LUM001 -305 
Protocol Title:  A MULTICENTER EXTENSION STUDY TO EVALUATE THE 
LONG -TERM SAFETY AND DURABILITY OF THE THERAPEUTIC 
EFFECT OF LUM001, AN API[INVESTIGATOR_827137] -DEPENDENT BILE 
ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT 
OF CHOLESTATIC LIVER DISEASE IN PEDIATRIC SUBJECTS 
WITH ALAGILLE SYNDROME  
Amendment:  6.1 
Date:  [ADDRESS_1147697] the change of sponsorship from Lumena 
Pharmaceuticals LLC (Lumena Pharmaceuticals LLC is an indirect wholly -owned subsidiary of 
Shire North American Group, Inc)  to Mirum Pharmaceuticals, Inc.   
The follow ing changes have been made to the Protocol Amendment 6 (25 Jun 2018). Note that 
correction of typos and grammatical errors are not captured in the below table.  
New text indicated in bold; deleted text indicated in strikethrough.  
Protocol Amendments  
Summary of  Change(s) Since Last Version of Approved Protocol  
Section(s) Affected 
by [CONTACT_827228] , Sponsor;  
Title Page , Sponsor; 
Sponsor Signature 
[CONTACT_3490] , Sponsor; 
Protocol Signature 
[CONTACT_3264] , Sponsor  Replaced Shire’s address with the new sponsor’s 
address.  To provide new Sponsor’s 
(Mirum) address  
Title Page , Medical 
Lead and Premier 
Medical Monitor; 
Protocol Signature 
[CONTACT_3264] , Sponsor 
(Mirum)  Approval  Updated the Medical Lead and add Premier medical 
monitor information.  To provide updated and correct 
information.  
Product Quality 
Complaints  Replaced Shire’s contact [CONTACT_827229]’s 
contact.  To provide new Sponsor’s 
contact [CONTACT_3031].  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 173 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 Protocol Amendments  
Summary of  Change(s) Since Last Version of Approved Protocol  
Schedule D  
 Footnote added to eligibility assessment at Week 
[ADDRESS_1147698] eligibility re-
assessed  
Added drug dispensation at Week 144  To claritfy for subjects entering 
PA6 
Schedule E  Added Drug Compliance to be done at Weeks 2 and 
4 To ensure compliance is assessed  
 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 174 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 16.9.2  Protocol Amendment 6 Summary of Changes  
 
Protocol Number:  LUM001 -305 
Protocol Title:  A MULTICENTER EXTENSION STUDY TO EVALUATE THE 
LONG -TERM SAFETY AND DURABILITY OF THE THERAPEUTIC 
EFFECT OF LUM001, AN API[INVESTIGATOR_827137] -DEPENDENT BILE 
ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT 
OF CHOLESTATIC LIVER DISEASE IN PEDIATRIC SUBJECTS 
WITH ALAGILLE SYNDROME  
Amendment:  6 
Date:  [ADDRESS_1147699] of the following occurs: (i) the subjects complete 72  weeks of additional 
treatment (after Week 144 [long -term, optional follow -up treatment p eriod]), or (ii) the subjects 
are eligible to enter another LUM001 study.  
The following changes have been made to the Protocol Amendment 6 (25 Jun 2018). Note that 
correction of typos and grammatical errors are not captured in the below table.  
New text indicated in bold; deleted text indicated in strikethrough.  
Protocol Amendments  
Summary of Change(s) Since Last Version of Approved Protocol  
Amendment 
Number  6 Amendment Date  
25 Jun 2018  Global/Country/Site Specific  
Global  
Section(s) Affected 
by [CONTACT_827230] , Medical 
Lead  Updated phone number for Shire Medical Lead.  To provide updated contact 
[CONTACT_3031].  
Emergency Contact 
[CONTACT_7171] , Premier 
Medical Monitor  Updated the Premier medical monitor information.  To provide updated and correct 
information.  
Section  1, Study 
Design; Section 5.1, 
Study Design; 
Section  5.5, Overall 
Study Duration and 
Follow -up Updated study design text to reflect addition of new 
long-term optional follow -up treatment period -2 of 
72 weeks. Stated that eligible su bjects will remain 
on treatment until either of the following occur: (i) 
subjects complete 72 weeks of additional treatment 
(after Week 144 [long -term optional follow -up To extend the treatment period to 
allow continued participation in 
the study.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 175 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 Protocol Amendments  
Summary of Change(s) Since Last Version of Approved Protocol  
Amendment 
Number  6 Amendment Date  
25 Jun 2018  Global/Country/Site Specific  
Global  
treatment period]), or (ii) the subjects are eligible to 
enter another LUM001 study.  
Section 7.1, Inclusion 
Criteria  Moved inclusion criteria from Section 7.[ADDRESS_1147700] misplacement of 
Protocol Amendment 5 inclusion 
criteria as these were erroneously 
included in Section 7.2 in prior 
protocol version.  
Section  1, Inclusion 
Criteria; Section 7.1, 
Inclusion Criteria  Updated inclusion criteria for Protocol Amendment 
5 to clarify that eligible subjects either completed 
Week  96 or received permission from the sponsor 
and ChiLDReN protocol chair, not the Premier 
medical monitor.  To clarify that permission for re -
entry into the study should come 
from the ChiLDReN protocol 
chair, not the Premier medical 
monitor.  
Section  1, Inclusion 
Criteria; Section 7.1, 
Inclusion Criteria  Added inclusion criteria for Protocol Amendment 
6:  
1. The subject has completed the protocol through 
either Week 144, or the ET visit, or has received 
permission from the sponsor and the ChiLDReN 
protocol chair to re -enter the study in the long -
term optional follow -up period -2.  
2. Females  of child -bearing potential must have a 
negative urine or serum pregnancy test (β -
human chorionic gonadotropin [β -HCG]) at the 
time of entry into the long -term optional follow -
up treatment period -2. 
3. Males and females of child -bearing potential 
who are sexu ally active, or are not currently 
sexually active, but become sexually active 
during the study or for [ADDRESS_1147701] agree to use acceptable 
contraception during the study.  
4. Informed consent and assent (per IRB/EC) as 
appropriate.  
5. Caregivers (and age appropriate subjects) must 
have access to phone for scheduled calls from 
study site.  
6. Caregivers (and age appropriate subjects) must 
be willing to follow the rules of eDiary 
completion.  To specify inclusion criteria for 
Protoc ol Amendment 6.  
Section  1, Exclusion 
Criteria; Section 7.2, 
Exclusion Criteria  Exclusion Criteria:  
All exclusion criteria for the original LUM001 -305 
study apply upon re -entry into the long -term 
optional follow -up treatment period -2. To specify exclu sion criteria for 
Protocol Amendment 6.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 176 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 Protocol Amendments  
Summary of Change(s) Since Last Version of Approved Protocol  
Amendment 
Number  6 Amendment Date  
25 Jun 2018  Global/Country/Site Specific  
Global  
Section  1, Study Drug 
Dosage and 
Administration; 
Section  5.5.[ADDRESS_1147702] the addition of the 
long-term optional treatment 
period -2. 
Section  1, Study Drug 
Dosage and 
Administration; 
Section [IP_ADDRESS] , Long -
term Optional Follow -
up Treatment Period -
2; Section  8.1.11 , 
Long -term Optional 
Follow -up Treatment 
Period -2 Added text describing enrollment of subjects into 
the long-term optional follow -up treatment period -
2. 
 
Added new sections [IP_ADDRESS] and 8.1.11, Long -term 
Optional Follow -up Treatment Period -2.  
 
Added text stating that subjects who choose to 
participate in the long -term optional follow -up 
treatment period -[ADDRESS_1147703] the addition of the 
long-term optional treatment 
period -2. 
Section  1, Study Visit 
Schedule and 
Procedures; 
Section  5.5, Overall 
Study Duration and 
Follow -up Updated text under schematic describing study 
procedures for Week 96 – Week 148 to indicate 
that subjects with dose interruptions >7  days 
between Week 96 and Week 100 should use thi s 
schedule to dose escalate.  To clarify for study sites that 
subjects with dose interruptions 
>7 days between Week 96 and 
Week  100 should re -enter the 
study at PA5 RI -2 and dose 
escalate.  
Section  1, Study Visit 
Schedule and 
Procedures; 
Section  5.5, Overall 
Study Duration and 
Follow -up; 
Section  8.1.11 , Long -
term Optional Follow -
up Treatment Period -
2; Section 8.1.12 , End 
of Treatment or Early 
Termination Visit; 
Section  8.1.[ADDRESS_1147704] 
the addition of the long -term optional follow -up 
treatment period -2, including the addition of 2 new 
sections: 8.1.12, End o f Treatment or Early 
Termination Visit; and Section 8.1.13, End of Study 
Visit.  
 
Added new text describing the study activities that 
will occur during the end of treatment (EOT)/early 
termination (ET), and end of study (EOS) visits.  
 
Added new study sche matic showing study 
activities for subjects who roll over into the long -
term, optional follow -up treatment period -2. To reflect the addition of the 
long-term optional treatment 
period -2. 
Section  1, Drug Level 
Evaluations  Plasma levels of LUM001 will be evaluated at 
Baseline and Weeks 2, 4, 8, 12, 24, 36, 48, 96, 144 
216 (EOT/ET) and 148 220 (EOS).  To update the timing of PK 
sample coll ections, per the 
addition of the long -term 
optional treatment period -2. 
Section  1, Safety and 
Tolerability 
Evaluations  Added text to indicate that SAEs would also be 
evaluated.  To clarify the scope of the safety 
analysis.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 177 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 Protocol Amendments  
Summary of Change(s) Since Last Version of Approved Protocol  
Amendment 
Number  6 Amendment Date  
25 Jun 2018  Global/Country/Site Specific  
Global  
Section  1, Efficacy 
Evaluations; Section 
[IP_ADDRESS] , Efficacy 
Variables  Updated text to indicate that secondary and 
exploratory endpoints would be evaluated from 
baseline to Week 216 (EOT).  
 
Added text updating the electronic diary (ItchRO) 
requirements to reflect the addition of the long -term 
optional treatment period -2. 
 
Added text indicating that additional exploratory 
evaluations will be specified in the SAP and may 
include evaluations between Week 144 (EOT/ET) 
and Week 148 (EOS) and between Week 216 
(EOT/ET) and Week 220 (EOS) for subjects who 
complete Protocol Amendment 5 and 6, 
respectively.  To update the scope of the 
efficacy analysis.  
 
Section  8.1.8 ; Long -
term Optional Follow -
up Treatment Period  Added text indicating that dose of LUM001 may be 
increased during the dose escalation period up to 
280 µg/kg/day.  
Added text indicating that PA5 Schedule D 
Week  [ADDRESS_1147705].  
To clarify requirement of 
electronic diary for subjects 
rolling over into Protocol 
Amendment 6.  
Section  8.1.9 ; Week 
[ADDRESS_1147706] extended treatment 
period under Protocol 
Amendment 6 and to clarify the 
electron ic diary completion 
requirements.  
Section  [IP_ADDRESS] , Visit 
Schedule Following 
Dose Interruption for 
Stable Dosing and 
Safety Monitoring 
Periods  Updated text to indicate that total LUM001 
exposure should not exceed [ADDRESS_1147707] the addition of the 
long-term optional treatment 
period -2. 
Section [IP_ADDRESS] , Visit 
Schedule Following 
Dose Interruption for 
Long -term, Optional 
Follow -up Treatment 
Periods  Updated text to indicate that subjects with dose -
interruptions greater than 7 consecutive days should 
receive permission from the Sponsor and 
ChiLDReN protocol chair when following the re -
entry dose escalation schedule.  
Clarified timin g of dosing interruptions.  To clarify that permission should 
be obtained from both the 
Sponsor and ChiLDReN protocol 
chair.  
To specify timing of permitted 
dose interruptions.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 178 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 Protocol Amendments  
Summary of Change(s) Since Last Version of Approved Protocol  
Amendment 
Number  6 Amendment Date  
25 Jun 2018  Global/Country/Site Specific  
Global  
Section  5.5.3 , Follow -
up Added text indicating that for subjects who 
participate in the long -term optional follow -up 
treatment period -2, the follow -up safety phone call 
will be replaced by [CONTACT_56421] 220 (EOS) clinic 
visit.  To reflect the addition of the 
long-term optional treatment 
period -2. 
Section 5.6, Study 
Termination  Updated text to indicate that subjects who 
participate in the long -term, optional, follow -up 
treatment period -2, will be considered completed if 
they participate in the Week 216 (EOT) visit.  To reflect the addition of the 
long-term optional treatment 
period -2. 
Section  6.1, 
Enrollment  Added text describing the assessment of eligibility 
and enrollment process for subjects rolling over 
into the long -term optional follow -up treatment 
period -2.  To reflect the addition of the 
long-term optional treatment 
period -2. 
Section  8.2, Physical 
Examination, Weight 
and Height, Vital 
Signs; Section  8.4.1 , 
Itch Reported 
Outcome (ItchRO™); 
Section 8.4.2 , 
Clinician Scratch 
Scale; Section 8.4.3 , 
Clinician Xanthoma 
Scale; Section 8.4.4 , 
Pediatric Quality of 
Life Inventory 
(PedsQL); Section 
8.4.[ADDRESS_1147708] additional time points for these 
assessments that will occur during the long -term 
optional follow -up treatment period -2.  
 
In section 8.4.1, ItchRO, added text:  
 
In cases where an observer can no longer 
observe the subject (eg, no lo nger living with the 
subject), the ItchRO(Obs) will not need to be 
completed; however, ItchRO(Pt) will need to be 
completed by [CONTACT_130690] ≥[ADDRESS_1147709] from home (eg, at college); 
therefore, the daily completion of 
the ItchRO(Obs) may no longer 
be feasible.  
Section  [IP_ADDRESS] , 
Secondary, 
Exploratory and Other 
Efficacy Analyses  Removed text:  
Change from baseline in Xanthoma scale will be 
categorized as improved, stable or worsened  and 
will be compared between treatment groups using 
the chi -square test.  
P-values from the secondary and exploratory 
efficacy analyses will be interpreted as hypothesis 
generating and not definitive.  To correct erroneous text; the chi 
square test is not relevant for this 
extension study.  
Section  16.1, 
Schedule of 
Procedures C  Added a footnote to ItchRO assessment at Week [ADDRESS_1147710] an oversight in the 
prior protocol amendment.  
Section  16.1, 
Schedule of 
Procedures  D Added a new row for informed consent/eligibility 
assessment for Protocol Amendment 6 with the 
following footnote:  
1. Subjects can consent to roll over into the long -
term optional follow -up treatment period -2, per 
Schedule F.  To reflect the addition of t he 
long-term optional treatment 
period -2. 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 179 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 Protocol Amendments  
Summary of Change(s) Since Last Version of Approved Protocol  
Amendment 
Number  6 Amendment Date  
25 Jun 2018  Global/Country/Site Specific  
Global  
Section  16.1, 
Schedule of 
Procedures D  Added a footnote to the EOS visit:  
9. Subjects who elect not to participate in the 
long-term, optional follow -up treatment period -2 
(Protocol Amendment 6) should return to the 
study site [ADDRESS_1147711] the addition of the 
long-term option al treatment 
period -2. 
Section  16.1, 
Schedule of 
Procedures E  Updated table title to clarify that subjects who 
either previously completed up to We ek 96, or has 
received permission from the sponsor and the 
ChiLDReN protocol chair (not the Premier medical 
monitor) may re -enter the study using Scheduled E.  
 
Added a footnote to the PA5 RI -2 visit:  
h. Subjects with dose interruptions prior to 
Week  [ADDRESS_1147712] the addition of the 
long-term optional treatment 
period-2. 
To clarify for study sites that 
subjects with dose interruptions 
>7 days prior to Week 96 or who 
early terminated should re -enter 
the study at PA5 RI  -2 and dose 
escalate.  
Section  16.1, 
Schedule of 
Procedures F  Added Schedule of Procedures F - Long -term, 
Optional Follow -up Treatment Period -2: Week 144 
– Study Completion/Termination, applicable as 
follows:  
• If another study becomes available for 
subjects prior to completion of Protocol 
Amendment 6, the subject will complete 
EOT assessments as outlined for Week 216.  
• Subjects who complete [ADDRESS_1147713] the addition of the 
long-term optional treatment 
period -2. 
Section  16.7; 
Caregiver Impression 
of Chan ge (C)  Edited text to reflect additional time points for CIC 
assessments that will occur during the long -term 
optional follow -up treatment period -2.  To reflect the addition of the 
long-term optional treatment 
period -2. 
Section 16.9, Protocol 
History; 16.9.[ADDRESS_1147714] Protocol Amendments 
5 and 6.  
 
 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 180 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 16.9.3  Protocol Amendment 5 Summary of Changes  
 
Protocol Number:  LUM001 -305 
Protocol Title:  A MULTICENTER EXTENSION STUDY TO EVALUATE THE 
LONG -TERM SAFETY AND DURABILITY OF THE THERAPEUTIC 
EFFECT OF LUM001, AN API[INVESTIGATOR_827137] -DEPENDENT BILE 
ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT 
OF CHOLESTATIC LIVER DISEASE IN PEDIATRIC SUBJECTS 
WITH ALAGILLE SYNDROME  
Amendment:  5 
Date:  13 Nov 2017*  
 *NIDDK DSMB Approval Date: [ADDRESS_1147715] of the following occurs: (i) the subjects complete 48  weeks of additional 
treatment (after Week 96 [safety monitoring period]), or (ii) the subjects are eligible to enter 
another LUM001 study.  
The following changes have been made to the Protocol Amendment 5 (13 Nov 2017). Note that 
correction of typos and grammatical errors are not captured in the below table.  
New text indicated in bold; deleted text indicated in strikethrough.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 181 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 Section  Description of Change  
Title Page, Medical 
Lead;  
Protocol Signature [CONTACT_3264], 
Sponsor (Shire) 
Approval  Changed from:  
 
Medical Lead:  Beatriz Caballero, MD  
 Shire  Human Genetic Therapi[INVESTIGATOR_014],Inc.  
 Zahlerweg 10  
6300 Zug  
Switzerland   
 Phone:  +41(0) 41 288 42 30    
 Email: [EMAIL_15741]  
 
 
To:  
 
Medical Lead:  Nirav Desai, MD  
 Shire  
 [ADDRESS_1147716]  
Lexington, MA [ZIP_CODE]  
Phone:  (781) 869 -7756  
Email:  [EMAIL_15742]  
  Inserted new page containing emergency contact [CONTACT_301889] (SAEs) to be aligned with Shire protocol template.  
Product Quality 
Complaints  Inserted new page containing product quality complaint information for reporting of 
investigational product quality complaints to be aligned with Shire protocol template.  
Section  1, Objectives;  
Section  3, Study 
Objectives  Added new exploratory objective to evaluate the long -term effect of LUM001 on 
weight in pediatric subjects with ALGS.  
Section  1, Study Design;  
Section 5.1, Study 
Design; Section  5.5, 
Overall Study Duration 
and Follow -up Updated study design text to reflect addition of new long -term optional follow -up 
treatment period of 48 weeks. Stated that eligible subjects will remain on treatment 
until either of the following occur: (i) subjects complete 48 weeks of addition al 
treatment (after Week 96 [safety monitoring period]), or (ii) the subjects are eligible 
to enter another LUM001 study.  
Section  1, Inclusion 
Criteria; Section 7.2, 
Inclusion Criteria  Inclusion Criteria:  
1. The subject has completed the protocol either through Week 96, or the 
ET visit, or has received permission from the sponsor and the Premier 
Medical monitor to re -enter the study in the long -term, optional follow -
up treatment period.  
2. Female subjects of child -bearing potent ial must have a negative urine or 
serum pregnancy test (β -human chorionic gonadotropin [β -HCG]) at 
the time of entry into the long -term optional follow -up treatment 
period.  
3. Male and female subjects of child -bearing potential who are sexually 
active, or are  not currently sexually active, but become sexually active 
during the study or for [ADDRESS_1147717] agree to use acceptable contraception during the study.  
4. Informed consent and assent (per IRB/EC) as appropriate.  
5. Caregive rs (and age appropriate subjects) must have access to phone 
for scheduled calls from study site.  
6. Caregivers (and age appropriate subjects) must be willing and able to 
use an eDiary device during the study.  
Exclusion Criteria:  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147718] addition of new long -term optional follow -up 
treatment per iod of 48 weeks.  
Section  1, Study Drug 
Dosage and 
Administration; 
Section  5.5.1 , Treatment; 
Section 8.2, Physical 
Examination, Weight 
and Height, Vital Signs ; 
Section  10.1, Study 
Drug Administration  Updated text describing weight -based dosing adjustments to indicate that each 
subsequent 10% increase in weight will be considered the new baseline for 
determination of future dose adjustments  
 
Updated text to indicate that dosing will occur up to 144 weeks of treatmen t. 
Section  1, Study Drug 
Dosage and 
Administration; Section 
[IP_ADDRESS] , Long -term 
Optional Follow -up 
Treatment Period -2 
Section  8.1.11 , Long -
term Optional Follow -up 
Treatment Period -2 Added text describing enrollment of subjects into the long -term optional follow -up 
treatment period -2. 
 
Added new sections [IP_ADDRESS] and 8.1.11, Long -term Optional Follow -up Treatment 
Period -[ADDRESS_1147719] dose of study drug.  
Section  1, Study Visit 
Schedule and 
Procedures; 
Section  8.1.8 , Long -term 
Optional Follow -up 
Treatment Period;  
Section 8.1.9 , Week 144; 
Section 8.1.10 , Week 
148; Section  8.1.12 , End 
of Treatment (EOT) or 
Early Termination (ET) 
visit; Section  8.1.13. , 
End of Study Visit  Updated descriptions of study design text to reflect the addition of the long -term 
optional follow -up treatment period -2, including updates to study activities during the 
long-term optional treatment period, Week 144/ET visit, Week  148 visit (EOS). 
Added new text describing the study activities that will occur during the long -term 
optional follow -up treatment period, the end of treatment (EOT)/early termination 
(ET), and en d of study (EOS) visits.  
 
Added new study schematics showing study activities for subjects who roll over into 
the long -term, optional  follow -up treatment period -2. 
 
Added new sections 8.19, End of Treatment or Early Termination Visit and 8.1.10, 
End of St udy Visit.  
Section  1, Drug Level 
Evaluations  Plasma levels of LUM001 will be evaluated at Baseline and Weeks 2, 4, 8, 12, 24, 36, 
48, 96, 144 (EOT/ET) and 148 (EOS).  
 
Section  1, Efficacy 
Evaluations; 
Section  [IP_ADDRESS] , 
Efficacy Variables  The primary evaluation will be the mean change from baseline (Day 0) of LUM001 -
301 and baseline (Day 0) of LUM001 -305 baseline  to Week 48 in:  
• Fasting serum bile acid level.  
 
Secondary evaluations will be t he mean change from baseline (Day 0) of LUM001 -
301 and baseline (Day 0) of LUM001 -305 through baseline to Weeks 12, 48, 96 
and Week 144/ET  in: 
• Biochemical markers of cholestasis and liver disease ( eg, alanine 
aminotransferase [ALT], alkaline phosphate [ALP ], gamma -
glutamyltransferase [ GGT] and bilirubin [total and direct]) . 
• Pruritus as measured by [CONTACT_827217] (ItchRO(Obs)TM, caregiver 
instrument/ItchRO(Pt)TM patient instrument).  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147720] 12 weeks of the study, the electronic diary (ItchRO) 
will be completed twice daily (AM & PM). During the stable 
dosing period (Weeks 13 -48), twice daily completion of the 
electronic diary (ItchRO) for 4 consecutive weeks will be required 
following the Week 24 and Week 44 clinic visits. For subjects who 
continue in the safety monitoring period, twice daily completion of 
the electronic diary ( ItchRO ) will be required  for 2 consecutive 
weeks will be required  following the Week 60, 72, and 84 clinic 
visits. For subjects who continue in the long -term optional 
follow -up treatment period, twice daily completion of the 
ItchRO will be required for 2 consecutive weeks following the 
Week 96, 108, 120, and 132 clinic v isits and for 4  weeks 
following the 144/ET clinic visit.  
• Xanthomas as measured by [CONTACT_827181].  
• Clinician  scratch scale  
• Fasting serum bile acid levels  
 
The exploratory evaluation will be the mean change in weight z -score from 
Baseline (Day 0) of LUM001 -301 and baseline (Day 0) of LUM001 -305 through 
Week 144/ET.  
Section  1, Statistical 
Considerations; 
Section  [IP_ADDRESS] , 
Adverse Events  Updated safety analysis text to indicate that AEs will be summarized overall and by 
[CONTACT_827216] (LUM001 -301).  
Section  4.4.2 , Previous 
Clinical Experience  Added text describing safety and efficacy results for the completed Phase 2 
randomized, double -blind, placebo -controlled study has been completed in pediatric 
subjects from 12 months to 18 years with ALGS (LUM001 -302 – IMAGO).  
Section  4.5, Rationale 
for Dose and Schedule 
of Administration  Added reference to completed Phase 2 study LUM001 -301. 
Section  [IP_ADDRESS]  Visit 
Schedule Following 
Dose Interruption  for 
Long -term Optional 
Follow -up Treatment 
Period  Added new section [IP_ADDRESS], Visit Schedule Following Dose Interruption for Long -
term, Optional Follow -up Treatment Period  
 
Added text and study schematic describing study procedures to be followed for 
subje ct with LUM001 dosing interruptions >7 consecutive days prior to entry into 
Protocol Amendment 5.  
 
Added “Dosing Interruptions: Reintegration to Study Visit Schedule during Protocol 
Amendment 5” table to show study visit assignments for subjects with LUM00 1 
dosing interruptions >7 consecutive days.  
Section  5.5.3 , Follow -up Added text indicating that the 30 -day safety phone call will apply for subjects who 
participate in all version of the protocol up through Protocol Amendment 4.  
Added text indicating tha t for subjects who participate in the long -term optional 
follow -up treatment period, this phone call will be replaced by [CONTACT_56421] 148 (EOS) 
clinic visit.  
Section 5.6, Study 
Termination  Updated text to indicate that a subject will be considered to have co mpleted the study 
based on the version of the protocol they participated under. For subjects who 
participate in the long -term, optional, follow -up treatment period, they will be 
considered completed if they participate in the Week 144 (EOT) visit.  
Section  6.1, Enrollment  Added text describing the assessment of eligibility and enrollment process for 
subjects rolling over into the long -term optional follow -up treatment period.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 184 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 Section  Description of Change  
Section 8.2, Physical 
Examination, Weight 
and Height, Vital Signs; 
Section 8.4.1 , Itch 
Reported Outcome 
(ItchRO™); 
Section 8.4.2 , Clinician 
Scratch Scale; Section 
8.4.3 , Clinician 
Xanthoma Scale; Section 
8.4.4 , Pediatric Quality 
of Life Inventory 
(PedsQL); Section 8.4.5, 
Caregiver Impression of 
Change  Edited text to reflect additional time points for these assessments that will occur 
during the long -term optional follow -up treatment period.  
Section 10.3, 
Concomitant 
Medications  Added text indicating that concomitant medications should not be collected prior to 
informed consent or during gap periods when the subject is not participating in the 
study.  
Section 10.5.1, General 
Monitoring Rules  If an individual subject exhibits a CTCAE Grade 3 treatment emerge nt toxicity 
laboratory abnormality , with the exception of the specific rules outlined below 
(Section 10.5) dosing  will can be suspended . Continued dosing with study drug may 
be considered  or continued as per the in vestigator’s judgment and  following 
discussion with the ChiLDReN protocol chair  and the Sponsor Medical Monitor. 
The Investigator and Sponsor Medical Monitor  sponsor medical monitor. If 
suspended, the investigator, the ChiLDReN protocol chair,  and sponsor medical 
monitor will evaluate the subject’s safety data and make a decision to either restart 
dosing at the same level, restart dosing at a lower dose level, or discontinue dosing.  
Section  10.5.2 , Safety 
Monitoring Rules  Of note: the INR retest should be  conducted by [CONTACT_2237], but may 
also be conducted at a local laboratory on an as needed basis.  
 
Subjects who do not meet the stoppi[INVESTIGATOR_827162], the ChiLDReN protocol chair , and the sponsor medical 
monitor (or appropriately qualified designee) should confer as to whether 
additional close monitoring of the subject is appropriate.  
 
The investigator should also assess the need to capture an AE, its severity 
according to the CTEAE  directives and potential causality. These assessments 
should also include an evaluation of whether criteria for an SAE are fulfilled 
(see Section 11.2.3 ). 
Section  [IP_ADDRESS] , 
Stoppi[INVESTIGATOR_827163]; 
Section  [IP_ADDRESS] , Safety 
Monitoring for 
Triglycerides; Section 
[IP_ADDRESS] , Safety 
Monitoring for Fat 
Soluble Vitamins 
Section  [IP_ADDRESS] , 
Monitoring/Stoppi[INVESTIGATOR_827164] g interruptions would be 
conducted in coordination with the ChiLDReN protocol chair, in addition to the 
investigator and sponsor medical monitor.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page [ADDRESS_1147721] is not enrolled in the study during 
a gap period (ie, prior to enrollment in Protocol Amendment 5) will be collected 
as medical history unless the AE started within [ADDRESS_1147722] signs the 
informed consent/assent form and stop [ADDRESS_1147723] 
signs the informed consent/assent form and stop [ADDRESS_1147724] dose of study 
drug.  
Section [IP_ADDRESS] , 
Severity  Please also refer to Section 10.5.[ADDRESS_1147725] or in 
the partner of a male study participant during the study…  
Section  11.4.3 ; 
Abnormalities of 
Laboratory Tests  Added language indicating that all clinically significant abnormalities will be 
monitored by [CONTACT_093], sponsor medical monitor, an d ChiLDReN protocol 
chair.  
Section [IP_ADDRESS] , Subject 
Disposition  The number and percentage of subjects enrolled, completed, and withdrawn, along 
with reasons for withdrawal, will be tabulated overall, and by [CONTACT_827231] . assigned at 
LUM001 -305 study entry.  
In addition, for subjects who had dose gaps or re -initiated to all protocol 
amendments, the number of days of the off -drug period will be summarized.  
Section [IP_ADDRESS] , 
Laboratory Tests  Changes within a treatment group for selected safety measures will be assessed at 
Weeks 8, 12, 24, 36 and at the final study evaluation visit (Week 48) using methods 
to be specified in the SAP,  48, 96, and at additional time points during the long -
term optional follow -up treatment period.  
Section 16.1, Schedule 
of Procedures D -E Added Schedule of Procedures D - Long -term, Optional Follow -up Treatment Period: 
Week 96 – Study Completion/Termination for those subjects with ≤[ADDRESS_1147726] dose of LUM001 applicable as follows:  
• If another study becomes available for subjects prior to completion of Protocol 
Amendment 5, the subject will complete EOT assessments as outlined fo r 
Week 144.  
• Subjects who complete 48 weeks of additional treatment and who are not 
eligible for another study will complete EOS assessments as outlined for 
Week 148.  
Added Schedule of Procedures E - Long -term, Optional Treatment Period: Subject 
Re-entry un der Protocol Amendment 5, applicable as follows:  
• Subject either previously completed the follow -up period as defined under 
Protocol Amendment 4, or has received permission from the sponsor and the 
Premier medical monitor to re -enter the study under Protoco l Amendment 5 
and has subsequently experienced an interruption in LUM001 dosing >7days.  
• Subject is considered eligible for study re -entry under Protocol Amendment 
5. 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 186 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
  
16.9.4  Protocol Amendment 4 Summary of Changes  
 
Protocol Number:  LUM001 -305 
Protocol Titl e: A MULTICENTER EXTENSION STUDY TO EVALUATE THE 
LONG -TERM SAFETY AND DURABILITY OF THE THERAPEUTIC 
EFFECT OF LUM001, AN API[INVESTIGATOR_827137] -DEPENDENT BILE 
ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT 
OF CHOLESTATIC LIVER DISEASE IN PEDIATRIC SUBJECTS 
WITH ALAGILLE SYNDROME  
Amendment:  4* 
Date:  27 April 2016*  
 *NIDDK DSMB Approval Date: 24 June 2016  
 
Note: Original NIDDK DSMB approval for Amendment [ADDRESS_1147727] previously unidentified 
inconsistencies within the protocol. Shire then approved the corrected version  of Amendment 3 
on 27 April 2016. Because edits were made after the NIDDK DSMB approved Amendment 3, the 
revised protocol (version date 27 April 2016) was up -versioned to Amendment 4 (version date 27 
April 2016). Amendment 4 was approved by [CONTACT_827232] 24 June2016 and by [CONTACT_827233] 
28 June 2016. Amendment 3 was never operationalized.  
Protocol Amendment 2 (12 February 2015) was amended to extend the duration of the study to 
100 weeks. Additional edits, as captured in the below table, were made to Protoc ol Amendment 
2 and Amendment 3 to improve the clarity of the protocol and/or correct minor inconsistencies. 
Note that correction of typos and grammatical errors are not captured in the below table.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 187 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 New text indicated in bold; deleted text indicated in stri kethrough.  
Section  Description of Change  
Title page; Medical Lead  Changed from:  
 
Sponsor Contact:   [CONTACT_827234], PhD  
 Lumena Pharmaceuticals, Inc.  
 Phone:  [PHONE_17256] -337 -7922  
 Email: [EMAIL_15743]  
 
To:  
 
Medical Lead:  Beatriz Caballero, MD  
 Shire, Inc.  
 Zahlerweg 10  
6300 Zug  
Switzerland  
 Phone:  +41(0) 41 288 42 30   
 Email: [EMAIL_15741]  
Cover page; Sponsor  
Title page; Sponsor  
Sponsor Signature [CONTACT_3264], 
Sponsor  Changed from:  
 Lumena Pharmaceuticals LLC  
 [ADDRESS_1147728]  
San Diego, CA [ZIP_CODE]  
[LOCATION_003]  
 
To:  
Lumena Pharmaceuticals LLC* * 
[ADDRESS_1147729]  
Lexington, MA [ZIP_CODE]  
[LOCATION_003]  
 
**Lumena Pharmaceuticals, LLC is an indirect wholly -owned subsidiary of 
Shire North American Group, Inc  
Study Synopsis ; Study 
Design  
Section 5.1; Study 
Design  
Section 8.1.4 ; Stable 
Dosing Period  The study is divided into 3 4parts: a dose escalation period, a dose optimization 
period, and a stable dosing period , and a safety monitoring period . Planned 
participation for each subje ct enrolled in the study is 48 approximately 100 
weeks (inclusive of the safety follow -up contact [CONTACT_3450] [ADDRESS_1147730] dose of LUM001) . 
Stable Dosing Period  and Safety Monitoring Periods  
Following completion of the [ADDRESS_1147731] of the study.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 188 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 Study Synopsis ; 
Exclusion Criteria  
Section 7.2; Excl usion 
Criteria  
 2. Any conditions or abnormalities (including laboratory abnormalities) 
which, in the opi[INVESTIGATOR_827165],  may compromise the safety of the subject, or interfere with the 
subject partici pating in or completing the study.  
Study Synopsis ; Study 
Drug Dosage and 
Administration  
Section 5.5.1 ; Treatment  
Section [IP_ADDRESS] ; Dose 
Escalation Period  
Section [IP_ADDRESS] ; Stable 
Dosing and Safety 
Monitoring Periods  
Section 5.5.2 ; Dosing 
Interruptions ( new 
section)  
Section 10.6; Adjustment 
of Dose  Dosing will occur over a [ADDRESS_1147732] of the study.  
 
Stable Dosing Period  and Safety Monitoring Periods  
At the end of the Dose Optimization Period, subjects will continue dosing to complete 
48 the stable dosing and safety monitoring periods for up to 96  weeks of 
cumulative LUM001 exposure in this study.  
 
Subjects  who completed the 48 -week study prior to the implementation of 
Protocol Amendment #[ADDRESS_1147733]’s previously achieved highest tolerated dose. 
Study drug for each subject will remain blinded and will be prepared by [CONTACT_827235]’s specified dose -
escalation regimen (Table 5).  
 
Table  5: Dose Esca lation Regimen for Re -initiation of LUM001 when 
Dosing Interruption is Greater than 7 Consecutive Days  
 Study Week  
Week 1  
(μg/kg/day)  Week 2  
(μg/kg/day)  Week 3  
(μg/kg/day)  Week 4  
(μg/kg/day)  
LUM001 
Dose  [ADDRESS_1147734]’s LUM001 dosing 
interruption is reached.  
 
Visit Schedule Following Dose Interruption  
Upon re -initiation of study drug, subjects who undergo a dosing interruption of 
greater  than 7 consecutive days will follow the same visit schedule and 
procedures that are specified for the Baseline Day 0 Visit (Section 8.1.1) and 
during Dose Escalation Treatment Period (Section 8.1.2). Completion of the 
ItchRO electronic diary, however, wil l not be required during this time.  The visit 
schedule upon re -initiation of LUM001 dosing is shown in Figure 4.  
 
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 189 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
  
 
Figure 4 : Visit Schedule for Re -initiation of LUM001 Dosing When 
Dosing Interruption is Greater than 7 Consecutive Days  
 
 
 
Subjects with dosing interruptions of greater than 7 consecutive days will 
require reintegration in the study to ensure that 1) their resumed visit schedule 
aligns with the protocol, and 2) their total LUM001 exposure during the study 
does not exceed [ADDRESS_1147735] 
visit upon dose re -initiation (“RI Day 0” in Figure 4) should be assigned to that 
same Clinic Visit. If the decision to interrupt dosing occurred between Clinic 
Visits, the first visit upon dose re -initiation (“RI Day 0”) should be assigned to 
the next Clinic Visit. Table [ADDRESS_1147736] study visit upon 
dose re -initiation based  on when the dosing interruption occurred.  
 
 
Table 6:  Dosing Inte rruptions: Reintegration to Study Visit Schedule  
Dosing Interruption  Assignment of  
First Dose Re -initiation Study Visit  
Between Weeks 13 - 24 Week 24  
Between Weeks 25 - 36 Week 36  
Between Weeks 37 - 48 Week 48  
Between Weeks 49 - 60 Week 60  
Between Weeks 61 - 72 Week 72  
Between Weeks 73 - 84 Week 84  
 
After Week 84  To be managed on a case -by-case basis in 
consultation with the Medical Monitor and 
ChiLDReN Protocol Chair  
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 190 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 Study Synopsis ; 
Rationale for Dose and 
Schedule Selection  
Section 4.5; Rationale for 
Dose and Schedule of 
Administration  The dose may also be down -titrated, at the investigator’s discretion and in 
consultation with the ChiLDReN protocol chair and the Sponsor Medical 
Monitor, for subjects experiencing intolerance to a given dose.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 191 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 Study Synopsis ; Study 
Visit Schedule and 
Procedur es 
Section 5.5; Overall 
Study Duration and 
Follow -up 
Section 8.1.4 ; Stable 
Dosing Period  
Section 8.1.5 ; Safety 
Monitoring Period ( Week 
49 to Week  96)  
Section 8.1.6 ; 
Week  96/Study 
Termination (End of 
Study)  
Section 8.1.8 ; Early 
Termination  Changed:  
For an individual subject, the study participation period will consist of a [ADDRESS_1147737] dose 
of LUM001 . Study activities will be conducted as described in the Schedule of 
Procedures (Section  16.1) . 
Study Scheme (as described below):  
Day 0 – Week 48  
 
 
Week 49 – Week 100:  
 
 
 
Stable Dosing Treatment Period (Week 13 to Week 48) :  
… However, if a subject experiences intolerance due to gastrointestinal symptoms the 
investigator, in consultation with the ChiLDReN protocol chair  and Sponsor 
Medical Monitor…  
 

Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 192 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 With the exception of the Week 44, A additional study drug will be supplied at e ach 
clinic visit during the stable dosing period.   
 
Safety Monitoring Period (Week 49 to Week 96) : During the safety monitoring 
period, subjects will return to the clinic every 3  months, at Weeks 60, 72, 84, and 
96.  
• Safety and clinical laboratory evaluations and a physical exam (including 
collection of vital signs, height, and weight measurements) wi ll be completed at 
each clinic visit. The clinician scratch scale will also be completed at each clinic 
visit and study drug compliance will be assessed. The PedsQL, Caregiver 
Impression of Change (CIC), and the Clinician Xanthoma scale will also be 
admini stered  at Weeks 60, 72, 84, and 96.  Subjects/caregivers will receive follow -
up phone calls at Weeks 52, 56, 64, 68, 76, 80, 88, 92, and 100. Concomitant 
medications and any adverse events will be evaluated and recorded at all clinic 
visits and at scheduled  telephone contacts.  
Twice daily completion of the electronic diary will be required by [CONTACT_827236] 2 weeks following the Week 60, 72, and 84 
clinic visits. Review of electronic diary data and assessment of complianc e will 
occur during scheduled telephone contacts at Week 64, 76, and 88 and during 
the Week 96 clinic visit. Electronic diaries will be provided to subjects and 
caregivers at these visits and re -training on the use of the diary will occur, as 
appropriate.  
At the physician investigator’s discretion, withdrawal of concomitant 
medications used for the treatment of pruritus may occur during the safety 
monitoring period.  
With the exception of the Week 96 visit, additional study drug will be supplied at 
each cl inic visit during the follow -up treatment period.  
Week 96  / Study Termination (End of Study): At the Week 48 96/Study Termination 
Visit, a physical exam (including collection of vital signs, height and weight 
measurements)…  
Early Termination: Any subject who withdraws from the study prior to completion of 
all treatment period clinic visits should undergo the procedures specified for the Week 
48 96/Study Termination Visit.  
Subjects will be encouraged to complete all study acti vities and visits. Any subject 
who withdraws from the study prior to completion of all treatment period clinic visits 
should undergo the procedures specified for the Week 48 96/ Study Termination visit 
(Section  16.1).  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 193 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 Study Synopsis ; Efficacy 
Evaluations  
Section [IP_ADDRESS] ; Efficacy 
Variables  The primary evaluation for the durability of the therapeutic effect will be the mean  
change from Baseline (Day 0) to Week 48  in:  
 
Second ary evaluations for the durability of the therapeutic effect will be the mean  
change from Baseline (Day 0) to Week  Weeks  48 and 96 and the change from Week 
12 to Week  Weeks  48 and 96 in: 
 
For subjects who continue in the safety monitoring period, twice dai ly 
completion of the electronic diary (ItchRO) for [ADDRESS_1147738], 
will be specified in the statistical analysis plan.  
Study Synopsis ; 
Statistical Considerations  
Section 12; Statistical 
Considerations  Special attention will be paid to change from baseline for those on placebo at baseline 
and to durability of effect during the first 12 weeks for those on active study drug at  
baseline and to durability during the stable dosing period for all subjects at all dose 
levels.  
Section 8.4.1 ; Safety 
Monitoring Period  During the safety monitoring periods, daily completion of the diary will be 
required by [CONTACT_827237] 2 consecutive weeks that 
follow the Week 60, Week 72, and Week 84 clinic visits. At these visits, 
subjects/caregivers will be provided with the electronic diary and re -trained on 
its use, as needed. Su bjects/caregivers will be instructed to bring their electronic 
diary with them when they return for their next clinic visit. The electronic diary 
will be collected at Week 96.  
Section 8.4.2 ; Clinician 
Scratch Scal e This assessment will be completed at Baseline (Day 0) and at all clinic visits 
thereafter (Weeks 2, 4, 8, 12, 24, 36, 48, 60, 72, 84, and 4896).  
Section 8.4.3 ; Clinician 
Xanthoma Scale  This assessment will be c ompleted at Baseline (Day 0) and at Weeks 24, 36, 48,  60, 
72, 84, and 96 ).  
Section 8.4.4 ; Pediatric 
Quality of Life Inventory 
(PedsQL)  In addition to the core generic PedsQL module, the multidimensional fatigue a nd 
family impact questionnaires will also be administered at the Baseline (Day 0) and 
Week  Weeks  24, 48,  60, 72, 84,  and 96 clinical visits using the age -appropriate 
module…  
Section 8.4.5 ; Caregiver 
Impression of Change  
Section 16.7, Caregiver 
Impression of Change 
(CIC)  The CIC will be completed by [CONTACT_827238]  48, 60, 72, 84,  and 
96 visits.  
Section 10.5.2 ; Safe ty 
Monitoring Rules  
 Stoppi[INVESTIGATOR_86556]:  If any of the stoppi[INVESTIGATOR_37466] (refer to 
Section 10.5.1) are confirmed, the physician investigator in consultation with the 
ChiLDReN protocol chair  and the  Sponsor Medical Monitor or appropriately 
qualified designee (s), will permanently d iscontinue…  
Section [IP_ADDRESS] ; Safety 
Monitoring for Liver 
Chemistry Tests  Additional liver evaluations, including gastroenterology/hepatology consultations, 
hepatic CT or MRI scans, may be performed at the discret ion of the Investigator, in 
consultation with the ChiLDReN protocol chair and the  Sponsor Medical Monitor.  
Section 10.6; Adjustment 
of Dose  This decision should be made in consultation with the ChiLDReN protocol c hair 
and Sponsor Medical Monitor.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 194 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 Section 11.3.1 ; Serious 
Adverse Events  In the interest of subject safety, and in order to fulfill regulatory requirements, all 
SAEs (regardless of their relationship to study drug ) should be reported to the 
Sponsor or designee  within 24 hours of the study center’s first knowledge of the 
event. The collection of SAEs will begin after the subject signs the informed consent 
form and stop at the end of the subject’s follow -up period wh ich is defined as 
Week  [ADDRESS_1147739] dose of study drug for those subjects that 
terminate the prior to the Week 48 96 visit.  
Section 11.3.2 ; Non -
Serious Adverse Events  The recording of non -serious AEs will begin after the subject signs the informed 
consent form and will stop at the end of the subject’s follow -up period, which is 
defined as Week  [ADDRESS_1147740] all obs erved or volunteered AEs on the Adverse Event Case Report Form.  
Section 16.1; Schedule of 
Procedures  Added:  
Removed “ / Study termination” from title and the “follow -up” column from the 
Schedule of Procedure for the Stable Dosing Period (Week 16 -Week 48).  
 
Added new Schedule of Procedures for the Safety Monitoring Period (Week 52 – 
Week 96/Study Termination.  
Overall  Throughout the protocol, reference to evaluating durability of effect of LUM001 wa s 
removed to better reflect the correspondence of analyses to study objectives which 
characterize the evaluation of long -term LUM001 effects on efficacy, and which do 
not characterize these effects as “durability of effect.”  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 195 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 16.9.5  Protocol Amendment 2 Sum mary of Changes  
Protocol Number:  LUM001 -305 
Protocol Title:  A MULTICENTER EXTENSION STUDY TO EVALUATE THE 
LONG -TERM SAFETY AND DURABILITY OF THE THERAPEUTIC 
EFFECT OF LUM001, AN API[INVESTIGATOR_827137] -DEPENDENT BILE 
ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT 
OF CHOLESTATIC LIVER DISEASE IN PEDIATRIC SUBJECTS 
WITH ALAGILLE SYNDROME  
Amendment:  2 
Date:  February 12, [ADDRESS_1147741] been made to Protocol Amendment 1:  
• The date of the document has been changed throughout to February 12, 2015.  
• The logo on the protocol’s cover page was updated to reflect the Childhood Liver Disease 
Research Network’s (ChiLDReN) current design.  
The following table provides a summary list of changes to the protocol:  
Section  Description of Change  
Header  Date  changed to February 12, 2015  
Cover Page  Date changed to February 12, 2015  
Sponsor Signature [CONTACT_827241] 12, 2015  
Title Page  Date changed to February 12, 2015  
Protocol Signature [CONTACT_827241] 12, 2015  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 196 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 16.9.6  Protocol Amendment 1 Summary of Changes  
Protocol Number:  LUM001 -305 
Protocol Title:  A MULTICENTER EXTENSION STUDY TO EVALUATE THE 
LONG -TERM SAFETY AND DURABILITY OF THE THERAPEUTIC 
EFFECT OF LUM001, AN API [INVESTIGATOR_827137] -DEPENDENT BILE 
ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT 
OF CHOLESTATIC LIVER DISEASE IN PEDIATRIC SUBJECTS 
WITH ALAGILLE SYNDROME  
Amendment:  1 
Date:  January 29, [ADDRESS_1147742] been made to the original protocol:  
The number of subjects enrolled in the study has been increased from [ADDRESS_1147743] (IRB) blood volume limits for laboratory 
testing.  
The statistical section has been revised to address the statistical management of data generated 
from siblings enrolled in the study and to clarify the interpretation of p -values from secondary 
and exploratory analyses.  
Minor changes have been made to the text to improve the clarity of the protocol and/or correct 
minor inconsistencies.  
The following table provides a summary list o f changes to the protocol:  
Section  Description of Change  
Number of Subjects (Synopsis, Section 5.4), 
Statistical Considerations (Section 12)  Changed number of subjects from [ADDRESS_1147744] current number of subjects 
planned in the LUM001 -301 protocol  
Inclusion Criteria (Synopsis, Section 7.1)  Added inclusion criterion requiring the ability of 
eligible subjects to adhere to local Ethics Committee 
or Institutional Review Board (IRB) blood volume 
limits for laboratory testing  
Itch Reported Outcome (Section 8.4.4)  Clarified that age at the screening visit will be used as 
the age for the determination of the appropriate use of 
the electronic diary for the duration of the study, 
regardless of subsequent birthdays during the study.  
Mirum Pharmaceuticals, Inc.  CONFIDENTIAL  Page 197 
LUM001 -305 Protocol Amendment 6.2 
SHP625  13 May 2019  
 
 Section  Description of Change  
Study Schedule (Section 8.1)  Clarified that samples for the determination of fat 
soluble vitamins are not collected at Weeks 2 and 4. 
Note:  Blood samples for the determination of fat -
soluble vitamins are to be collected at the following: 
Baseline, Week 8, Wee k 12, Week 24, Week 36 and 
at Week 48  
PedsQL (Section 8.4.4)  Clarified that the age at the LUM001 -301 baseline 
visit will be used as the age for the determination of 
the appropriate questionnaire to be used for the study. 
This same module will be used for  the duration of the 
study regardless of subsequent birthdays throughout 
the study.  
LUM001 (Section 9.1.1)  Tables [ADDRESS_1147745] quantity 
of LUM001 per 1.0 mL and 0.5 mL oral solutions  
Synopsis, Statistical Considerations  
(Section 12.2.2)  Language was added to address the statistical 
management of data generated from siblings enrolled 
in the study.  
Statistical Considerations (Section [IP_ADDRESS])  Clarified that the p -values from the seco ndary and 
exploratory analyses will be interpreted as hypothesis 
generating and not definitive.  
Section 16.[ADDRESS_1147746] of analytes. Urine 
pregnancy tests, as indicated, are performed during 
this protocol.  
All Sections, as appropriate  Reference to a ‘core LUM001 treatment protocol’ was 
changed to the ‘LUM001 -301 protocol’. Only 
subjects who completed participation in protocol 
LUM001 -301 are eligible for participation in this 
study (LUM001 -305).  
All Sections, as appropriate  Sponsor name [CONTACT_827242], Inc. to Lumena Pharmaceuticals 
LLC  
All Sections  Minor changes have been made to the text to improve 
the clarity of the protocol and/or correct minor 
inconsistencies and typographical errors.  
 